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GENERAL INTRODUCTION 
This thesis deals with effects of catecholamines on human 
lymphocyte ß2-adrenergic receptors and on several parameters of 
lymphocytes concerning immune function. The following section 
gives a concise description of the sympathetic nervous system 
and of the lymphocytes. Special attention is given to the 
adrenergic receptors, the structures playing a crucial role in 
signal transmission of the sympathetic nervous system. The chapter 
is concluded with a summing up of questions that will be addressed. 
THE SYMPATHETIC NERVOUS SYSTEM 
Visceral functions of the body are controlled by the autonomic 
nervous system, also called the involuntary nervous system, 
referring to the fact that many of the activities take place at 
the unconscious level. Its primary function is to help to maintain 
a stable internal environment in the body against those forces 
that tend to alter it. The autonomic nervous system is represented 
in both the central and peripheral nervous system. Signals are 
transmitted to different organ systems of the body through two 
major subdivisions called the fortho-; sympathetic (1) and 
parasympathetic system. In general, the sympathetic system 
stimulates those activities which are most dramatically expressed 
and mobilized during emergency and stress situations, popularly 
called the "fight, fright, and flight activities". In contrast, 
the parasympathetic system stimulates those activities that are 
associated with the conservation and restoration of the energy 
stores. Together the two systems function in concert to maintain 
the cellular activities at a level proportional to the intensity 
of the stress situation and the emotional state of the individual. 
Both the sympathetic and parasympathetic system consist of 
preganglionic and postganglionic neurons. Messages transported 
along the nervous fibres (pre- as well as postganglionic) are 
finally translated into the release of a neurotransmitter at the 
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nerve endings. Whereas the neurotransmitter substance acetyl-
choline is released at each synaptic junction between pre- and 
postganglionic neurons, the nature of the neurotransmitter 
substances released by the postganglionic neurons of the two 
systems is different. The neurotransmitter substance at the 
parasympathetic postganglionic effector junction is acetylcholine 
and the system is referred to as a "cholinergic system". The 
postganglionic nerve endings of the sympathetic nervous system 
usually secrete norepinephrine, one of the catecholamines, and 
are said to be noradrenergic (derived from noradrenaline, the 
British name for norepinephrine). Norepinephrine is synthesized 
from the amino acid tyrosine by the following biochemical pathway: 
tyrosine — > dopa (dihydroxyphenylalanine) — > dopamine — > 
norepinephrine. Synthesis of norepinephrine begins in the axoplasm 
of the nerve endings, but dopamine is transported into the 
norepinephrine storage vesicles, where norepinephrine synthesis 
takes place. 
An action potential at the sympathetic postganglionic nerve 
terminal results in release of norepinephrine into the synaptic 
cleft. The released norepinephrine within the synaptic cleft has 
several fates. Most of it is inactivated by re-uptake into the 
noradrenergic nerve terminals themselves through active trans-
port. Then there is diffusion away from the nerve endings into 
the surrounding body fluids. Furthermore there is metabolic 
degradation by monoamine oxidase (intraneuronally) and by 
catechol-O-methyl transferase (extracellularly). Essential for 
continuing transport of the signal, however, is binding of 
norepinephrine with receptor sites on the postsynaptic membrane. 
In general, the receptor-site is a protein molecule located in 
the cell membrane. Binding of the neurotransmitter with its 
receptor causes a basic change in the structure of the protein 
molecule. Transmembrane signalling then occurs via a change in 
the activity of the effector, usually an ion channel or an enzyme 
in the cell membrane. Interaction of receptor and effector is 
accomplished by coupling proteins which are regulated by guanine 
nucleotides such as guanosine triphosphate. 
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ADRENOCEPTORS 
The receptors that bind norepinephrine are called adrenergic 
receptors or adrenoceptors, derived from adrenaline (the British 
name for epinephrine, the catecholamine that is formed by 
N-methylation of norepinephrine and that mimics the action of 
norepinephrine). On effector cells innervated by the sympathetic 
nervous system, two types of chemically defined adrenoceptors 
exist: alpha (a) and beta (ß) adrenoceptors. This subdivision is 
based on different relative rank orders of potency of several 
catecholamines for stimulating a variety of physiological effects 
in different organ systems (2). α-Adrenoceptors have a higher 
affinity for epinephrine and norepinephrine than for isoprenaline, 
a synthetic catecholamine. ß-Adrenoceptors, on the other hand, 
have a higher affinity for isoprenaline than for epinephrine and 
norepinephrine. According to differences in rank order of potency 
of agonists and antagonists, subtypes of a- (3,4) and ß-adre-
noceptors (5,6) are defined. a^^-Adrenoceptors cause changes in 
the concentration of intracellular calcium, which turns on the 
highly complex calcium regulatory system. aj-Adrenoceptors are 
inhibitorily coupled to the membrane-bound enzyme adenylate 
cyclase, which upon stimulation generates the second messenger 
3'5'-cyclic adenosine monophosphate. ß-Adrenoceptors are exci-
tatorily coupled to the adenylate cyclase (Figure 1). 
ATP cAMP 
Figure 1. Schematic representation of adrenoceptor transmembrane signalling. 
Rg, stimulatory receptor; RL, inhibitory receptor; Gs, stimulatory G-protein; 
CL, inhibitory G-protein; AC, adenylate cyclase; ATP, adenosine triphosphate; 
CAMP, cyclic adenosine monophosphate. 
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Activation of effector cells by the sympathetic nervous 
system occurs either directly or indirectly (7). The indirect 
effects are accomplished via stimulation of the adrenal glands. 
The adrenal medullae are controlled by the preganglionic cho-
linergic fibers of the sympathetic system (8). Upon sympathetic 
stimulation the adrenal gland secretes large guantities of 
epinephrine and norepinephrine (10-20%) into the circulating 
blood. Norepinephrine is produced in one type of cell in the 
adrenal gland by the same pathway as described above. Epinephrine 
is formed in another type of cell by the methylation of nore-
pinephrine. In this respect these catecholamines act as hormones. 
They are carried via the blood to all tissues of the body and 
have almost the same effects on the different organs as those 
caused by direct sympathetic stimulation. However, whereas the 
norepinephrine secreted directly in a tissue by noradrenergic 
nerve endings remains active for only a few seconds, the effects 
of the humoral catecholamines are much more sustained because 
they are deactivated relatively slowly. 
Most organs innervated by the autonomic nervous system are 
dominantly controlled by either the sympathetic or the para-
sympathetic nervous system. Regulation of the activity of the 
organs occurs by decreasing or increasing either the sympathetic 
or the parasympathetic drive. Due to the existence of a basal 
tone, a change in the degree of autonomic stimulation can lead 
to a change in the activity of the organ in two directions, i.e. 
a decreased or an increased effect. The overall sympathetic tone 
results from basal secretion of epinephrine and norepinephrine 
by the adrenal medullae, in addition to the tone resulting from 
direct sympathetic stimulation. Apart from variation in the degree 
of stimulation, the activity of the organs is believed also to 
depend on the density of the receptors present on the organs. 
The concentration of the adrenergic receptors on cells is not 
fixed but dynamically regulated by a wide variety of physiological 
and pathophysiological variables and may be either increased or 
decreased in different conditions. Patients suffering from 
diseases such as asthma, hypertension, congestive heart failure, 
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ischemie heart disease and thyroid disease have been shown to 
display altered adrenergic receptor densities on tissues involved 
in the disease (9,10). An altered adrenergic receptor concen-
tration may contribute to or determine an altered tissue 
sensitivity to catecholamine effects. The sympathetic nervous 
system innervates three types of effector cells: smooth muscle 
cells, cardiac muscle cells, and glandular cells. Thus, adrenergic 
receptors are widely distributed in humans. They exist for example 
on organs of the respiratory, the circulatory, the digestive, 
the urinary and the reproductive systems, but also in the brain, 
on adipocytes, and on blood cells. 
LYMPHOCYTES 
Peripheral blood lymphocytes contain a homogeneous population 
of ß2-adrenergic receptors (11) excitatorily coupled to the 
adenylate cyclase, and, since they are readily accessible, provide 
a convenient source of material for study of the adrenergic 
receptors (12). Most of our knowledge of the human ß-adrenergic 
receptor-effector system has emerged from studies on the lym-
phocyte ß2-adrenergic receptor. However, relatively little 
attention has been given to the significance of the system for 
lymphocyte function. 
Lymphocytes are part of the immune system, together with 
the macrophages they play a role in acquired immunity. The cells 
develop in primary lymphoid organs. There are two major primary 
lymphoid organs, the thymus gland in which Τ lymphocytes (thy-
mus-derived) develop, and the bursa of Fabricius (avian) or its 
equivalent the bone marrow (mammals), in which В lymphocytes 
(bursa-derived) develop. Proliferation and differentiation occurs 
in secondary lymphoid organs such as the spleen, the lymph nodes 
and the tonsils. В lymphocytes have a humoral immune function: 
they synthesize and secrete antibodies. Τ lymphocytes have a 
cellular immunomodulatory function at various levels of the immune 
response. According to their most prominent function, three 
subclasses of Τ cells can be distinguished. Helper Τ cells serve 
a stimulatory immunomodulatory function: they help В cells to 
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produce antibodies and regulate many aspects of the immune response 
by the release of lymphokines. They can also help to generate 
cytotoxic Τ cells. Cytotoxic Τ cells are effector cells with an 
important role in the immune reaction against intracellular 
parasites and viruses. Suppressor Τ cells serve a suppressive 
immunomodulatory function in the way that they suppress the 
function of the helper Τ cells and of the В cells. In addition, 
another subclass of lymphocytes, the natural killer (NK) cells, 
has a cytotoxic function. The NK cells recognize cell surface 
changes that occur on some virally infected cells and some tumour 
cells. They bind to these target cells and kill them. 
The existence of subtype-specific markers on the surface of 
the lymphocytes enables identification of the functionally 
different subclasses of lymphocytes (13). Furthermore, there are 
several naturally occurring substances that are mitogenic for, 
i.e. have the capacity to bind to, and to trigger proliferation 
and differentiation of, many clones of lymphocytes in a way 
similar to the antigenic activation of lymphocytes in vivo (14). 
For example, two plant glycoproteins (lectins), concanavalin A 
and phytohemagglutinin, are potent mitogens for Τ cells and are 
useful in the identification and study of the function of this 
class of cells. Pokeweed mitogen is considered to be mitogenic 
for both Τ cells and В cells. The lectins interact with specific 
receptors on the lymphocytes. These receptors couple to the 
phospholipase C/inositoltriphosphate (IP3)/diacylglycerol (DAG) 
pathway (15). Activation of the receptor results in the phos­
pholipase C-mediated hydrolysis of phosphatidylinositol-bis-
phosphate into IP3 and DAG, molecules which both have second 
messenger functions (16). IP3 mobilizes intracellular Ca2+, and 
DAG activates protein kinase С (Figure 2) . Similar to the adenylate 
cyclase/cyclic AMP pathway, also in this signalling pathway, the 
receptors seem to be coupled to the effector by G-proteins (17-19) . 
It is generally accepted that the immune system can be 
modulated by endocrine and nervous factors, including the sym­
pathetic nervous system (20). Moreover, stress is increasingly 
б 
PIP, ІР
Э
 + DAG 
Figure 2. Schematic representation of phospholipage C/inositoltriphosphate 
(IP3)/diacylglycerol (DAG) transmembrane signalling. R, receptor; G, G-pro-
tein; PLC, phospholipase С; PIP2» phosphatidylinositol-bisphosphate. 
reported in association with immunosuppression (21) . On the other 
hand, lymphocyte ß2-adrenoceptors are very sensitive to acute 
conditions of stress (22-26). The adaptation which occurs, an 
increase in ß2-adrenoceptors, has thus far only been observed in 
lymphocytes and might be lymphocyte-specific. Thus, lymphocytes 
are an interesting model to investigate the relation between the 
sympathetic nervous system and the immune system. 
AIMS OF THE STUDY 
Studies were designed to discover the mechanism underlying 
the rapid increases of lymphocyte ß2-adrenoceptors in vivo 
following acute catecholamine exposure. A standardized method of 
infusion of isoprenaline into healthy volunteers was used to 
provoke the increases in ß2-adrenoceptors on peripheral lym-
phocytes. A panning technique for preparation of purified lym-
phocyte subsets was developed so that ß2-adrenoceptor densities 
could be measured not only on non-fractionated lymphocytes but 
also on separate subsets. To evaluate effects of activation of 
the sympathetic nervous system on lymphocyte immune function, in 
addition to measurements of ß2-adrenoceptor density, the subset 
composition of peripheral blood mononuclear leucocytes and 
lymphocyte in vitro proliferative responses to various mitogenic 
agents were determined. In search for a biochemical point of 
contact, also in vitro stimulation of lymphocyte ß2-adrenoceptors 
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was investigated in relation to lymphocyte immune function. For 
this purpose mitogenic agents were used to mimic the activation 
of resting lymphocytes by antigens, and formation of inositol 
phosphates and increases in intracellular calcium were determined. 
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CHAPTER 1. Agonist-specific and non-specific in vitro desensi-
tization of human lymphocyte ß2-adrenoceptors 
X-L Wang. LJH van Tits and NM Deiqhton 
Biochemisches Forschungslabor, Medizinische Klinik und 
Poliklinik, Abteilung für Nieren- und Hochdruckkrankheiten, 
Universität Essen, D-4300 Essen, Fed. Rep. Germany 
Running Title: Lymphocyte ß2-Adrenoceptor Desensitization 
Key-Words: - ß-Adrenoceptors -
- Human Lymphocytes -
- Phorbol Esters -
- Homologous Desensitization -
- Heterologous Desensitization -
ABSTRACT — To study agonist-induced desensitization of human 
ß-adrenoceptors we determined in vitro the effects of 
catecholamines, prostaglandin E1 (PCE^ , and the phorbol ester 
12-0-tetradecanoyl-phorbol-13-acetate (TPA) on lymphocyte 
ß-adrenoceptor function. Incubation of lymphocytes in autologous 
plasma at 37DC with catecholamines resulted in a time- and 
concentration-dependent decrease in ß2-adrenoceptor density and 
-responsiveness (cyclic AMP response to 10 μΜ isoprenaline); the 
order of potency was isoprenaline > adrenaline > noradrenaline. 
This catecholamine-induced decrease in ß2-adrenoceptor function 
was completely abolished by the ß2-adrenoceptor antagonist ICI 
118,551 (50 nM) , but not affected by the ß-adrenoceptor antagonist 
bisoprolol (500 nM) . Incubation of lymphocytes with 10 μΜ PGEj^  
did not affect ß2-adrenoceptor function, but significantly 
attenuated cyclic AMP responses to 10 μΜ PGEj. Incubation of 
lymphocytes with 10 μΜ TPA had no effect on ß2-adrenoceptor 
density, but markedly diminished cyclic AMP responses to 10 μΜ 
isoprenaline and PGEj^ ; this effect was completely suppressed by 
the protein kinase inhibitor H-7 (10 μΜ). In contrast, cyclic 
AMP response to 10 μΜ forskolin was enhanced following TPA 
incubation. It is concluded that human lymphocyte ß2-adrenoceptors 
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can undergo homologous (i.e. agonist-specific) and heterologous 
desensitization. TPA-induced heterologous desensitization seems 
to involve activation of protein kinase C. 
INTRODUCTION 
Desensitization, i.e. a diminished cellular responsiveness 
following long-term exposure to agonists, seems to be a general 
mechanism of cellular adaptation to agonist stimulation with time 
(1-3). Two major types of desensitization have been described: 
"homologous" desensitization results in an attenuated cellular 
response only to stimulation of the desensitizing hormone and 
seems to be cyclic AMP independent. In contrast "heterologous" 
desensitization results in a diminished cellular response also 
to additional ligands, and seems to be cyclic AMP dependent. For 
the ß-adrenoceptor/adenylate cyclase system it has been shown in 
various animal model systems, that after long time exposure to 
ß-adrenoceptor agonists the ß-adrenoceptor responsiveness is 
attenuated. The mechanism underlying this homologous desensi-
tization has been intensively investigated in the last few years, 
and the following concept has emerged, at least for high agonist 
concentration (for references see 4-6): agonist activation of 
the ß-adrenoceptor seems to induce translocation of the (cyto-
solic) enzyme ß-adrenoceptor protein kinase (ßARK) from the 
cytosol to the plasma membrane to phosphorylate the receptor and 
hence to uncouple it from the stimulatory guanine-nucleotide-
binding protein (Gg) . Accordingly, subsequent stimulation of the 
receptor cannot result in activation of adenylate cyclase. This 
"uncoupling,,-process is followed by a sequestration of the 
receptor within the cell in a still unknown compartment resulting 
in a decrease in the number of cell surface receptors. 
However, it has recently been shown in turkey (7,8) and duck 
erythrocytes (9) that in addition to ß-adrenoceptor agonists 
phorbol esters - agents known to be potent activators of protein 
kinase С (10) - can induce ß-adrenoceptor desensitization. This 
heterologous desensitization seems to involve phosphorylation of 
the ß-adrenoceptor by either the cyclic AMP dependent protein 
12 
kinase A or by protein kinase С (4-6) . Relatively little is known 
about homologous and heterologous desensitization of human 
ß-adrenoceptors. Circulating lymphocytes, containing a homo-
geneous population of ß2-adrenoceptors excitatorily coupled to 
the adenylate cyclase, are a frequently used model to study 
ß-adrenoceptor changes in man (for recent reviews see 3,11,12). 
The aim of this study was, therefore, to investigate whether 
human lymphocyte ß2-adrenoceptors may underlie similar regulatory 
mechanisms as have been demonstrated in the various mammalian 
and avian model systems. For this purpose we determined in vitro 
the effects of catecholamines, prostaglandin E-^ (PGEj) and the 
phorbol ester 12-0-tetradecanoyl-phorbol-13-acetate (TPA) on 
lymphocyte ß2-adrenoceptor density (assessed by (-)-[ 125I]-io-
docyanopindolol (ICYP) binding) and on the lymphocyte cyclic AMP 
response to 10 μΜ isoprenaline stimulation. 
METHODS 
For preparation of lymphocytes 100 ml EDTA-blood was taken from 
healthy volunteers (aged 24-33 years) after 30 min of rest in 
the supine position. The EDTA-blood was centrifuged at 2 50 g for 
15 min at room temperature and plasma was carefully removed. The 
remaining blood was diluted with an equal volume of phospha­
te-buffered saline (PBS) and lymphocytes were isolated by the 
method of Böyum (13), three times washed with PBS and finally 
resuspended in autologous plasma to yield a concentration of 
approximately 5xl06 cells per ml. 
In vitro desensitization of lymphocyte ßn-adrenoceptors: Two 
ml of the lymphocyte-suspension were incubated with the 
catecholamines isoprenaline, adrenaline and noradrenaline in the 
presence and absence of 50 nM ICI 118,551 or 500 nM bisoprolol, 
or with PGE^ and TPA for the indicated times at 370C. The incubation 
was stopped by rapid dilution of the samples with 10 ml of ice-cold 
PBS and the whole reaction mixture was centrifuged at 400 g for 
10 min. The resulting pellets were washed three times with 10 ml 
ice-cold PBS and the lymphocytes were finally resuspended in 
incubation buffer (12 mM Tris-HCl, 154 mM NaCl buffer pH 7.2, 
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that contained 30 μΜ phentolamine and 0.55 mM ascorbic acid; for 
ICYP-binding) or in PBS containing 0.2% BSA and 100 μΜ theophylline 
(for cyclic AMP determination). Lymphocyte ß2-adrenoceptor 
density was assessed in intact cells by ICYP-binding at 6-8 
concentrations ranging from 10-150 pM at 370C for one hour; 
non-specific binding was measured in the presence of 1 μΜ of 
(±)-CGP 12177. Lymphocyte cyclic AMP content was measured by the 
protein binding assay of Gilman (14) as modified by Schwabe and 
Ebert (15) . Details of the method have been described elsewhere 
(16). In some experiments ß2-adrenoceptor density was determined 
in lymphocyte membranes. For this purpose, after the final wash, 
lymphocytes were lyzed in ice-cold hypotonic buffer (5 mM Tris-HCl, 
5 mM EDTA buffer pH 7.4), homogenized at 40C with a glass teflon 
homogenizer (Braun, Melsungen, F.R.G.), centrifugea at 50000 g 
for 15 min and resuspended in incubation buffer (10 mM Tris-HCl, 
154 mM NaCl buffer pH 7.4 containing 0.55 mM ascorbic acid). 
Statistical evaluations: All data given in text and the figures 
are means ± SEM of N experiments. The maximal number of binding 
sites (Bmax) and the equilibrium dissociation constant (KD) for 
ICYP were calculated either from plots according to Scatchard 
(17) or by the iterative curve-fitting program LIGAND (18). Both 
methods yielded identical results. Students t-test was used to 
evaluate statistical significances; a P-value smaller than 0.05 
was considered to be significant. 
Drugs: (-)-Adrenaline bitartrate, (-)-Noradrenaline bitartrate, 
(-)-Isoprenaline sulphate (IPN), Prostaglandin E1, TPA 
(12-0-tetradecanoyl-phorbol-13-acetate) and Forskolin were 
purchased from Sigma (München, F.R.G.), H-7 
(1-(5-isoquinoline-sulfonyl)-2-methyl-piperazine) from Calbio-
chem (Frankfurt, F.R.G.). Bisoprolol hemifumarate (EMD 33,512; 
bis-(1-(4-((2-isopropoxyethoxy)-methyl)-phenoxy)-3-isopropylam 
ino-2-propanol) was kindly donated by Merck (Darmstadt, F.R.G.), 
ICI 118,551 hydrochloride (erythro-(±)-1-(7-methylindan-4-ylox 
y)-3-isopropylaminobutan-2-ol) by ICI-Pharma (Plankstadt, 
F.R.G.) and (±)-CGP 12177 hydrochloride (4-(3-tertiarybutylami 
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no-2-hydroxy-propoxy)-benzimidazole-2-on) by CIBA-GEIGY (Basel, 
Switzerland). (-)-[125I]-Iodocyanopindolol (specific activity 
2200 Ci/mmol) and [3H]-cyclic AMP (specific activity 34.5 Ci/mmol) 
were obtained from New England Nuclear (Dreieich, F.R.G.). All 
other drugs were of the highest purity grade commercially 
available. 
RESULTS 
B2-Adrenoceptor Desensitization Induced by Isoprenaline. Figure 
1 shows the time course of the effects of 10 μΜ isoprenaline on 
lymphocyte fl2-adrenoceptor density and lymphocyte cyclic AMP 
response to 10 μΜ isoprenaline. Isoprenaline induced a rapid 
decline in the lymphocyte cyclic AMP response amounting about 
70% and 90% after 15 and 60 min respectively (Fig. 1A). On the 
other hand, ß2-adrenoceptor density in the intact lymphocytes 
declined much more slowly: it decreased by about 15% and 35%-40% 
after 30 min and 2 hours, respectively (Fig. 1A). However, when 
incubation was carried out for 24 hours ß2-adrenoceptor density 
decreased to a similar extent as lymphocyte cyclic AMP response 
(i.e. 85% reduction; data not shown). On the other hand, when 
ß2-adrenoceptor density was assessed in lymphocyte membranes after 
the isoprenaline incubation, a decrease of 35%, 50% and 70% was 
obtained at 30, 60 and 120 min, respectively (Fig. IB) . The 
KD-values of ICYP, however, were not affected by the isoprenaline 
incubation; they amounted to 10-16 pM both in intact cells and 
membranes. 
Effects of Catecholamines on Lymphocyte ßj-Adrenoceptor Density. 
Incubation of lymphocytes with isoprenaline (1 nM to 100 μΜ) and 
adrenaline (10 nM to 100 μΜ) for 60 min at 370C resulted in a 
concentration-dependent decrease in ß2-adrenoceptor density (Fig. 
2) . Isoprenaline (EC50 = 41 nM) was 10 times more potent than 
adrenaline (EC50 = 411 nM) . On the other hand, noradrenaline did 
not affect lymphocyte ß2-adrenoceptor density in concentrations 
up to 1 μΜ. At higher concentrations a slight reduction in 
lymphocyte ß2-adrenoceptor density was observed (Fig. 2) . The 
highly selective ß2-adrenoceptor antagonist ICI 118,551 (50 nM) 
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Fig. 1. Time course of the effects of 10 μΜ isoprenaline on ß2" a d r e n o c eP t o r 
density in both intact lymphocytes (A) and membranes (B), and 10 μΜ isopre-
naline-induced cyclic AMP increase in intact lymphocytes (A). Lymphocytes 
were incubated with 10 μΜ isoprenaline at 37<,C in autologous plasma and at 
certain time intervals lymphocyte ß2-adrenoceptor density (squares) and the 
10 μΜ isoprenaline- (IPN) induced cyclic AMP increase (triangles) were 
determined. Each point is a mean value of 4 separate experiments. The vertical 
bars represent SEM. 
completely suppressed the isoprenaline (10 μΜ) -induced decrease 
in lymphocyte ßj-adrenoeeptor density and cyclic AMP response 
(Fig. 3); but the highly selective ß1-adrenoceptor antagonist 
bisoprolol (500 nM) did not affect isoprenaline-induced effects 
on lymphocyte ß2-adrenoceptor function (Fig. 4). 
16 
100-1 
¡л 80-
Ol о 
О _^ 
о о 
і£ 
"О 
ΐχ 40-
с 
ч 
10*9 10"В 10"7 10"6 10"5 
[ß-Adrenergic Agonists] 
IO'4 M 
Fig. 2. Influence of isoprenaline, adrenaline and noradrenaline on lymphocyte 
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Fig. 3. Effects of 50 nM ICI 118,551 (ICI) on 10 μΜ isoprenaline-evoked changes 
in lymphocyte ß2 _ a^ r e n o c eP t o l : density (upper panel) and 10 μΜ isoprenaline-
evoked lymphocyte cyclic AMP increase (lower panel) . Lymphocytes were incubated 
for 60 min at 37eC in autologous plasma with 10 μΜ isoprenaline (IPN) in the 
presence or absence of 50 nM ICI 118,551 and lymphocyte ß2-adrenoceptor density 
and 10 μΜ isoprenaline- (IPN) evoked cyclic AMP increase were determined. 
Given are mean values ± SEM; number of experiments are given at the bottom 
of the columns. **) ρ < 0.01, *) ρ < 0.05 vs. the corresponding control (i.e. 
lymphocytes incubated for 60 m m at 37°C in autologous plasma with PBS). 
Effects of 10 μΜ Prostaglandin E1 (PGE1) on Lymphocyte 
fl2-Adrenoceptor Density. Incubation of lymphocytes for 60 min at 
37"C with 10 μΜ PGEj^ neither affected lymphocyte ß2-adrenoceptor 
density nor lymphocyte cyclic AMP response to 10 μΜ isoprenaline 
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Fig. 4. Effects of 500 nM bisoprolol (Biso) on 10 μΜ isoprenaline-evoked 
changes in lymphocyte ß2-adrenoceptor density (upper panel) and 10 μΜ 
isoprenaline-evoked lymphocyte cyclic AMP increase (lower panel). Lymphocytes 
were incubated for 60 min at 370C in autologous plasma with 10 μΜ isoprenaline 
(IPN) in the presence or absence of 500 nM bisoprolol and lymphocyte 
ß2-adrenoceptor density and 10 μΜ isoprenaline- (IPN) evoked cyclic AMP 
increase were determined. Given are mean values ± SEM; number of experiments 
are given at the bottom of the columns. **) ρ < 0.01, *) ρ < 0.05 vs. the 
corresponding control (i.e. lymphocytes incubated for 60 min at 37<,C in 
autologous plasma with PBS). 
(Fig. 5) . On the other hand, at this concentration PGE1 sig­
nificantly decreased the lymphocyte cyclic AMP response to 10 μΜ 
PGEi (Fig. 6). 
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E f f e c t s of the Fhorbol Ester TPA on Lymphocyte ß2-Adrenoceptor 
Funct ion. I n c u b a t i o n of lymphocytes w i th 10 μΜ TPA f o r 30 min a t 
37"С had no e f f e c t on lymphocyte ß2 -ad renocep to r d e n s i t y ( c o n t r o l : 
996 ± 102 ICYP b i n d i n g s i t e s pe r c e l l , N=10; a f t e r TPA: 1072 ± 
144 ICYP b i n d i n g s i t e s pe r c e l l , N=10); however, t h e b a s a l 
lymphocyte c y c l i c AMP c o n t e n t ( c o n t r o l : 3.2 ± 0.4 pmol pe r 106 
c e l l s , N=10; a f t e r TPA: 8.9 ± 2.2 pmol pe r 106 c e l l s , N=10, ρ < 
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Fig. 6. Effect of 10 μΜ PGEi o n Ю M*1 PGEj-evoked increase in lymphocyte 
cyc l ic AMP c o n t e n t . Lymphocytes were incubated for 60 min a t 37°C with 10 μΜ 
PGEi i n autologous plasma and t h e 10 μΜ PGE^-evoked c y c l i c AMP i n c r e a s e was 
determined. Given a re mean values ± SEM; number of experiments a re given a t 
the bottom of t h e columns. **) ρ < 0.01 vs . c o n t r o l ( i . e . lymphocytes incubated 
in autologous plasma for 60 min a t 370C with PBS). 
0.05) a s w e l l a s t h e lymphocyte c y c l i c AMP r e s p o n s e t o 10 μΜ 
f o r s k o l i n ( F i g . 7) was s i g n i f i c a n t l y i n c r e a s e d . On t h e o t h e r 
hand, t h e lymphocyte c y c l i c AMP r e s p o n s e t o 10 μΜ i s o p r e n a l i n e 
o r 10 μΜ PGEj was r e d u c e d , a l t h o u g h t h i s d i d n o t r e a c h s t a t i s t i c a l 
s i g n i f i c a n c e ( F i g . 7 ) . P r o l o n g i n g t h e i n c u b a t i o n of lymphocytes 
w i t h TPA up t o 2 h o u r s r e s u l t e d i n a f u r t h e r d e c r e a s e i n 10 μΜ 
i s o p r e n a l i n e - and 10 μΜ PGEj-induced c y c l i c AMP a c c u m u l a t i o n , 
w h i l e 10 μΜ f o r s k o l i n - i n d u c e d a c c u m u l a t i o n of c y c l i c AMP remained 
a t t h e s t i m u l a t e d l e v e l ( F i g . 7) ; lymphocyte ß 2 - a d r e n o c e p t o r 
d e n s i t y , however, was s t i l l unchanged ( a f t e r 2 hou r s TPA: 889 ± 
122 ICYP b i n d i n g s i t e s pe r c e l l , N=5). The e f f e c t s of 2 hour s 
i n c u b a t i o n w i t h TPA on lymphocyte c y c l i c AMP r e s p o n s e t o 10 μΜ 
i s o p r e n a l i n e o r 10 μΜ PGEÍ were comple te ly a b o l i s h e d by t h e p r o t e i n 
k i n a s e С i n h i b i t o r H-7 (10 μΜ, F i g . 8) . 
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Fig. 7. Effect of ΤΡΑ on lymphocyte cyc l ic AMP response t o 10 μΜ i s o p r e n a l i n e , 
PGEj and f o r s k o l i n . Lymphocytes were incubated in autologous plasma for 30 
and 120 mm, r e s p e c t i v e l y , a t 370C with 10 μΜ ΤΡΑ and t h e 10 μΜ i s o p r e n a l i n e -
(IPN), PGEi-, or forskolin-evoked increase in lymphocyte c y c l i c AMP content 
was determined. Given are mean values ± SEM; number of experiments are given 
a t t h e bottom of t h e columns. **) ρ < 0 .01, *) ρ < 0.05 vs. control ( i . e . 
lymphocytes incubated in autologous plasma for 30 mm at 370C with PBS). 
DISCUSSION 
I n t h e p r e s e n t s t u d y , c a t e c h o l a m i n e s caused d e s e n s i t i z a t i o n of 
lymphocyte ß 2 - a d r e n o c e p t o r s wi th an o r d e r of po tency t y p i c a l fo r 
ß 2 - a d r e n o c e p t o r s ( 1 9 , 2 0 ) : i s o p r e n a l i n e > a d r e n a l i n e > n o r a d r e -
n a l i n e . The h i g h l y s e l e c t i v e ß 2 - a d r e n o c e p t o r a n t a g o n i s t ICI 
118,551 (21) comple te ly a b o l i s h e d i s o p r e n a l i n e - i n d u c e d 
d e s e n s i t i z a t i o n of lymphocyte ß2 -ad renocep to r f u n c t i o n , wh i l e t h e 
h i g h l y s e l e c t i v e ß 1 - a d r e n o c e p t o r a n t a g o n i s t b i s o p r o l o l (22) a t 
a c o n c e n t r a t i o n t h a t occup ie s about 95% of ß j - a d r e n o c e p t o r s and 
20% of ß 2 - a d r e n o c e p t o r s (23) , had no e f f e c t . These r e s u l t s s t r o n g l y 
s u p p o r t t h e view t h a t t h e c a t e c h o l a m i n e - i n d u c e d d e s e n s i t i z a t i o n 
of lymphocyte ß - a d r e n o c e p t o r s i s a s e l e c t i v e ß2 -ad renocep to r 
dependent p r o c e s s . 
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Fig. θ. Effect of H-7 on TPA-effects on lymphocyte cyclic AMP response to 10 
μΜ isoprenaline or PGE}. Lymphocytes were incubated in autologous plasma for 
120 min at 370C with 10 μΜ TPA in the presence or absence of 10 μΜ H-7 and 
the 10 μΜ isoprenaline- (IPN) or PGE^-evoked increase in lymphocyte cyclic 
AMP content was determined. Given are mean values ± SEM; number of experiments 
are given at the bottom of the columns. **) ρ < 0.01, n.s. = not significantly 
different vs. control (i.e. lymphocytes incubated in autologous plasma for 
120 min at 37°C with PBS). 
Whereas isoprenaline caused a rapid decrease in the lymphocyte 
cyclic AMP response to isoprenaline stimulation, the density of 
ß2-adrenoceptors declined more slowly. On the other hand, PGEj 
(a potent activator of lymphocyte adenylate cyclase, 24) did not 
affect lymphocyte ß2-adrenoceptor density and cyclic AMP response 
to isoprenaline, but significantly decreased lymphocyte cyclic 
AMP responses to PGEj^  stimulation. These results demonstrate that 
lymphocyte ß2-adrenoceptors undergo ß-adrenoceptor agonist 
induced homologous desensitization similar to those demonstrated 
for ß-adrenoceptors in various animal model systems (see 
introduction) . 
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It is, therefore, tempting to speculate that lymphocyte 
ß2-adrenoceptors after activation by μΜ concentrations of iso­
prenaline may be phosphorylated by the enzyme ßARK resulting in 
an uncoupling of the receptor from the Gs-protein/adenylate 
cyclase complex later followed by sequestration of the receptors 
within the cell (4,5). This assumption is strongly supported by 
the fact that after 15 min of incubation with isoprenaline, the 
lymphocyte cyclic AMP response to isoprenaline was decreased by 
about 70%, while ß2-adrenoceptor density was only slightly 
reduced. In this respect, it is worthwhile to note that lymphocyte 
ß2-adrenoceptor density decreased more rapidly following iso-
prenaline incubation, when determined in membranes than in intact 
cells. This may be due to the fact, that in the present study 
intact lymphocytes were incubated with the ß-adrenoceptor 
radioligand ICYP for a rather long period (60 min); during this 
period it is possible that part of the desensitized ß2-adreno-
ceptors may be resensitized (25), thus masking a more pronounced 
decrease in receptor number. Furthermore, the present results 
clearly indicate, that homologous desensitization of ß-adreno-
ceptors in human lymphocytes is also cyclic AMP independent (4-6) 
since after incubation with PGE1 (which produces in lymphocytes 
marked increases in cyclic AMP content) at a concentration 
sufficient to desensitize PGE1-mediated effects (cf. Fig. 6) 
neither lymphocyte ß2-adrenoceptor density nor lymphocyte cyclic 
AMP response to isoprenaline stimulation were affected. 
It has recently been reported that the tumor promoting phorbol 
ester TPA, a potent protein kinase С activator (10), can affect 
the ß-adrenoceptor/adenylate cyclase system. The effects of TPA 
on ß-adrenoceptor function, however, depend on the cell type 
studied: it increased ß-adrenergic activation of adenylate cyclase 
in S49 lymphoma cells (26,27) and frog erythrocytes (28) but 
diminished responses of the adenylate cyclase to isoprenaline in 
rat reticulocytes (29), C6 glioma cells (30), and in turkey (7,8) 
and duck erythrocytes (9). In the present study, incubation of 
human lymphocytes with TPA resulted in an increase in basal cyclic 
AMP content and an enhanced cyclic AMP response to forskolin (cf. 
24 
Fig. 7) , which directly activates the catalytic unit of the 
adenylate cyclase (31). A similar augmentation of the fors-
kolin-induced activation of adenylate cyclase following incu-
bation with TPA has recently been observed in several intact 
cells and cell-free preparations (26,27,32-34). The effect was 
ascribed to a protein kinase C-induced phosphorylation of the 
inhibitory guanine-nucleotide-binding regulatory component of 
adenylate cyclase (G^), which results in the suppression of the 
tonic inhibition of adenylate cyclase activity (35,36). 
Incubation of lymphocytes with TPA did not affect lymphocyte 
ß2-adrenoceptor density, but led to a marked reduction in lym-
phocyte cyclic AMP response to ß-adrenergic (isoprenaline) as 
well as PGEj^-stimulation. These effects seemed to be mediated by 
protein kinase С activation since they could be completely 
prevented by simultaneous incubation of the lymphocytes with the 
protein kinase С inhibitor H-7 (37) . Similar results have recently 
been described by Meurs et al. (38) who observed in human 
mononuclear leucocytes that TPA did not affect ß-adrenoceptor 
density, but caused a concentration-dependent desensitization of 
isoprenaline-, histamine- and PGEj^-stimulated adenylate cyclase 
activity. The mechanism of heterologous desensitization of the 
human lymphocyte ß-adrenoceptor/adenylate cyclase system induced 
by phorbol esters is not known at present. However, it might be 
due to an impairment of Gg-protein function and/or the ability 
of the ß-adrenoceptor to couple to Gs. Further studies are 
necessary to elucidate the precise mechanism of phorbol 
ester-induced heterologous desensitization of the human lym-
phocyte ß-adrenoceptor/adenylate cyclase system. 
In summary: the present results clearly demonstrate that 
ß2-adrenoceptors in circulating lymphocytes undergo homologous 
and heterologous desensitization in a manner which is similar to 
that observed in various mammalian and avian model systems. Since 
the properties of lymphocyte ß2-adrenoceptors resemble those of 
ß2-adrenoceptors in other human tissues (eg. human heart and human 
saphenous vein; see 11) , and since it has recently been shown 
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that lymphocyte ß2-adrenoceptor changes can mirror precisely 
ßj-adrenoceptor changes in solid human tissues like heart (39), 
myometrium (40) or lung (41) , it is concluded that lymphocyte 
ß2-adrenoceptors are an useful model for studying the regulation 
of human ß2-adrenoceptors in vitro. 
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CHAPTER 2. Catecholamines increase lymphocyte ßj-adrenergic 
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ABSTRACT 
We investigated the mechanisms underlying the increase in 
mononuclear leukocyte (MNL) ß2-adrenergic receptor (AR) number 
and responsiveness after acute infusion of catecholamines. 
Infusion of isoproterenol and epinephrine, but not of norepi-
nephrine, acutely increased MNL ß2-adrenoceptor density, and this 
was blocked by the ß2-selective antagonist ICI 118,551 but not 
by the ßa-selective antagonist bisoprolol, suggesting a ß2-AR-
mediated effect. Infusion of isoproterenol but not of norepi-
nephrine also induced a lymphocytosis, with an increase in the 
number of circulating suppressor/cytolytic Τ (T
s
/C)- and natural 
killer (NK)-cells but a decrease in helper Τ (Th)-cells, leading 
to a decreased Th-/Ts/c-cell ratio. ß-AR density was higher in 
Ts/c-cells than in Th-cells. After isoproterenol infusion, ß-AR 
density was elevated in all lymphocyte subsets but not in monocytes 
or platelets, suggesting a lymphocyte-specific phenomenon. 
Infusion of isoproterenol in splenectomized patients did not 
alter lymphocyte subset composition and only slightly increased 
ß2-AR density. In healthy subjects lymphocyte proliferation in 
response to various mitogens was attenuated after infusion of 
isoproterenol but not of norepinephrine; this effect was abolished 
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in splenectomized patients. We conclude that the elevated MNL 
ß-AR density after acute exposure to ß-adrenergic agonists is 
caused by a release of lymphocyte subsets from the spleen into 
the circulation and/or by an exchange of lymphocyte subsets 
between the spleen and the circulation, whereby freshly released 
splenic lymphocytes appear to carry more ß-AR than those found 
in the circulation. This appears to impair immune responsiveness 
in a dual manner, by decreasing the Th-/Tg//c-cell ratio and by 
rendering lymphocytes more sensitive to the antiproliferative 
effects of catecholamines via a higher ß-AR density. 
INTRODUCTION 
GROWING EVIDENCE SUGGESTS that the immune system is at least 
partly under the control of the sympathetic nervous system. Immune 
responsiveness is altered in various animal models of stress (31, 
32, 39, 43). In humans, conditions of chronically heightened 
sympathetic activity, like congestive heart failure, can also be 
associated with an altered immune status (3, 25, 35). However, 
little is known about the mechanisms by which the sympathetic 
nervous system can modulate immune function. 
The sympathetic nervous system and the immune system are 
anatomically linked by a dense innervation of the spleen and 
other immunological tissues. In these tissues, lymphocytes and 
sympathetic nerve endings form contacts at a distance that is 
even shorter than that in a synapse (for review see Ref. 27). 
The presence of surface receptors for the sympathetic neuro-
transmitters makes lymphocytes susceptible to sympathetic 
stimulation. These receptors are of the ß2-adrenergic subtype 
and couple to stimulation of adenylate cyclase (for review see 
Ref. 13). In vitro, stimulation of ß2-adrenergic receptors (AR) 
(by isoproterenol) and other adenylate cyclase-linked receptors 
can inhibit lymphocyte proliferation, mitogen-induced secretion 
of interleukin 2 (IL-2), and expression of IL-2 receptors (6, 
26, 33) . ß-AR agonists might also have an antiproliferative effect 
in vivo, as isoproterenol treatment reduces the number of thymic 
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lymphocytes in mice (24) . Whether the same holds true for plasma 
catecholamines in physiological concentrations, however, remains 
unclear at present. 
The density of lymphocyte ß2-AR is not static but is dynamically 
regulated by a wide variety of neurotransmitters and hormones, 
physiological and pathophysiological conditions (10, 45) , making 
a comparison with other solid human tissues questionable. As in 
most other tissues (30) , long-term administration of ß-AR agonists 
(e.g., procaterol, terbutaline, hexoprenaline) decreases the 
number and responsiveness of ß-AR on circulating human lymphocytes 
(4, 11, 40, 42). This ß-AR downregulation might protect the 
lymphocyte against antiproliferative effects of a prolonged 
exposure to ß-AR agonists. Acute stimulation of the activity of 
the sympathetic nervous system by dynamic exercise or mental 
arithmetic stress, however, increases the ß-AR density on 
circulating human lymphocytes (12, 16, 17, 22, 29). This increase 
can also be demonstrated by infusion of isoproterenol (15,48) 
and can be blocked by propranolol (14), suggesting that it is 
mediated by a ß-AR. Such a receptor increase might render 
circulating lymphocytes more sensitive to the antiproliferative 
effects of ß-AR agonists. 
The mechanism underlying the increase in lymphocyte ß-AR after 
dynamic exercise or catecholamine infusion in vivo is not well 
understood. It could be because of an increase in ß-AR in some 
or all of the circulating mononuclear leukocytes (MNL), or it 
could be caused by differences between the MNL obtained before 
and after catecholamine exposure. The rapid time course (within 
15 min) makes de novo synthesis of ß-AR very unlikely. It has 
been postulated that receptors might be uncovered that may have 
been blocked before (47) . A variation of this hypothesis is the 
idea that lymphocyte ß-AR can exist in several cellular com-
partments (21, 44) , and acute sympathetic stimulation might shift 
them from sequestered compartments to the cell surface. A third 
possibility is based on the finding that subsets of circulating 
lymphocytes differ in their ß-AR density (34, 36) and that acute 
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sympathetic stimulation might selectively alter the homing 
properties of lymphocyte subsets releasing them into or removing 
them from the circulation, thus mimicking ß-AR regulation. 
The present study was designed to investigate the mechanisms 
responsible for the increase of lymphocyte ß-AR after acute ß-AR 
stimulation and the possible immunological consequences of such 
alterations. Therefore, we infused isoproterenol, epinephrine, 
and norepinephrine into healthy volunteers and splenectomized 
patients. Before and after infusion, the MNL ß2-AR density and 
responsiveness and the subset composition of circulating MNL were 
determined. Additionally, we measured lymphocyte in vitro pro-
liferative response to various mitogens before and after cate-
cholamine infusion. 
METHODS 
Volunteers and infusion scheme. Infusion tests were performed 
in 62 healthy volunteers (49 males and 13 females, age 26.3 ± 
0.7 (22-34) yr) after having given informed written consent. All 
volunteers were drug free for at least 3 wk before study, and 
had undergone physical and electrocardiogram examination to 
exclude signs of cardiovascular or pulmonary diseases. The 
isoproterenol infusions were repeated in a subgroup of 10 male 
healthy subjects [age 25.9 ±0.5 (24-28) yr], who had received 
50 mg of the ß2-selective antagonist ICI 118,551 (5) or 30 mg of 
the ß1-selective antagonist bisoprolol (9) orally 4 or 2.5 h 
before the test, respectively. This timing and dosing of the two 
selective ß-adrenergic antagonists were chosen because they cause 
plasma levels corresponding to an occupancy of ~ 75-85% of lii 
(bisoprolol) and ß2-AR (ICI 118,551) , but < 10% of ßj- (bisoprolol) 
and ßj-AR (ICI 118,551), respectively (15,50). 
Additional infusion tests were performed in five male patients 
(age 30 ± 2 yr) who had undergone splenectomy because of Hodgkin's 
disease (4 patients) or trauma (1 patient). The time interval 
between splenectomy and isoproterenol infusion was 8-15 days for 
the Hodgkin's patients and 15 days for the non-Hodgkin's patient, 
respectively. Before, during, and after the surgery, patients 
34 
зосн 
• - • Control 
A - i Bisoprolot (BOmgpo 
2 5h before Infusioni 
· - · IC1118551 (50mg po 
í.h before Infusion) 
~i— Ì5 — ι — 175 — ι 70 0  7  35 
Isoproterenol lng/kg/min for 5mm each) 
• - a Control 
І - Д Bisoprolol (30mgpo 
2 5h before Infusion) 
· - · IC1118551 (50mg po 
4h before Infusion) 
FIG. 1. A: effects of isoproterenol 
infusion on lymphocyte ІІ2-adrenergic 
receptor (AR) density in 10 male 
healthy volunteers in presence or 
absence of bisoprolol (30 mg orally 
2.5 h before infusion) or ICI 118,551 
(50 mg orally 4 h before infusion). 
Isoproterenol was infused in doses of 
3.5, 7, 17.5, 35 and 70 ng kg - 1 m m - ! 
for 5 min each; immediately before 
infusion and after 10, 15, 20 and 25 
m m of infusion hepannized blood was 
withdrawn for lymphocyte ß2-AR 
determination. Ordinate: lymphocyte 
ß2-AR density, determined by Scatchard 
analysis (46) of i-flSSjj. 
lodocyanopindolol binding in intact 
cells, in percent of preinfusion level 
(= 100%). Abscissa: dose of 
isoproterenol in ng kg-l m m - 1 for 5 
min each. B: effects of isoproterenol 
infusion on 10 μΜ isoproterenol 
(ISO)-induced in vitro cAMP increase 
in 10 male healthy volunteers in 
presence of bisoprolol (30 mg orally 
2.5 h before infusion) or ICI 118,551 
(50 mg orally 4 h before infusion). 
For details see A. Ordinate: 10 μΜ 
isoproterenol-induced in vitro 
increase in cAMP content in intact 
cells in percent of preinfusion level 
(= 100%). Abscissa: dose of 
isoproterenol in ng kg - 1 m m - 1 for 5 
min each. Values are means ± SE. ** Ρ 
< 0.01, * Ρ < 0.05 vs. control. 
35 175 35 70 
Isoproterenol (ng/Kg/mm for 5 mm each) 
did not receive ß-adrenergic agonists or antagonists. However, 
the non-Hodgkin's patient received immediately after splenectomy 
a small dose of dopamine (3 дд kg-l-min"! for 2 days) to maintain 
renal function. 
After an initial rest period of 1 h in the supine position, 
isoproterenol (sequential doses of 3.5, 7, 17.5, 35 and 70 
ng· kg-l-πύη"1 for 5 min each), epinephrine (50 ng kg-i-min"! for 
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90 min) or norepinephrine (50 ng kg-1 min-1 for 90 min) were 
infused. Blood pressure and heart rate were recorded automatically 
by a Tonomed (Speidel & Keller, Jungingen, FRG) and an elec­
trocardiogram. If not otherwise stated, immediately before and 
after infusion, blood was withdrawn with 500 IU heparin/10 ml 
blood. 
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FIG. 2. Effects of epinephrine infusion 
on lymphocyte ß2-adrenergic receptor 
(AR) density in 21 healthy volunteers. 
Ordinatesi Д, lymphocyte П2-АК den­
sity, determined by Scatchard analysis 
(46) of i-[125I]-iodocyanopindolol 
(ICYP) binding in intact cells, in ICYP 
binding sites/cell; B, lymphocyte 
ß2-AR density, determined by Scatchard 
analysis (46) of ICYP binding in 
membranes, in fmol ICYP specifically 
bound/mg protein. Abscissas: time of 
infusion in min. Values are means ± 
SE; η = no. of experiments. Horizontal 
lines and broken lines, means ± SE of 
preinfusion levels. Ρ < 0.01, * Ρ 
< 0.05 vs. corresponding preinfusion 
levels. 
FIG. 3. Effects of norepinephrine 
infusion on lymphocyte Л2"" а с* г е п е г9 1 С 
receptor (AR) density in 10 healthy 
volunteers. Ordinatesi Л, lymphocyte 
ß2-AR density, determined by Scatchard 
analysis (46) of i-t^Sij-
lodocyanopindolol (ICYP) binding in 
intact cells, in ICYP binding 
sites/cell; B, lymphocyte ß2-AR den-
sity, determined by Scatchard analysis 
(46) of ICYP binding in membranes, in 
fmol ICYP specifically bound/mg pro-
tein. Abscissas: time of infusion in 
min. Values are means ± SE; л = no. of 
experiments. Horizontal lines and 
broken lines, means ± SE of preinfusion 
levels. 
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Cell isolation. Heparinized blood was centrifuged for 15 min 
at 300 g, and platelet-rich plasma was removed. In some experiments 
platelets and platelet membranes were prepared from the plasma 
as described previously (49) . MNL were prepared by Ficoll gradient 
centrifugation of the pellet according to the method of Böyum 
(7) with minor modifications (11). For monocyte isolation 
RPMI-1640 medium was used to dilute the blood to four times the 
original volume before the Ficoll centrifugation. For lymphocyte 
subset isolation phosphate buffered saline (PBS) without Ca2+ and 
Mg2+ was used. The recovery of leukocytes and lymphocyte subsets 
as given below was quantified microscopically with a Neubauer 
counting chamber. 
Purified lymphocyte subsets were prepared from the final MNL 
pellet by a panning technique by means of negative selection with 
monoclonal antibodies. Briefly, MNL were suspended in 5% fetal 
calf serum (FCSJ-PBS, and transferred into petri dishes that had 
been coated with appropriate monoclonal antibodies. A mixture of 
0KB2, Bl, and JotlO was used for isolation of pan-T-cells; of 
Jot8, Jot4, JotlO, LeuMl, and 0KT16 for isolation of B-cells; of 
0KB2, Jot8, JotlO, and Bl for isolation of helper Τ (Th)-cells; 
and of OKB2, Jot4a, JotlO, and Bl for isolation of suppressor 
/cytolytic Τ (T
s
;
c
)-cells. The dishes were incubated at room 
temperature for 1 h. Nonadherent cells were then carefully 
collected, washed once, and transferred into another set of Petri 
dishes for a repetition of the purification process. T-, T h- and 
T
s
/
c
-subsets isolated with this technique had a purity of >95%, 
and B-cells of >85%, as determined by indirect immunofluorescence 
(see below). 
Monocytes were isolated from MNL by adherence to plastic. 
Briefly, the MNL pellet was suspended in 20% FCS-RPMI 1640 medium 
and transferred into plastic Petri dishes. The dishes were 
incubated at 37 "С in a humidified atmosphere of 5% COj in air 
for 1 h. The nonadherent cells were then decanted and the dishes 
were gently washed. Adherent cells were collected by vigorous 
pipetting after incubation with 0.8% Xylocaine in 20% FCS-RPMI 
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TABLE 1. R e i a t i v e and absolute distribution of leukocytes in 10 healthy 
subjects before and after isoproterenol infusion 
Leukocytes 
Monocytes 
Lymphocytes 
B-cells 
T-cells 
Th-cells 
TB/c-cells 
NK-cells 
Th-to-Tg/c cell ratio 
Isoproterenol Infusion 
Bef 
Rel (%) 
3.2±0.б 
41.3+2.6 
14.1±1.0 
76.311.2 
43.5±1.0 
26.4±1.6 
3.8±0.6 
ore 
Abs 
(cells/μΐ) 
5095±547 
2055±210 
285+31 
1556±149 
879191 
520+46 
72 + 10 
1.7±0.1 
After 
Rel (%) 
3.411.0 
50.415.2 
11.0+1.2 
78.2+1.7 
20.511.9 
41.3+1.6 
12.3+2.2 
Abs 
(cells/μΐ) 
53901593 
2490+137* 
274131 
19431105* 
506146** 
1024160** 
301149** 
0.5+0.1** 
Values are means i SE of 10 experiments. I soproterenol was infused in doses 
of 3.5, 7, 17.5, 35 and 70 ng kg _ l m i n - l for 5 min each; immediately before 
infusion and a f t e r 25 min of infusion h e p a n n i z e d blood was withdrawn for 
determinat ion of d i s t r i b u t i o n of monocytes and lymphocyte subse t s . Rel %, 
r e l a t i v e %; abs, a b s o l u t e ; Th, helper T - c e l l ; T
s
/C, suppressor/cyto ly t ic 
T - c e l l ; NK, n a t u r a l k i l l e r . ** Ρ < 0 .01, * Ρ < 0.05 vs. t h e corresponding 
pre infus ion l e v e l s . 
1640 for 20 min a t 4 0 C. Cell suspensions i s o l a t e d with t h i s 
technique had a p u r i t y of >95% as determined with presta ined 
s l i d e s for d i f f e r e n t i a l blood counts (Boehringer, Mannheim, FRG) . 
MNL and enriched lymphocyte subpopulations were analyzed by 
i n d i r e c t immunofluorescence with the following monoclonal 
a n t i b o d i e s : 0KT3, J o t 3 , and Leu5b for pan-T c e l l s ; Jot4a, Leu3, 
and BMA040 for T h - c e l l s ; Jot8a, Leu2, and TÜ102 for T s / c - c e l l s ; 
TÜ39 and aDR for B-ce l l s ; JotlO and Leu7 for natura l k i l l e r 
(NK)-cells; Tiik-l for monocytes. Fluorescein isothiocyanate 
(FITC)-labeled goat anti-mouse immunoglobulin G (IgG) + IgM was 
used as the second antibody. 
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TABLE 2. Relative distribution oí monocytes and lymphocyte subsets in 5 healthy 
subjects before, during, and alter norepinephrine infusion 
Monocytes 
B-cells 
T-cells 
Th-cells 
Tg/c-cells 
NK-cells 
Th-to-Tg/c cell ratio 
Norepinephrine Infusion 
Before 
rel % 
4.2±0.5 
15.4±1.0 
78.Oil.8 
41.8±1.9 
31.6±1.8 
3.2±0.5 
1.4±0.1 
30 min 
rel % 
4.0±0.4 
16.2+1.1 
77.4±1.6 
39.6±1.4 
30.2±1.5 
3.0±0.5 
1.3±0.1 
60 m m 
rel % 
5.2±1.3 
16.211.5 
77.8±1.4 
40.4±1.2 
31.6±2.2 
3.6±0.2 
1.3±0.1 
90 min 
rel % 
5.0±1.3 
18.4±2.5 
76.811.7 
40.4±1.2 
30.0±1.4 
3.810.4 
1.410.1 
Values are means i SE of 5 experiments. See Table 1 for abbreviations. 
Norepinephrine was infused at a dose of 50 ng kg-l min-^ for 90 min; immediately 
before infusion and after 30, 60, and 90 min of infusion, hepannized blood 
was withdrawn for determination of distribution of monocytes and lymphocyte 
subsets. 
Determination of ß-AR density and responsiveness. Lymphocyte 
and monocyte ßj-AR were identified in intact cells by radioligand 
binding with [125I]iodocyanopindolol (ICYP) at 6-8 concentrations 
of ICYP ranging from 10 to 150 pM (11). It should be noted that 
our assay conditions detect very likely only cell surface ß2-AR, 
as we perform the assay in the presence of 30 μΜ phentolamine 
(that inhibits uptake of ICYP into the cells, for references see 
Ref. 10) and define non-specific binding by 1 μΜ of the hydrophylic 
ß-AR antagonist (±)-CGP 12177. However, a redistribution of 
sequestered receptors to the cell surface during the incubation 
period (1 h, 37 0C) cannot be excluded. Thus additional experiments 
were performed in cell membrane preparations under similar 
conditions. Platelet ß2-AR were labeled with [ 125I]iodopindolol 
(IPIN) according to previously published techniques (49). MNL, 
pan-T-, and B-cell ß2-AR were determined in the blood of 5 subjects, 
and monocyte, Th- and Tg/c-cell ß-AR in the blood of another 5 
subjects, because we were not able to isolate all six fractions 
in sufficient quantities from 200 ml of blood. 
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The accumulation of adenosine S'.S'-cyclic monophosphate (cAMP) 
in intact cells during a 10-min incubation in the absence and 
presence of 10 μΜ isoproterenol was measured according to 
previously published techniques (11) . 
0-« ' • ' — - (H r- 1— 1 — гт г-; ь0 
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FIG. 4. Effects of isoproterenol (ISO) infusion on lymphocyte ß2-adrenergic 
receptor (AR) density (A) and isoproterenol-induced in vitro activation of 
lymphocyte adenylate cyclase (B) in 5 male healthy volunteers. Isoproterenol 
was infused in doses of 3.5, 7, 17.5, 35 and 70 ng kg-l min-^ for 5 min each; 
immediately before infusion and after 25 m m of infusion hepannized blood 
was withdrawn for determination of lymphocyte ß2-AR density and adenylate 
cyclase activity. Ordinates: A, lymphocyte ß2-AR density, determined by 
Scatchard analysis (46) of J-[125j]-iodocyanopindolol (ICYP) binding in 
membranes, in fmol ІСУР specifically bound/mg protein; B, adenylate cyclase 
activity in lymphocyte membranes expressed either in pmol cAMP formed mg 
protein-* min-l or in percent of basal activity (=100%) before (ieft) and 
after isoproterenol infusion (right). Abscissa in B: molar concentrations of 
isoproterenol. Values are means ± SE; no. of experiments in parentheses. ** 
Ρ < 0.01, * Ρ < 0.05 vs. corresponding preinfusion levels. 
Adenylate cyclase activity was measured in MNL membranes. The 
MNL pellet was frozen in liquid nitrogen and stored at -80 0C 
for maximally 8 days. No loss of adenylate cyclase activity was 
observed during this time interval. At the day of the assay, the 
pellet was suspended in 1 ml of buffer [10 mM tris(hydroxyme-
thyl)-aminomethane (Tris)-HCl, 2 mM МдСІ2, 0.1 mM ethylene 
glycol-bisiß-aminoethyletherJ-N^N' ,N' (EGTA) , pH 7.4] and three 
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times freeze-thawed in liquid nitrogen. The resulting suspension 
was diluted to a volume of 10 ml with buffer, centrifuged at 
29,000 g for 10 min at 4 "С, and the pellet finally suspended 
again in buffer. Membranes (2-6 дд of protein) were incubated at 
37 0C for 10 min in total volume of 100 μΐ containing 25 mM 
Tris-HCl buffer, 5 mM MgClj, 0.5 mM ATP, 5 mM creatine phosphate, 
50 lU/ml creatine Phosphokinase, and 10 μΚ guanosine 5'-tris-
phosphate at pH 7.4, in the absence or presence of isoproterenol. 
The reaction was stopped by immersing the incubation tubes in 
boiling water for 5 min. After cooling, samples were centrifuged 
at 12,000 g for 10 min and the cAMP concentration was determined 
in aliquots of the supernatant with a radio-immunoassay kit, by 
means of the nonacetylated procedure. Protein was determined by 
the method of Bradford (8) with bovine serum albumin as a standard. 
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FIG. 5. Effects of in vitro incubation (60 min, 37 0C) of lymphocytes obtained 
immediately before isoproterenol infusion, with autologous plasma, obtained 
immediately after isoproterenol infusion (3.5, 7, 17.5, 35, and 70 ng -kg-! -min-* 
for 5 min each) on ß2-adrenergic receptor (AR) density. Ordinates: A, lymphocyte 
ß2-AR density, determined by Scatchard analysis (46) of i-[125j]_ 
iodocyanopindolol (ICYP) binding in intact cells, in ICYP binding sites/cell; 
B, lymphocyte ß2-AR density, determined by Scatchard analysis (46) of ICYP 
binding in membranes, in fmol ICYP specifically bound/mg protein. Values are 
means ± SE; л = no. of experiments. 
Functional mononuclear cell tests. Monuclear cell function was 
monitored by the ability of cells to proliferate (assayed by 
[3H]thymidine incorporation) on mitogenic stimulation with 
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phytohemagglutinin (PHA; 0.45, 0.9, 1.8, and 3.6 ßg/ml), con-
canavalin A (СопА; 4.5, 9, 18, and 36 дд/ші), pokeweed mitogen 
(PWM; 0.6, 1.1, 2.3, and 4.6 ßg/ml), anti-T-cell globulin (ATG; 
45, 90, 180, and 360 ßq/ml) , and staphylococcus enterotoxin (STE; 
0.0225, 0.045, 0.09, and 0.18 ßg/ml). Cells were cultured for 4 
days at 37 0C at a density of 2 χ IO5 cells/well in microtiter 
plates in 220 μΐ RPMI 1640 with 0.29 mg/ml L-glutamine, 0.16 
mg/ml gentamicin-sulfate, 10% heat-inactivated pooled human 
serum, and the above indicated mitogens. For the last 16 h the 
cultures were labeled with 2 дСі [3H]thymidine/well. The cells 
were harvested with a multiple-sample precipitator (Skatron, 
Lier, Norway) and incorporated radioactivity was measured in a 
scintillation counter (LKB 1212, Freiburg, FRG). 
Drugs and monoclonal antibodies. (-) - [ 125I]ICYP and 
(~)-[125I]IPIN (specific activity 2,200 Ci/mmol) , and a radio­
immunoassay for cAMP were purchased from Du Pont-New England 
Nuclear, and [3H]thymidine (5 Ci/mmol) was from Amersham. 
Isoproterenol (Aludrin) was obtained from Boehringer (Ingelheim, 
FRG) , and epinephrine (Suprarenin) and norepinephrine (Arterenol) 
were from Hoechst (Frankfurt, FRG). Tablets of ICI 118,551 and 
bisoprolol were kindly provided by ICI Pharma (Plankstadt, FRG) 
and Merck (Darmstadt, FRG), respectively, and (±)-CGP 12177 
hydrochloride (4-(3-tertbutylamino-2-hydroxy-
propoxy)benzimidazole-2-one) were provided by Ciba-Geigy (Basel, 
Switzerland). 
RPMI 1640, FCS, L-glutamine, and gentamicin-sulfate were obtained 
from Nunc (Wiesbaden, FRG), and Xylocaine was from Astra Chemicals 
(Wedel/Holstein, FRG). PHA (T-cell specific) was from Welcome 
(Beckenham, UK), ConA (T-cell specific) was from Sigma Chemical 
(Deisenhofen, FRG), PWM (stimulates T- and B-cells) was from 
Boehringer, ATG (T-cell specific) was from Fresenius (Oberursel, 
FRG), and STE (T-cell dependent) was from Serva (Heidelberg, 
FRG). All other chemicals were from Sigma Chemical and of the 
highest purity grade available. 
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FITC coupled goat anti-mouse IgG + IgM was purchased from Medac 
(Hamburg, FRG). Monoclonal mouse anti-human antibodies were 
obtained from the following sources (specificities in 
parentheses): 0KB2 (CD24) , 0KT3 (CD3), and 0KT16 (CD7) f rom Ortho 
Diagnostic Systems (Neckargemünd, FRG); BI (CD20) from Coulter 
Immunology (Krefeld, FRG); Jot3 (CD3), Jot4 (CD4), Jot8 (CD8), 
and JotlO (NK-cell marker) from Immunotech Dianova (Hamburg, 
FRG); LeuMl (CD15), Leu2 (CD8), Leu3 (CD4), Leu5b (CD2), Leu7 
(NK-cell marker), and aDR (class II) from Becton Dickinson 
(Heidelberg, FRG); BMA040 (CD4) from Behring (Frankfurt/Main, 
FRG); and Tük-1 (CDllb) , TÜ39 (class II), and TÜ102 (CDS) were 
kindly provided by Dr. Ziegler (Tübingen, FRG). 
Data evaluation. The maximal number of binding sites (Bmax) and 
the equilibrium dissociation constant (Kd) for ICYP and IPIN 
binding were calculated from plots according to Scatchard (46). 
The experimental data given in text, figures, and tables are 
means ± SE of л experiments. The significance of differences was 
estimated by two-tailed Student's t test; a Ρ value < 0.05 was 
considered to be significant. 
RESULTS 
Isoproterenol infusion in healthy volunteers increased the 
ß2-AR density of unfractionated MNL (as determined by binding to 
intact cells) dose-dependently with a maximal increase at the 
highest dose of - 125-150% (Fig. 1A). Similarly, 10 μΜ 
isoproterenol-induced in vitro increases in intracellular cAMP 
content were enhanced after isoproterenol infusion (Fig. IB) . 
Pretreatment of the volunteers with the ß2-selective AR antagonist 
ICI 118,551 markedly shifted the dose response-curve for the 
isoproterenol-induced increase in ß2-AR density and cAMP accu-
mulation to the right to higher doses, whereas pretreatment with 
the ß1-selective AR antagonist bisoprolol did not attenuate the 
isoproterenol-induced increase in either parameter, suggesting 
a ß2-AR mediated effect (Fig. 1). Infusion of the nonselective 
endogenous catecholamine epinephrine also markedly increased the 
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FIG. 6. Ef fects of i s o p r o t e r e n o l (ISO)-infusion on ß2-adrenergic receptor 
(AR) dens i ty in lymphocyte subse ts in 10 male heal thy vo lun t ee r s . I sopro terenol 
was infused in doses of 3 .5 , 7, 17.5, 35 and 70 ng k g - 1 min - 1 for 5 mm each; 
immediately before infusion and a f t e r 25 mm of infusion hepann ized blood 
was withdrawn for lymphocyte ß2-AR determinat ion in the lymphocyte subse t s . 
Ordinate : ß2-AR dens i ty in lymphocyte subse t s , determined by Scatchard ana lys i s 
(46) of I - [125i ) - iodocyanopindolol (ICYP) binding in i n t a c t c e l l s , in ICÏP 
binding s i t e s / c e l l . Values are means ± SE; η = no. of experiments. x x Ρ < 
0.01 vs . T - c e l l s ; * Ρ < 0.05 vs. T h - c e l l s . For a l l lymphocyte subsets ß2-AR 
dens i ty a f t e r i sopro te reno l infusion was s i g n i f i c a n t l y higher than before 
i sop ro te reno l infusion (P < 0 .01) . Percent increases in ß2-AR dens i ty amounted 
to 106.2 ± 10.1 in mononuclear leukocytes (MNL), Θ9.7 ± 9.2 in B-cel l s , 162.4 
± 17.9 in T - c e l l s , 96.5 ± 13.4 in T h - c e l l s , and 77.2 ± 12.5 in T s / c - c e l l s . 
ß2-AR dens i ty of c i r c u l a t i n g MNL (as measured on i n t a c t c e l l s , 
Fig. 2A), whereas the same dose of norepinephrine (38) increased 
MNL ß2-AR densi ty only marginally (Fig. ЗА). 
As ß-AR can e x i s t on the c e l l surface as well as in a sequestered 
pool, and can migrate from one compartment to another (21, 44), 
we repeated our experiments with binding to MNL membranes instead 
of i n t a c t c e l l s . Under these condi t ions i soproterenol infusion 
a l so e levated the MNL ß2-AR densi ty (Fig. 4A) ; concomitantly 
b a s a l - as well as i soproterenol -s t imula ted adenylate cyclase 
a c t i v i t y increased independently of whether expressed in absolute 
values ( i . e . , pmol cAMP formed -mg prote in - 1 -min - 1 ) or as percent 
increase above the corresponding basal a c t i v i t y (Fig. 4B) . The 
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EC5o (- 1 ДМ) for the concentration-response curve was not changed 
(cf. Fig. 4B) . A 90-inin infusion of epinephrine (Fig. 2B) but 
not an equal dose of norepinephrine (Fig. 3B) also increased the 
MNL ß2-AR density as determined in membranes. 
In contrast to the in vivo effects in vitro incubation of intact 
MNL for 60 min at 37 0C with different concentrations isopro-
terenol, epinephrine, and norepinephrine resulted in a concen-
tration-dependent decrease in MNL ß2-AR density; the rank order 
of potency of the catecholamines was isoproterenol > epinephrine 
>> norepinephrine (23). In addition, incubation of lymphocytes 
obtained before the infusion in autologous plasma obtained 
immediately after the isoproterenol infusion for 60 min at 37 0C 
did not influence ß2-AR density at all, independently whether 
ßj-AR density was determined in intact cells or in membranes 
(Fig. 5). 
Because it has been demonstrated that MNL subsets have different 
numbers of ß-AR (34, 3 6), we determined whether an isoproterenol 
infusion might change the subset composition of circulating MNL. 
Infusion of isoproterenol did not significantly alter the total 
leukocyte counts or the circulating numbers of monocytes and 
B-cells (Table 1) but increased the number of peripheral blood 
lymphocytes by 26 ± 7% (P < 0.05; Table 1) , resulting in a relative 
lymphocytosis. The increased lymphocyte counts resulted from a 
slight decrease of Th-cell number (41 ± 3%) and a large increase 
of both Tg/C- and NK-cell number (107 ± 18% and 346 + 74%, 
respectively; Table 1). Thus, isoproterenol decreased the 
Th-/Ts/c-cell ratio from 1.7 to 0.5 (Table 1). Infusion of the 
rather ß1-AR selective agonist norepinephrine, however, did not 
change the number of any type of circulating leukocytes (Table 
2). 
We then asked whether this change in the subset composition of 
circulating lymphocytes might explain the increase in MNL ß2-AR 
density after isoproterenol infusion. Therefore, we measured ß-AR 
density in each MNL subtype separately (Fig. 6) . B-cells had 
significantly more ß-AR than T-cells (1,779 ±121 vs. 1,047 ± 54 
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ICYP binding sites/cell respectively; Ρ < 0.01), which is in 
reasonable agreement with the average number of ß-AR on 
unfractionated MNL (1,146 ± 59 ICYP binding sites/cell) and the 
proportion of T- and B-cells. Among the T-cells, T3,c-cells had 
more ß-AR than Th-cells (1,511 ± 134 vs. 1,086 + 120 ICYP binding 
sites/cell, respectively; Ρ < 0.05). In addition, in two 
experiments we could determine ß-AR density in NK-cells: it 
amounted to - 2,000 ICYP binding sites/cell. The affinity of the 
radioligand ICYP for the ß-AR (Kd-value: 16.9 ± 1.6 pM, η = 30), 
however did not significantly differ between lymphocyte sub-
populations. Thus an increased relative number of Tg/c-cells 
(which have more ß-AR than Th-cells) could be one reason for the 
increase in ß-AR of unfractionated MNL after isoproterenol 
infusion. 
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FIG. 7. Effects of isoproterenol (ISO)-infusion on monocyte and platelet 
ß2-adrenergic receptor (AR) density in 5 male healthy volunteers. Isoproterenol 
was infused in doses of 3.5, 7, 17.5, 35 and 70 ng-kg-1-min-1 for 5 min each; 
immediately before infusion and after 25 min of infusion heparinized blood 
was withdrawn for determination of monocyte and platelet ß2-AR density. 
Ordinates: left, monocyte ß2-AR density, determined by Scatchard analysis 
(46) of i-(125I]-iodocyanopindolol (ICYP) binding in intact cells, in ICYP 
binding sites/cell; right, platelet ß2-AR density, determined by Scatchard 
analysis (46) of iodopindolol (IPIN) binding in membranes, in fmol IPIN 
specifically bound/mg protein. Values are means ± SE; η = no. of experiments. 
To determine whether other factors might also participate in 
the isoproterenol-induced elevation of MNL ß-AR, we measured 
ß2-AR density in each subset of the fractionated MNL after 
isoproterenol infusion (Fig. 6). We found that infusion of the 
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ß-AR agonist increased the ß-AR density in B-, pan-T-, Th-, and 
TB/c-cells by - 100%, suggesting that the change in MNL subset 
distribution does not explain the increase in ß-AR of unfrac-
tionated MNL after isoproterenol infusion. Monocyte and platelet 
ß2-AR, however, were not altered by isoproterenol infusion (Fig. 
7), suggesting a lymphocyte-specific phenomenon. The affinities 
(Kd values) of ICYP (lymphocytes and monocytes) and IPIN (pla-
telets) for the ß2-AR were not affected by the isoproterenol 
infusion. 
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FIG. 8. Effects of isoproterenol 
infusion on lymphocyte ß2-adrenergic 
receptor (AR) density in 5 splenec-
toroized patients (for details see 
METHODS). Isoproterenol was infused in 
doses of 3.5, 7, 17.5, 35 and 70 
ng-kg-l min-* for 5 min each; 
immediately before infusion and after 
25 min of infusion hepannized blood 
was withdrawn for determination of 
lymphocyte ß2-*R density. Ordinate: 
lymphocyte ß2-AR density, determined 
by Scatchard analysis (46) of 
i-I^SlJ-iodocyanopindolol (ICYP) 
binding in intact cells, in ICYP 
binding sites/cell. Given are indi-
vidual data of 5 patients who had been 
splenectomized because of Hodgkin's 
disease (·, 4 patients) or trauma (o, 
1 patient). * Means ± SE of ß2-AR 
density of the 5 patients was sig-
nificantly (P < 0.05) higher after 
isoproterenol infusion vs. preinfusion 
level. 
Because the spleen is the largest source of lymphocytes in the 
body, we tried to assess the role of this organ in the isoproterenol 
infusion-induced changes in subset distribution and ß-AR density 
of circulating lymphocytes. For this purpose two patients who 
suffered from Hodgkin's disease were infused with isoproterenol 
before as well as after splenectomy and two Hodgkin's and one 
non-Hodgkin's patient, who was splenectomized because of trauma, 
were infused with isoproterenol after splenectomy only. Infusion 
of isoproterenol in the two Hodgkin's patients before splenectomy 
induced similar changes as in healthy subjects (cf. Fig. 1) : 
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ß2-AR densi ty on unfract ionated MNL increased by - 130% (from 676 
t o 1,552 ICYP binding s i t e s / c e l l ) and was accompanied by a 
r e d i s t r i b u t i o n of lymphocyte subse t s : T s /C- and NK-cell counts 
increased, whereas T h -ce l l counts decreased (data not shown). 
Thus the T h - /T s / c - ce l l r a t i o was decreased from 1.5 to 0 .7. After 
splenectomy, however, i soproterenol infusion increased ß2-AR 
densi ty on unfract ionated MNL only by - 40% (Fig. 8) and, apart 
from an increase in NK-cell number, lymphocyte subset composition 
was not affected (Table 3 ) . 
TABLE 3 . Relative distribution of monocytes and lymphocyte subsets in 5 
splenectomized patients before and after isoproterenol infusion 
Monocytes 
B-cells 
T-cells 
Th-cella 
Ts/c-cells 
NK-cells 
Th" to Ts/C -cell ratio 
Isoproterenol Infusion 
Before 
rel % 
11.2±1.9 
17.8±3.2 
55.8±2.7 
34.2±3.1 
19.0±3.0 
3.6±0.8 
1.7±0.3 
After 
rel % 
13.6±3.1 
15.6±2.7 
52.0±6.0 
26.4±3.0 
19.6±3.4 
8.4±2.4* 
1.410.2 
Values are means ± SE of 5 experiments. See Table 1 for abbrev ia t ions . 
I soproterenol was infused in doses of 3 .5 , 7, 17 .5 , 35 and 70 ng kg-^· min -^ 
for 5 mm each; immediately before infusion and a f t e r 25 min of infusion 
heparinized blood was withdrawn for determination of d i s t r i b u t i o n of monocytes 
and lymphocyte subse t s . * Ρ < 0.05 vs. corresponding preinfus ion l e v e l . 
As a further measure of functional changes in lymphocyte 
responsiveness after infusion of isoproterenol, we determined 
the in vitro proliferation of unfractionated MNL (obtained before 
and after isoproterenol infusion) in response to various con­
centrations of ConA, PHA, ATG, STE, and PWM. After isoproterenol 
infusion, the maximal increment in [3H]thymidine uptake was 
depressed by - 40-50% on PHA-, ConA-, and ATG-stimulation, 60% 
on STE-stimulation, and 70% on PWM-stimulation (Fig. 9) . However, 
a slight shift in the optimal stimulatory concentration toward 
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lower concentrations was observed for PHA (Fig. 9). We did not 
observe any alteration of the in vitro proliferation after infusion 
of norepinephrine (Fig. 10). In splenectomized patients, apart 
from a slight depression at 0.6 дд PWM/ml, the in vitro lymphocyte 
proliferative response on mitogenic stimulation was not influenced 
by isoproterenol infusion (Fig. 11). 
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FIG. 10. Effects of norepinephrine (NE) infusion (50 ng kg - 1-min - 1 for 90 
min) on in vitro proliferative response of lymphocytes on mitogen stimulation 
in 3 healthy volunteers. See FIG. 9 for abbreviations. Ordinatesi [3H)thymidine 
incorporation into lymphocytes in counts/min (cpm) χ 10-3. Abscissas: mitogen 
concentrations in μg/ml. Values are means ± SE; л = no. of experiments. 
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FIG. 9. Effects of i sopro te reno l (ISO) infusion on in v i t r o p r o l i f e r a t i v e 
response of lymphocytes on mitogen s t imula t ion in 9 heal thy vo lun tee r s . 
I sopro te renol was infused in doses of 3 .5 , 7, 17 .5 , 35 and 70 ng k g - 1 min - 1 
for 5 min each; immediately before infusion and a f t e r 25 min of infusion 
hepar inized blood was withdrawn for determination of lymphocyte response t o 
mitogen s t imu la t i on . ConA, concanavalin A; PHA, phytohemagglutinin; STE, 
staphylococcus Enterotoxin; ATG, a n t i - T - c e l l g lobu l in ; PWM, pokeweed mitogen. 
Ord ina tes : [-Ή]thymidine incorporat ion i n t o lymphocytes in counts/min (cpm) 
x 10 _ 3. Abscissas: mitogen concentrat ions in pg/ml. Values are means ± SE; η 
= no. of experiments. ** Ρ < 0 .01 , * Ρ < 0.05 vs. t h e corresponding pre infus ion 
l e v e l s . 
DISCUSSION 
I t h a s r e p e a t e d l y been r e p o r t e d by s e v e r a l g roups of i n v e s t i g a t o r s 
t h a t dynamic e x e r c i s e , menta l s t r e s s , o r exogenous c a t e c h o l a m i n e s 
can a c u t e l y i n c r e a s e t h e d e n s i t y of MNL ß-AR (12, 14-17 , 22, 29, 
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FIG. 11. Effects of isoproterenol (ISO) infusion on in vitro proliferative 
response of lymphocytes on mitogen stimulation in 5 splenectomized patients 
(for details see METHODS). Isoproterenol was infused in doses of 3.5, 7, 17.5, 
35 and 70 ng kg - 1 m m - 1 for 5 min each; immediately before infusion and after 
25 m m of infusion hepannized blood was withdrawn for determination of 
lymphocyte response to mitogen stimulation. See FIG. 9 for abbreviations. 
Ordinates: [^HJthymidme incorporation into lymphocytes in counts/min (cpm) 
x 10_3. Abscissas: mitogen concentrations in μg/ml. Values are means ± SE; η 
= no. of experiments. * Ρ < 0.05 vs. corresponding preinfusion level. 
48) . Enhanced cAMP generation in response to isoproterenol 
stimulation in vitro after dynamic exercise suggests that the 
additional ß-AR are functional(12) . In the present investigation, 
we used infusions of adrenergic agonists for a more detailed 
analysis of this phenomenon, because this allows a better control 
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of the experimental conditions. With this approach we extend the 
earlier observations by showing that the heightened MNL ß-AR 
density is found not only when assessed by radioligand binding 
to intact cells (Figs. 1 and 2) but also by binding to a plasma 
membrane preparation (Figs. 2 and 4) . These data suggest that 
the ß-AR increase is not likely to be caused by redistribution 
of receptors between cellular compartments. Measurements of 
adenylate cyclase activity in a broken cell preparation show an 
increased isoproterenol-induced cAMP generation after isopro-
terenol infusion. Thus acute catecholamine exposure elevates the 
number and responsiveness of MNL ß-AR apparently independent of 
the intracellular compartmentation of the receptors. No such 
alteration was observed with platelet and isolated monocyte ßj-AR 
in vivo, and in vitro exposure of MNL to catecholamines or 
autologous plasma obtained after isoproterenol infusion did not 
increase ß-AR density. Thus the catecholamine infusion-induced 
increase in ß-AR appears to be a lymphocyte-specific effect that 
can only be demonstrated in vivo. 
Further experiments were designed to characterize pharmaco-
logically the receptor mediating the increase in ß-AR number and 
responsiveness after acute catecholamine exposure. We have 
previously shown that acute pretreatment with propranolol can 
block this increase (14) . This and the fact that it can be elicited 
by the ß-AR agonist isoproterenol suggest mediation via a ß-AR. 
By acutely pretreating our volunteers with either the ß2-selective 
antagonist ICI 118,551 or the ß1-selective antagonist bisoprolol 
(Fig. 1), and by infusing the nonselective catecholamine epi-
nephrine and the rather ßj-selective (38) norepinephrine (Figs. 
2 and 3) , we demonstrated that the ß-AR involved is of the 
ß2-subtype. This finding is in good agreement with our previous 
observation that chronic pretreatment with ICI 118,551, but not 
bisoprolol, can also block the isoproterenol-induced increase in 
lymphocyte ß2-AR (15). 
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Isoproterenol infusion not only elevated the MNL ß-AR density 
but also caused a relative lymphocytosis (Table 1) . A similar 
lymphocytosis has been reported after injections of epinephrine 
(19) or after dynamic exercise (2, 28). The exercise-induced 
lymphocytosis (like the exercise-induced increases in MNL ß-AR) 
can be blocked by propranolol (2, 28). However, according to our 
data, the number of circulating cells is not equally increased 
in all MNL subsets. Whereas the number of total leukocytes, 
monocytes, and B-cells remains fairly constant, only the numbers 
of circulating T-cells and NK-cells increase. Among the T-cells 
Th-cells decrease, but this is more than compensated by an increase 
in the number of circulating Ts/c-cells (Table 1) . Thus the 
Th-/TB/c-cell ratio decreased. A decreased Th-/Ts/c-cell ratio 
after mental stress, dynamic exercise, or injections of 
isoproterenol or epinephrine has also been demonstrated by other 
investigators (19, 37). 
This alteration of the subset composition of circulating 
lymphocytes might contribute to the increase in MNL ß-AR, as Ts/C-
and NK-cells have significantly more ß-AR than Th-cells (see Fig. 
6 and Ref 34) . However, we demonstrated that isoproterenol infusion 
increased the ß-AR density in each subset of circulating lym-
phocytes (Fig. 6). Furthermore, a markedly attenuated increase 
in the MNL ß-AR density was observed in splenectomized patients 
(Fig. 8). We therefore conclude that the increase in MNL ß-AR 
after acute isoproterenol infusion is caused by a subset-specific 
release of lymphocytes from the spleen into the circulation and/or 
by an exchange of lymphocyte subsets between the spleen and the 
circulation, whereby freshly released splenic lymphocytes appear 
to have more ß-AR than those found in the circulation. The subset 
selectivity of this cell-mobilization process can likely be 
explained by the fact that different lymphocyte subsets are found 
in different regions of the spleen, which differ in their sym-
pathetic innervation (for a review see Ref. 27): catecholamines 
might influence the migration in (distinct regions of) the spleen 
or may act directly at the ß2-AR of specific lymphocyte subsets. 
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The still remaining slight increase in ß-AR density in the 
splenectomized patients might be explained by the fact, that 
after isoproterenol infusion NK-cells (containing a rather high 
number of ß-AR, see above) had significantly increased. Another 
possible explanation might be that lymphocytes are mobilized from 
tissues other than the spleen (thoracic duct?) but to a lesser 
extent. 
Two possibilities might account for the higher ß-AR densities 
of lymphocytes freshly released from the spleen (or other tissues) 
compared with those in the circulation. Circulating (i.e., 
extrasplenic) lymphocytes might be chronically exposed to higher 
concentrations of epinephrine, and thus have tonically downre-
gulated ß-AR. This assumption is supported by the evidence that 
treatment of healthy subjects and patients with ß-AR antagonists 
will upregulate the number of MNL ß-AR (1, 13, 15, 41). A second 
possibility arises from the functional differences between splenic 
and circulating lymphocytes. Although most circulating lympho-
cytes are in a resting state, it is possible that lymphocytes 
freshly released from the spleen might have undergone some 
preactivation. This idea is supported by the finding that activated 
lymphocytes express an enhanced responsiveness of ß-AR compared 
with resting lymphocytes (20). This elevated ß-AR responsiveness 
should render the circulating lymphocytes more susceptible to 
the antiproliferative effects of ß-AR agonists like epinephrine, 
and thus would further enhance the impairment of immune function 
by stress. 
Our investigations of the dose-response relationships between 
infused catecholamine and the increase in MNL ß-AR (Fig. 1) and 
the previous studies with dynamic exercise or mental arithmetic 
stress suggest that the above-described phenomena are not 
restricted to our experimental setting but might very well occur 
as part of the physiological stress reaction in daily life. To 
determine the relevance of such alteration for immune function, 
we assessed the in vitro proliferation of peripheral blood 
lymphocytes obtained before and after isoproterenol infusion in 
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response to various mitogens (Fig. 9). After infusion of 
isoproterenol but not after norepinephrine (Fig. 10) lymphocyte 
proliferation in response to each mitogen was reduced by at least 
40% (Fig. 9). A reduced mitogenic response to PHA, ConA and PWM 
has also been reported after epinephrine injections (18). Thus, 
after acute increases in plasma catecholamines (endogenously or 
exogenously), immune responsiveness seems to be impaired. This 
appears to be a transient effect as lymphocyte mitogen respon-
siveness had returned to predrug values 2 h after the injection 
of epinephrine (18). Whether the reduced mitogenic response of 
the lymphocytes after isoproterenol infusion is because of the 
increased ß-AR number or reflects an intrinsic reduction in the 
mitogenic responsiveness of the freshly released lymphocytes 
remains to be elucidated in further studies. 
We conclude that the previously observed increase in MNL ß2-AR 
number and responsiveness does not represent receptor regulation 
but instead is a lymphocyte specific phenomenon; it is obviously 
caused by a release of lymphocyte subsets from secondary lymphoid 
organs into the circulation and/or by an exchange of lymphocyte 
subsets between secondary lymphoid organs and the circulation, 
whereby freshly released lymphocytes appear to carry more ß2-AR 
than those found in the circulation. Isoproterenol infusion (and 
probably also endogenous acute sympathetic stimulation) appears 
to impair immune responsiveness in a dual manner: by increasing 
the relative and absolute number of Ts/c-cells, and by making the 
circulating T-cells more responsive to inhibitory effects of 
ß-adrenergic stimulation in the face of elevated plasma 
catecholamines. The effect of chronically elevated sympathetic 
activity on immune function remains to be determined. 
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CHAPTER 3. Effects of insulin-induced hypoglycemia on ß2-adre-
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Abstract 
We studied the effects of insulin (0.1 lU/kg BW, iv)-induced 
hypoglycemia on lymphocyte ß2-adrenoceptor function, lymphocyte 
subset distribution, and proliferative response to mitogen 
stimulation in 10 healthy volunteers. Thirthy minutes after 
insulin injection plasma glucose levels were markedly decreased; 
concomitantly, plasma epinephrine levels had increased about 
10-fold; plasma norepinephrine levels, however, increased only 
moderately. Lymphocyte ß2-adrenoceptor density and the cAMP 
response to 10 дтоІ/Ь isoproterenol stimulation were elevated; 
lymphocyte T
s
/
c
-cells had increased, whereas Th-cells had 
decreased, resulting in a decrease in the Th-/Ts/c-cell ratio 
from 1.7 to 1.0. These changes were accompanied by a significantly 
reduced lymphocyte proliferative response (measured as 
[3H]thymidine uptake) to mitogen stimulation. Two hours after 
insulin injection plasma catecholamines, lymphocyte ß2-adreno-
ceptor function, lymphocyte subset distribution, and prolife-
rative responses had returned to nearly preinsulin levels. We 
conclude that acute vigorous increases in endogenous epinephrine 
evoked by insulin-induced hypoglycemia are associated with 
increases in lymphocyte ß2-adrenoceptor function, redistribution 
of lymphocyte subsets, and an (at least transiently) attenuated 
in vitro immune responsiveness. 
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Introduction 
Determination of ß-adrenoceptors on circulating mononuclear 
leukocytes (MNL) is a frequently used approach to assess 
ß-adrenoceptor function in man (1-3). However, this model is of 
limited value because of two major reasons. 1) Circulating MNL 
contain a homogeneous population of ß2-adrenoceptors; thus, 
changes in these receptors might not adequately reflect changes 
in ßj-adrenoceptors (4-6). 2) Acute exposure of MNL to cate-
cholaminergic agonists іл vivo causes, in contrast to what has 
been observed in all other model systems, not a decrease, but a 
rapid increase in ß2-adrenoceptor number (7-11). This is a 
ß2-adrenoceptor-mediated effect, as it can be inhibited by the 
ß2-adrenoceptor antagonist ICI 118,551, but not by the ß1-adre-
noceptor antagonist bisoprolol (9,10). 
On the other hand, evidence has accumulated in man that the 
function of the immune system might be influenced by the sym-
patho-adrenal system, possibly via interaction with MNL 
ßj-adrenoceptors (12). Thus, in vitro stimulation of MNL 
ß2-adrenergic (by isoproterenol) and other adenylate cyclase-
linked receptors can inhibit MNL proliferation, mitogen-induced 
secretion of interleukin-2, and expression of interleukin-2 
receptors (13-18). ß-Adrenoceptor agonists might also have an 
antiproliferative effect in vivo, since we have recently shown 
that in healthy volunteers after isoproterenol, but not nore-
pinephrine, infusion the proliferative response of circulating 
MNL to various mitogens was markedly attenuated (10). 
Taken together, these findings suggest effects of 
catecholamines on MNL function; however, these effects have 
generally been investigated at rather high (nonphysiological) 
concentrations of the catecholamines. Whether (patho)physio-
logical elevations in plasma catecholamines may have similar 
effects on MNL function is still an open question. To answer this 
question we have determined in healthy volunteers the effects of 
insulin-induced hypoglycemia, known to vigorously elevate plasma 
epinephrine levels, on MNL ß2-adrenoceptor number and on the MNL 
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in vitro proliferative response to stimulation with the mitogens 
phytohemagglutinin (PHA), Concanavalin-A (Con-A), pokeweed 
mitogen (PWM), anti-T-cell globulin (ATG), and Staphylococcus 
enterotoxin (STE). 
Materials and Methods 
•Experimental protocol 
Ten healthy volunteers (eight males and two females, aged 
25-38 yr; mean age, 30.6 ± 3.1 yr) participated in the study 
after having given informed written consent. All subjects were 
physicians at the Department of Internal Medicine of the University 
of Essen Medical School. They were drug free and had undergone 
physical examination to exclude asthma, chronic pulmonary disease, 
diabetes mellitus, hypertension, cardiac disease, and other 
symptoms referable to the cardiovascular system. At 0800 hour an 
indwelling cannula was inserted into a forearm vein. In the 
opposite forearm a needle was placed into a large vein and kept 
patent with infusion of 0.9% saline. After an initial rest period 
of 30 min in the supine position insulin (0.1 lU/kg BW) or 1 mL 
0.9% saline was injected iv via the cannula. Immediately before 
injection (0 min) and 30, 60, 90, and 120 min after injection 
blood samples were withdrawn after first flushing saline from 
the infusion needle with about 3 mL blood. For determination of 
plasma catecholamines and MNL ß2-adrenoceptors blood was anti-
coagulated with EDTA, for determination of blood glucose levels 
with sodium citrate (1 mL 3.2% sodium citrate/10 mL blood), and 
for assessment of mononuclear cell function and analysis of MNL 
subsets with heparin (500 IU heparin/10 mL blood). Blood pressure 
and heart rate were recorded automatically by a Tonomed (Speidel 
and Keller, Jungingen, West Germany) and an electrocardiogram. 
Cell isolation 
MNL were prepared from whole blood by Ficoll gradient 
centrifugation according to the method of Böyum (19) with minor 
modifications (10). 
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Determination of 32-adrenoceptors 
MNL ß2-adrenoceptors were identified in intact cells by 
radioligand binding with (-) -[125I]iodocyanopindolol (ICYP) at 
six concentrations of ICYP ranging from 10-150 pmol/L in the 
presence and absence of 1 /imol/L (±)CGP 12177 (20). The accu-
mulation of cAMP in intact cells during a 15-min incubation in 
the absence and presence of 10 μιηοΐ/ΐι isoproterenol was measured 
according to previously described techniques (20). 
Functional MNL tests 
Mononuclear cell function was monitored by the ability of 
cells to proliferate upon mitogenic stimulation with PHA (3.6, 
1.8, 0.9 and 0.4 5 pg/mL), Con-A (36, 18, 9 and 4.5 ßg/mh), PWM 
(4.6, 2.3, 1.14 and 0.6 Mg/mL), ATG (360, 180, 90 and 45 Mg/mL) 
and STE (0.18, 0.09, 0.045 and 0.0225 μg/mL). Cells were cultured 
for 4 days at 37 "С in microtiter plates containing the mitogens 
in 220 μ!. RPMI-1640 with 0.29 mg/mL L-glutamine, 0.16 mg/mL 
gentamycin-sulfate, and 10% heat-inactivated pooled human serum 
at 2 χ 105 cells/well. For the last 16 h the cultures were labeled 
with 2 μ€ί [3H]thymidine/well. The cells were harvested with a 
multiple sample precipitator (Skatron, Lier, Norway), and 
incorporated radioactivity was assessed in a liquid scintillation 
counter (LKB 1212, Freiburg, West Germany). 
Analysis of MNL subsets 
MNL subsets were analyzed by indirect immunofluorescence 
with monoclonal antibodies (OKT3, Jot3 and Leu5b for pan-T cells; 
Jot4a, Leu3 and BMA040 for Th-cells; Jot8a, Leu2 and TÜ102 for 
Ts/c-cells; TÜ39 and aDR for B-cells; JotlO and Leu7 for NK-cells; 
Tük-1 for monocytes; fluorescein isothiocyanate (FITC)-labeled 
goat antimouse immunoglobulin G (IgG) plus IgM was used as the 
second antibody). In short, MNL were incubated with appropriate 
dilutions of monoclonal antibody for 40 min, washed, labeled with 
FITC-conjugated goat antimouse antibody for 40 min and washed; 
all procedures were performed at room temperature. Cells were 
scanned within 2 h under a Zeiss fluorescence microscope (Zeiss, 
Oberkochen, West Germany). 
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Plasma catecholamines were assessed by a high performance 
liquid chromatographic method with electrochemical detection. 
Data evaluation 
The maximal number of binding sites for ICYP binding was 
calculated from plots according to the method of Scatchard (21) . 
The experimental data given in text, figures and the table are 
the mean ± SEM of η experiments. Statistical significance of 
differences was estimated by two-tailed Student's t-test for 
paired data; Ρ < 0.05 was considered significant. 
Materials 
ICYP (SA, 2200 Ci/mmol) and a RIA for cAMP were purchased 
f rom New England Nuclear (Dreieich, West germany) and [3H] thymidine 
(5 Ci/mmol) from Amersham (Braunschweig, West Germany). Insulin 
(H-Insulin-Hoechst) was obtained from Hoechst (Frankfurt/Main, 
West Germany). 
(±)CGP 12177 hydrochloride [4-(3-tertiarybutylamino-2-hyd 
roxy-propoxy)benzimidazole-2-one] was provided by Ciba-Geigy 
(Basel, Switzerland). RPMI-1640, L-glutamine and gentamy-
cin-sulfate were obtained from Nunc (Wiesbaden, West Germany). 
PHA was from Welcome (Beckenham, United Kingdom), Con-Α from 
Sigma (Deisenhofen, West Germany), PWM from Boehringer (Mannheim, 
West Germany), ATG from Fresenius (Oberursel, West Germany), and 
STE from Serva (Heidelberg, West Germany). All other chemicals 
were from Sigma and of the highest purity grade available. 
FITC-coupled goat antimouse IgG plus IgM was purchased from 
Medac (Hamburg, West Germany) . Monoclonal antibodies were obtained 
from the following sources (specifications in parentheses): 0KT3 
(CD3) from Ortho Diagnostic Systems (Neckargemiind, West Germany) ; 
Jot3 (CD3), Jot4 (CD4), Jot8 (CD8) and JotlO (NK-cell marker) 
from Immunotech Dianova (Hamburg, West Germany); Leu2 (CD8), Leu3 
(CD4), Leu5b (CD2), Leu7 (NK-cell marker) and aDR (class II) from 
Becton Dickinson (Heidelberg, West Germany), BMA040 (CD4) from 
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Behring (Frankfurt/Main, West Germany); Tük-1 (CDllb), TÜ39 (class 
II) and TÜ102 (CD8) were kindly provided by Dr. Ziegler (Tübingen, 
West Germany). 
Results 
Thirty minutes after iv injection of insulin, blood glucose 
levels had decreased from 4.27 ± 0.17 to 1.44 + 0.33 mmol/L (Fig. 
1). Concomitantly, systolic blood pressure and heart rate 
increased significantly, whereas diastolic blood pressure fell 
by about 20 mm Hg (Fig. 2) . Plasma epinephrine had increased 
almost 10-fold (from 309 ± 82 to 3400 ± 1365 pmol/L); plasma 
norepinephrine, however, only moderately increased (from 1.91 ± 
0.26 to 2.77 ± 0.45 nmol/L; Fig. 1). During the following 90 min, 
blood glucose, plasma catecholamines, and heart rate returned to 
predrug levels. Physiological saline solution, on the contrary, 
had no significant effect on any of these parameters. 
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FIG. 1. Effects of insulin (0.1 lU/kg BW, iv) or 0.9% NaCl on blood glucose, 
plasma norepinephrine, and plasma epinephrine levels in 10 healthy volunteers. 
Ordinates from top to bottom, Blood glucose in millimoles per L, plasma 
norepinephrine levels in nanomoles per L, and plasma epinephrine levels in 
picomoles per L. Abscissae, Time after insulin or NaCl injection in minutes. 
Given are the mean ± SEM of 10 experiments. **, Ρ < 0.01; *, Ρ < 0.05 (vs. 
the corresponding predrug levels). 
The effects of insulin-induced hypoglycemia on ß2-adrenoceptors 
on MNL are shown in Fig. 3; 30 min after insulin injection (i.e. 
at a time when plasma epinephrine levels had markedly increased) 
ß2-adrenoceptor density was increased by about 150%. This increase 
in receptor density was associated with a similar increase in 
the 10 μιηοΙ/L isoproterenol-induced in vitro increase in 
intracellular cAMP, indicating that the increase in ß2-adreno-
ceptor number was an increase in real functional receptors. During 
the following 90 min, both MNL ß2-adrenoceptor density and cAMP 
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and hear t r a t e in 10 heal thy v o l u n t e e r s . Ordmates from top to bottom, S y s t o l i c 
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Time a f t e r i n s u l i n or NaCl i n j e c t i o n in minutes . Given are t h e mean ± SEM of 
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r e s p o n s e t o 10 μιηοΐ/ΐ, i s o p r o t e r e n o l r e t u r n e d t o p r e d r u g l e v e l s 
( F i g . 3) , a s d i d plasma c a t e c h o l a m i n e s (cf . F i g . 1) . P h y s i o l o g i c a l 
s a l i n e s o l u t i o n , on t h e o t h e r hand, had no s i g n i f i c a n t e f f e c t on 
MNL ß2 - ad renocep to r d e n s i t y or t h e 10 μιηοΙ/L i s o p r o t e r e n o l - i n d u c e d 
i n v i t r o i n c r e a s e i n CAMP ( F i g . 3 ) . 
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density and 10 |jmol/L isoproterenol (ISO)-evoked in vitro cAMP increase in 
five healthy volunteers. Ordinates, upper panel, MNL ß2-adrenoceptor density, 
determined by Scatchard analysis (21) of ІСУР binding in intact cells, in 
ICYP-binding sites per cell; lower panel, 10 μπιοΐ/ί isoproterenol-evoked m 
vitro increase m MNL cAMP content in picomoles cAMP per 10 6 cells. Abscissae, 
Time after insulin or NaCl injection in minutes. Given are the mean ± SEM of 
five experiments. **, Ρ < 0.01; *, Ρ < 0.05 (vs. the corresponding predrug 
levels). 
Analysis of MNL subsets revealed that, apart from a slight 
increase in B-cells 30 min postinjection, there were no changes 
in the relative percentages of total T-lymphocytes, B-lymphocytes, 
or monocytes after insulin administration (Table 1). The per­
centage of Τ,,-cells, however, declined from 35.0 before insulin 
injection to 25.6 and 28.8 30 and 60 min postinjection, 
respectively, and returned to baseline by 120 min. On the contrary, 
the percentage of T
s
/
c
-cells increased from 21.8 before insulin 
injection to 27.4 and 28.0 30 and 60 min postinjection, 
respectively, and returned to nearly baseline by 120 min (Table 
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1) . Accordingly, the T h -/T B / c -cel l r a t i o decreased from 1.7 before 
i n j e c t i o n t o 1.0 and 1.1 30 and 60 min post inj e e t ion, r e s p e c t i v e l y , 
and then increased to 1.5 120 min pos t in jec t ion (Table 1) . The 
percentage of NK-cells increased from a basel ine of 4.0 t o 6.6 
and 6.0 30 and 60 min p o s t i n j e c t i o n , re spect ive ly , and decl ined 
t o 4.8 120 min p o s t i n j e c t i o n (Table 1) . 
TABLE 1. Re la t ive d i s t r i b u t i o n of monocytes and lymphocyte subsets in f ive 
healthy sub ject s before and a f t e r i n s u l i n i n j e c t i o n (0.1 lU/kg BW) 
Monocytes 
B-cells 
T-cells 
Th-cells 
T
s
/
c
-cells 
NK-cells 
Th-to-TB/c cell ratio 
Before 
relative % 
5.211.3 
14.6±2.0 
64.2+2.8 
35.0±2.7 
21.8±2.6 
4.0±1.0 
1.7+0.3 
After insulin 
30 min 
relative % 
5.2+1.5 
16.8±2.1a 
62.212.9 
25.6+2.9b 
27.4+3.5 
6.6il.3a 
i.oio.Ia 
60 min 
relative % 
6.012.0 
13.611.9 
65.013.5 
28.8i2.3b 
28.0i2.2b 
6.0+1.0b 
1.1+0.Ia 
120 min 
relative % 
4.010.9 
17.013.1 
64.512.9 
34.3+1.5 
24.312.7 
4.811.1 
1.5+0.2 
Given are t h e mean 1 SEM of five experiments. 
a
 Ρ < 0.05 vs. t h e corresponding p r e i n s u l i n l e v e l s . 
k Ρ < 0.01 vs. t h e corresponding p r e i n s u l i n l e v e l s . 
Finally we assessed the effects of insulin-induced hypoglycemia 
on mononuclear cell function. For this purpose we measured the 
proliferative in vitro responses of unfractionated MNL to various 
concentrations of the mitogens PHA, Con-Α, PWM, ATG, and STE. As 
shown in Fig. 4, 30 and 60 min after insulin injection the maximal 
[3H]thymidine incorporation into MNL was significantly reduced 
upon stimulation with all mitogens investigated, whereas 120 min 
after insulin injection the responses had returned to nearly 
predrug levels. 
Discussion 
Tohmeh and Cryer (7) were the first to report that short 
term infusion of isoproterenol or epinephrine into healthy 
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volunteers causes an increase in the density of MNL ß2-adreno-
ceptors. We recently showed that this isoproterenol-induced 
increase in MNL ß2-adrenoceptor density can be antagonized by 
the selective ß2-adrenoceptor antagonist ICI 118,551, but not by 
the selective ß-^adrenoeeptor antagonist bisoprolol, demon-
strating that the ß-adrenoeeptor involved in this process is of 
the ß2-subtype (9,10). This conclusion is further supported by 
the fact that infusion of epinephrine, but not of an equal dose 
of (the rather ß^^-selective) norepinephrine caused similar 
increases in MNL ß2-adrenoceptors (10). 
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In the present study we wanted to determine whether such 
changes in MNL ß2-adrenoceptor function can be achieved not only 
by exogenously applied ß-adrenoceptor agonists used in rather 
high (nonphysiological) doses but also by (patho)physiological 
elevations of endogenous catecholamines. For this purpose we have 
used insulin-induced hypoglycemia, since this is known to be the 
most powerful stimulus to rapidly release epinephrine from the 
adrenal medulla. In fact, the marked decrease in plasma glucose 
levels 30 min after iv injection of insulin was associated with 
an about 10-fold increase in plasma epinephrine, but an only 
modest increase in plasma norepinephrine. The vigorous increase 
in plasma epinephrine was accompanied by about a 150% increase 
in MNL ß2-adrenoceptor number and MNL in vitro cAMP response to 
10 ßmol/h isoproterenol stimulation, increases comparable with 
(or higher than) those evoked by infusion of exogenous epinephrine 
or isoproterenol (10). A similar rapid acute increase in MNL 
ß2-adrenoceptors associated with rapid elevation of plasma 
epinephrine levels has recently been also observed in a patient 
with pheochromocytoma during a hypertensive crisis (22) . Taken 
together, these data strongly suggest that not only exogenously 
applied catecholamines, but also (patho)physiological increases 
in endogenous epinephrine can evoke marked increases in MNL 
ß2-adrenoceptor function. 
The rapid increase in MNL ß2-adrenoceptor density after 
acute ß-adrenergic stimulation with isoproterenol or epinephrine 
appears to be a lymphocyte-specific effect, since 1) it is not 
seen for ß2-adrenoceptors on monocytes or platelets (10), and 2) 
it has been demonstrated in rats that 15 min after isoproterenol 
injection pulmonary ß-adrenoceptor density is decreased (23) . We 
have recently shown that infusion of isoproterenol not only 
acutely increases MNL ß2-adrenoceptor density, but also causes 
a redistribution in MNL subsets (10). Thus, after isoproterenol 
infusion the percentages of Te/C- and NK-cells increased, whereas 
that of Th-cells decreased, resulting in a reduced Th-/Ts/c-cell 
ratio. As shown in Table 1, very similar changes in lymphocyte 
subsets occurred during insulin-induced hypoglycemia; 30 and 60 
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min after insulin application (i.e. at a time when plasma epi-
nephrine levels were elevated), the relative amount of Th-cells 
was decreased, and that of Tg/C- and NK-cells was increased, 
resulting in a diminished Th-/Ts /c-cell ratio. A decreased 
Th-/Ts/c-cell ratio after insulin-induced hypoglycemia as well 
as after epinephrine injection has also been demonstrated by 
other investigators (24-26) . 
As Tg/C- and NK-cells have nearly twice as many ß-adrenoceptors 
as Th-cells (10,27,28), such a redistribution may well contribute 
to the rapid increase in ß2-adrenoceptor density in unfractionated 
MNL during insulin-induced hypoglycemia. However, redistribution 
of lymphocyte subsets cannot completely explain the marked 
increase in MNL ß2-adrenoceptor density observed in the present 
study because 1) the increase is much higher than could be achieved 
assuming that it is only caused by redistribution, and 2) we 
recently demonstrated that after isoproterenol infusion (which 
increased MNL ß2-adrenoceptors to a similar extent) ß-adrenoceptor 
density in each subset had increased as well. On the other hand, 
in splenectomized patients the increase in MNL ß2-adrenoceptors 
after isoproterenol infusion was markedly blunted (10). Taken 
together, these results indicate that the marked increase in MNL 
ß2-adrenoceptor density after infusion of high (nonphysiological) 
doses of epinephrine or isoproterenol or accompanying the vigorous 
(patho)physiological increases in plasma epinephrine evoked by 
insulin-induced hypoglycemia is due to subset-specific release 
of lymphocytes from the spleen into the circulation; the lym-
phocytes obtained from peripheral blood after this vigorous acute 
catecholamine exposure obviously contain more ß-adrenoceptors 
than those present in the circulation before the catecholamine 
exposure (10). 
In the present study the insulin-induced acute increase in 
plasma epinephrine was not only accompanied by heightened MNL 
ß2-adrenoceptor density and redistribution of MNL subsets, but 
also by an attenuated proliferative response of MNL to various 
mitogens, as could be expected from the decrease in the 
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Th-/T8/c-cell ratio. Again, this effect is in very good agreement 
with our recent observation that after isoproterenol infusion 
into healthy volunteers the Th-/Tg/rc-cell ratio is decreased, and 
the mitogenic response of MNL to PHA, Con-Α, ATG, STE, and PWM 
is reduced (10). As the present results show, this appears to 
be, however, a transient effect; 30 and 60 min after insulin 
injection, when plasma epinephrine levels are markedly elevated, 
the mitogenic response was reduced, while after 120 min, when 
epinephrine levels had decreased to predrug values, the mitogenic 
response had nearly returned to predrug response. 
In conclusion, the present results demonstrate that acute 
increases in catecholamines (regardless of whether exogenously 
applied or endogenously elevated) generally lead to an increase 
in MNL ß2-adrenoceptor function. These changes are accompanied 
by a (spleen-dependent) redistribution of lymphocyte subsets and 
an (at least transiently) attenuated іл vitro immune respon­
siveness. Whether such transient changes in circulating lymphocyte 
subsets have any effect on immune responsiveness in vivo, however, 
remains to be elucidated in future experiments. Hypoglycemia is 
a commonly occurring phenomenon in insulin-dependent diabetic 
patients. Although the immunological parameter studied is only 
a crude assessment of immunocompetence (lymphocyte enumeration) 
and is of uncertain significance in regard to disease sus­
ceptibility, it might contribute to the frequent infections in 
insulin-dependent diabetic patients or other patients with acutely 
or chronically heightened sympathetic activity. Further under­
standing of the interaction between the sympatho-adrenal and the 
immune system may enable the development of new therapeutic 
approaches for immunological and inflammatory disorders in man. 
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CHAPTER 4. Cyclic ΑΗΡ counteracts mitogen-induced inositol 
phosphate generation and increases in intracellular 
Ca2+-concentrations in human lymphocytes 
"Lambertus J. H. van Tits, "'Martin С. Michel, 'Harvey J. Motulsky, 
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phates, calcium, human lymphocytes, immunoregulation 
1) The effects of increases in intracellular adenosine 
3',5'-cyclic monophosphate (cyclic AMP) on mitogen-induced 
generation of inositol phosphates and increases in intracellular 
Ca 2 + concentration were investigated in human peripheral blood 
mononuclear leukocytes (MNL). 
2) The mitogens concanavalin A (Con A ) , pokeweed mitogen (PWM) 
and phytohemagglutinin (PHA) concentration-dependently stimu­
lated generation of inositol phosphates. Catecholamines inhibited 
this process with an order of potency: isoprenaline > adrenaline 
> noradrenaline indicating involvement of ß2-adrenoceptors. This 
order of potency was also consistent with the catecholamine 
potencies for stimulating the generation of cyclic AMP. 
3) In addition to catecholamines the cyclic AMP formation-sti-
mulating agents prostaglandin Ει (PGE^ and forskolin concen­
tration-dependently inhibited mitogen-induced inositol phosphate 
generation, too. Moreover, the inhibitory effect of isoprenaline 
was potentiated by co-incubation with the phosphodiesterase 
inhibitor isobutylmethylxanthine demonstrating that these 
inhibitory effects were mediated by cyclic AMP. 
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4) Con A and PHA concentration-dependently increased the 
intracellular Ca 2 + concentration in human MNL (assessed by the 
fluorescent indicator dye Fura-2). This increase was almost 
completely blocked by chelation of extracellular Ca++, demon­
strating influx rather than mobilization from intracellular 
stores. 
5) The elevation of intracellular Ca2+ was not blocked by 
pre-treatment with pertussis toxin, 100 ng ml - 1 for 16 h. 
6) Isoprenaline, PGE^ and forskolin, however, inhibited the 
mitogen-stimulated elevation of intracellular Ca2+. This inhi­
bition was enhanced by the phosphodiesterase inhibitors isobu-
tylmethylxanthine and Ro 20-1724, demonstrating mediation by 
cyclic AMP. 
7) We conclude that catecholamines and other cyclic AMP increasing 
agents can inhibit mitogen-stimulated generation of inositol 
phosphates and elevation of intracellular Ca 2 + in resting human 
MNL. Since generation of inositol phosphates and increases in 
intracellular Ca2+ are very early events in activation of MNL, 
attenuation of these events might well contribute to the inhibitory 
effect of cyclic AMP on MNL function. 
Introduction 
The function of the immune system is regulated by various 
neurotransmitters and hormones. Of special interest are those 
agents which elevate lymphocyte adenosine 3',5'-cyclic mono­
phosphate (cyclic AMP) concentrations because they can inhibit 
lymphocyte function in multiple ways іл vitro (for reviews see 
Bourne et al., 1974; Feiten et al., 1987; Kammer, 1988). For 
example, it has been demonstrated that cyclic AMP increasing 
hormones can inhibit mitogen-stimulated lymphocyte proliferation, 
antibody formation by B-cells, and cytolytic activity of T-cells. 
These inhibitory effects of cyclic AMP formation stimulating 
hormones are mediated by cyclic AMP because they can also be 
elicited by receptor-independent stimulation of cyclic AMP 
formation (e.g. by the diterpene forskolin) and by compounds 
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mimicking cyclic AMP (e.g. 8-Br-cyclic AMP). Moreover, some data 
suggest that cyclic AMP increasing agents can also impair immune 
function in vivo. For example it has been shown that prolonged 
exposure to ß-adrenoceptor agonists can decrease the number of 
thymocytes in mice (Durant, 1986) and of circulating lymphocytes 
in man (Maisel et al., 1990). 
The activation of resting lymphocytes is a multistep process 
involving early biochemical alterations such as formation of 
inositol phosphates and increases in intracellular Ca2+ leading 
to activation of a protein kinase C, which occur during the first 
seconds and minutes of lymphocyte activation (Tsien et al., 1982; 
Wolff & Akerman, 1982; Taylor et al., 1984, Sugiura Ь Waku, 1984; 
Chen et al., 1986; Cambier et al., 1987; Hadden, 1988). These 
early alterations are followed within a couple of hours by later 
events such as secretion of interleukin-2 (11-2), and expression 
of 11-2 receptors and certain oncogenes. This second wave of 
biochemical events can also be inhibited by elevations of 
intracellular cyclic AMP (Feldman et al., 1987; Mary et al., 
1987; Johnson et al., 1988; Kammer, 1988). As secretion of 11-2 
and expression of 11-2 receptors depend on an elevation of 
intracellular Ca2+ and an activation of a protein kinase С (Cambier 
et al., 1987; Hadden, 1988), it is possible that cyclic AMP 
formation stimulating agents inhibit lymphocyte activation by 
attenuating the generation of these early biochemical signals. 
Therefore, we have investigated the effects of various cyclic 
AMP formation stimulating agents on the mitogen-stimulated 
generation of inositol phosphates and increases of intracellular 
Ca2* in resting human mononuclear leukocytes (MNL, mostly lym­
phocytes) , with special emphasis on the effects of ß-adrenoceptor 
agonists. 
Methods 
Mononuclear leukocyte preparation 
Mononuclear leukocytes (MNL), containing >95% lymphocytes, were 
prepared from the venous blood of healthy young volunteers 
according to the method of Böyum (1968). In some experiments, 
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MNL were cultured in RPMI medium supplemented with 20% foetal 
calf serum, 2 mM glutamine and 25 ßg ml-1 gentamycin in the absence 
or presence of 100 ng ml-1 pertussis toxin for 16-20 h prior to 
the Ca2+ measurements. These cells were washed twice in buffer 2 
h before the Ca2+ measurements in order to remove the pertussis 
toxin. 
Cyclic AMP measurements 
Accumulation of cyclic AMP was measured in intact MNL according 
to previously published techniques (Brodde et al. , 1985) . Briefly, 
MNL were suspended in phosphate buffered saline containing 0.1 
mM theophylline (in order to inhibit cyclic AMP degradation by 
phosphodiesterases) and 0.025% bovine serum albumin. Aliquots of 
300 μΐ (2xl06 cells) were incubated for 15 min at 37 0C in the 
presence or absence of indicated stimuli, in a total volume of 
330 μΐ. Incubation was terminated by boiling for 5 min. After 
cooling, samples were centrifugea at 12,000 g for 10 min, and 
cyclic AMP content was determined in 50 μΐ aliquots of the 
supernatant by radioimmunoassay. 
In some experiments MNL were preincubated with mitogens for 
15 min at 370C before theophylline (0.1 mM final concentration) 
and isoprenaline were added. Incubations were continued for 
another 15 min, and then stopped and samples processed as described 
above. 
Inositol phosphate generation 
Generation of inositol phosphates was determined according to 
published techniques (Minneman & Johnson, 1984) with minor 
modifications. MNL were suspended in Krebs-Henseleit solution 
containing (mM) : NaCl 118, KCl 4.7, CaClj 1.3, MgS04 1.2, KH2P04 
1.2, NaHC03 24.9, glucose·H2O 11, EDTA 1 μΜ and 0.1% bovine serum 
albumin, equilibrated with 95% 02/5% COj at 37 0C. Cells were 
incubated with [3H]-myo-inositol (10 μΟί ml - 1 with 3xl07 cells 
ml-1) for 2 hours at 37 0C. Thereafter, the cells were washed and 
resuspended in Krebs-Henseleit solution supplemented with 10 mM 
LiCl (to block inositol phosphate breakdown). Aliquots of this 
cell suspension (450 μΐ containing 5xl06 cells) were preincubated 
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for 15 min under 95% 02/ЪЧ COj; thereafter 50 μΐ of drug solution 
(mitogens in the presence or absence of cyclic AMP formation 
stimulating agents) was added. Samples were incubated for another 
30 min at 37 0C, and the reaction was stopped by addition of 1.5 
ml chloroform-methanol (1:2, v:v). Each sample was mixed tho­
roughly 4 times in a period of 1 hour, 0.5 ml of chloroform and 
0.5 ml of water added sequentially, mixed again twice and 
centrifuged at 3000 g for 12 min to separate the phases. Columns 
containing 1 ml of a 1:1 slurry of Dowex AG 1-X8 anion exchange 
resin (200-400 mesh) in the formate form, previously stored in 
0.1 M formic acid, were washed twice with 10 ml of 10 mM Tris-formate 
(pH 7.4) and once with 7 ml water. Aliquots of 1.5 ml of the 
upper phase of each sample were filled up to 5 ml with water and 
poured on the columns. After washing the columns with 5 ml of 
water and twice with 5 ml of 25 mM ammonium formate successively 
(to elute remaining [3H]-inositol), the [3H]-inositol phosphates 
retained on the columns were eluted with 1 ml of 2 M ammonium 
formate dissolved in 0.1 M formic acid; thus the eluate contained 
a mixture of inositolmonophosphate, -bisphosphate and -tris-
phosphate in which inositolmonophosphate is the major constituent 
(accumulating from breakdown of the other phosphates in the 
presence of LiCl). Scintillation fluid (9 ml) was added to the 
eluent and the samples were counted in a Beekman LS 9000 liquid 
scintillation counter (Beekman Inst., Fullerton, CA) at an 
efficiency of about 42%. Following each experiment, the columns 
were regenerated with 2 ml of 2 M ammonium formate dissolved in 
0.1 M formic acid and 2 ml of 1 M formic acid, washed with 10 ml 
of 10 mM Tris-formate (pH 7.4) and stored in 0.1 M formic acid. 
With this regeneration procedure, the columns could be used for 
up to 2 months without any loss of capacity. 
Ca 2 + measurements 
Intracellular Ca 2 + concentrations were measured with the fluor­
escent dye Fura-2 according to standard procedures previously 
described in detail (Motulsky ft Michel, 1988) . Briefly, loading 
of the cells with Fura-2 and the subsequent fluorescence 
measurements were performed at room temperature in buffer con-
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taining (mM) : NaCl 120, KH2P04 5, Мд(СНзСОО)2 l, СаС12 1, Hepes 
20 and glucose 1 mg ml - 1 at pH 7.4. Our calculations to convert 
raw fluorescence data into intracellular Ca 2 + concentrations 
included correction factors for dilution of cells by addition of 
drugs (1-2%), and for the presence of extracellular Fura-2 
(accounting for 10-25% of the total fluorescence), and (in some 
experiments) the presence of EGTA. Experiments at 37eC yielded 
qualitatively similar but more variable results as more dye leaked 
out of the cells; this dye leakage was attenuated by addition of 
2.5 mM probenecid but even under those conditions it accounted 
for at least 50% of total fluorescence after an incubation period 
of more than 10 min (data not shown). 
Chemicals 
Myo-[2-3H(N)]-inositol (specific activity 20 Ci mmol-1) and a 
radioimmunoassay for cAMP were purchased from New England Nuclear 
(Dreiech, FRG) and Amersham (Braunschweich, FRG), respectively. 
ICI 118,551 (erythro-(±)-1-(7-methylindan-4-yloxy)-3-isopropyl 
aminobutan-2-ol) was a gift from ICI-Pharma (Plankstadt, FRG), 
CGP 20712A (l-[2-((3-carbamoyl-4-hydroxy)phenoxy)ethylamino]-3 
-[4-(l-methyl-4-trifluoromethyl-2-imidazolyl)phenoxy]-2-propan 
ol methanesulphonate) from Ciba Geigy (Basel, Switzerland), Ro 
20-1724 (4-(3,4-dibutoxybenzyl)-2-imidazolidinone) from 
Hoffman-La Roche (Basel, Switzerland), and nifedipine from Pfizer 
(New York, N.Y., U.S.A.). Dowex AG 1-X8 anion exchange resin 
(200-400 mesh, formate form) was obtained from Bio-Rad Labora­
tories (Richmond, VA, U.S.A.), Fura-2 acetoxymethoxyester was 
obtained from Molecular Probes (Eugene, OR, U.S.A.), forskolin 
was from Calbiochem (La Jolla, CA, U.S.A.), and pertussis toxin 
from List (Campbell, CA, U.S.A.). Phytohaemagglutinin (PHA) for 
the experiments on cyclic AMP and inositol phosphate generation 
was from Welcome (Beckenham, U.K.), and the PHA for the Ca2"1-
experiments was from Sigma (St Louis, MO, U.S.A.); these two 
preparations differ with respect to their purity grades and, 
therefore, their potencies. Pokeweed mitogen (PWM) was from 
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Boehringer (Mannheim, FRG), concanavalin A (Con A) and all other 
Chemicals were from Sigma and of the highest commercially available 
purity grade. 
Data analysis 
Maximum and the half-maximal effective concentrations of agonists 
were calculated from concentration-response curves by fitting 
the experimental data to a sigmoid curve by computer-assisted 
non-linear regression analysis. To obtain optimal estimates for 
the maximal effect and the concentration of agonist causing 50% 
of the maximal effect (EC50) , the Hill-slope and the bottom of 
the curve were fixed at 1 and the measured basal value, 
respectively, during the curve fitting procedure. Data are shown 
as mean ± s.e.mean of η experiments. Differences between groups 
were compared with two-tailed t-tests as appropriate with Ρ < 
0.05 considered statistically significant. 
Results 
Cyclic AMP accumulation 
Isoprenaline, adrenaline, and noradrenaline concentration-de-
pendently increased the intracellular cyclic AMP content in human 
MNL (Table 1) . Although all three catecholamines elicited a 
similar maximal cyclic AMP accumulation, their potencies differed 
considerably with a rank order of isoprenaline > adrenaline > 
noradrenaline. Prostaglandin E^ (PGEj) and forskolin also 
stimulated cyclic AMP accumulation in MNL with maximal stimulatory 
effects 4-5 and 0.66 times as large as those in response to 
isoprenaline, respectively (Table 1) . 
As other investigators have reported enhanced hormone-stimulated 
cyclic AMP accumulation in the presence of mitogenic lectins 
(Fredholm et al., 1987; Dailey et al., 1988), we also determined 
isoprenaline-stimulated cyclic AMP accumulation following 
exposure to mitogens for 30 min. This protocol was chosen to 
yield a mitogen exposure of the MNL comparable to that during 
the inositol phosphate accumulation experiments. However, neither 
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Table 1: Concentration-response relationships for Catecholamine-, Prosta­
glandin Εχ- and Forskolin- stimulated c y c l i c AMP generation in human lym­
phocytes. 
Isoprenaline 
Adrenaline 
Noradrenaline 
Forskolin 
Prostaglandin Εχ 
ECso (nM) 
7.8+1.4 
48±12 
5100±29OO 
31OOO±7OO0 
1560±800 
Maximal cyclic AMP accumu­
lation 
(pmol/106 cells in 15 min) 
47.6±10.6 
49.4±8.6 
47.5±12.3 
31.4±10.5 
249±60 
Lymphocytes were incubated for 15 min a t 370C with 5-7 c o n c e n t r a t i o n s of t h e 
i n d i c a t e d a g o n i s t s in t h e presence of 0.1 mM t h e o p h y l l i n e , and t h e c y c l i c AMP 
content was determined as described in methods. The agonis t concentra t ion 
causing a half-maximal increase in cyc l ic AMP content , t h e maximal increase 
and t h e H i l l s lope were c a l c u l a t e d for each experiment by f i t t i n g the 
experimental data t o a sigmoid curve using computer a s s i s t e d non-l inear 
regres s ion a n a l y s i s . The H i l l slopes did not d i f f e r s i g n i f i c a n t l y from 1.0. 
Each value i s t h e mean ± SEM of 4 experiments. 
PWM (2 .4 ßg ml - 1 ) nor PHA (1 .8 дд m l - 1 ) s i g n i f i c a n t l y a l t e r e d t h e 
p o t e n c y o r maximal e f f e c t s of i s o p r e n a l i n e on MNL c y c l i c AMP 
a c c u m u l a t i o n ( F i g u r e 1 ) . 
I n o s i t o l phosphate accumulation 
I n c u b a t i o n of MNL, p r e l a b e l l e d w i t h [ 3 H ] - m y o - i n o s i t o l , w i t h 
v a r i o u s c o n c e n t r a t i o n s of PHA ( 0 . 2 - 1 4 . 4 ßg m l - 1 ) , Con A (0 .14-36 
ßg ml - 1 ) and PWM ( 0 . 1 5 - 4 . 8 ßg ml'1) fo r 30 min a t 370C concen-
t r a t i o n - d e p e n d e n t l y i n c r e a s e d t h e fo rmat ion of [ 3 H ] - i n o s i t o l 
p h o s p h a t e s ( F i g u r e 2 ) ; t h e maximal e f f e c t was h i g h e s t f o r Con A 
and PHA and lowes t f o r PWM. Al l f u r t h e r e x p e r i m e n t s were performed 
u s i n g 1.8 ßg ml"1 PHA, 18 ßg m l - 1 Con A, and 2 .4 ßg ml"1 PWM. 
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Figure 1 I soprenal ine-induced c y c l i c AMP generat ion in the absence and 
presence of pokeweed mitogen(PWM) and phytohaemagglutinin (PHA). Lymphocytes 
were preincubated for 15 min without (contro l ) or with PHA (1.8 jjg m l - l ) or 
PWM (2.4 μg ml~l) p r i o r t o addi t ion of i s o p r e n a l i n e . Values are mean of 4 
experiments for c o n t r o l (open c i r c l e s ; max. c y c l i c AMP generat ion 45.3±7.8 
pmol/106 c e l l s in 15 min), PHA ( f i l l e d diamonds; 50.415.9 pmol/106 c e l l s in 
15 min) and PWM ( c r o s s e s ; 47.6±4.9 pmol/10^ c e l l s in 15 min); v e r t i c a l bars 
show s.e.mean. Mean data were f i t t e d t o a sigmoid curve. 
ß-Adrenoceptor a g o n i s t s d e c r e a s e d m i t o g e n - s t i m u l a t e d i n o s i t o l 
phospha te g e n e r a t i o n by 30-50% depending on t h e mitogen used 
(F igu re 3 a - c ) . The maximal i n h i b i t o r y e f f e c t was s i m i l a r fo r a l l 
t h r e e c a t e c h o l a m i n e s bu t t h e i r po tency d i f f e r e d , t h e rank o r d e r 
b e i n g : i s o p r e n a l i n e > a d r e n a l i n e > n o r a d r e n a l i n e (F igu re 3 ) . The 
c a t e c h o l a m i n e - i n d u c e d i n h i b i t i o n of t h e i n o s i t o l phospha t e 
g e n e r a t i o n was comple te ly b locked by 100 nM of t h e ß2 -ad renocep to r 
s e l e c t i v e a n t a g o n i s t ICI 118,551 ( B i l s k i e t al., 1983) bu t was 
no t a f f e c t e d by 500 nM of t h e ßj^-adrenoceptor s e l e c t i v e a n t a g o n i s t 
CGP 20712A (Dooley e t a l . , 1986; F i g u r e 4 a - c ) . 
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Figure 2 Concentration-response curves for mitogen-induced accumulation of 
inositol phosphates in human lymphocytes. The EC50 values for pokeweed mitogen 
(PWM, crosses), phytohaemagglutinin (PHA, open circles) and concanavalin A 
(Con A, filled diamonds) were 0.6 μg ml~l, 1.3 μg ml -!,
 a n c
j 2.3 μg ml -^, 
respectively. Inset: Maximal Inositol phosphate generation by mitogens 
expressed as c.p.m. Data are mean of 3-5 experiments; vertical bars show 
s.e.mean. 
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Figure 3 Inhibition of mitogen-induced inositol phosphate generation by 
isoprenaline (open circles), adrenaline (filled circles) and noradrenaline 
(crosses) in human lymphocytes: (a) phytohaemagglutinin (PHA); (b) concanavalin 
A (Con A) and (c) pokeweed mitogen (PWM) . Mean data were fitted to a competition 
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Figure 4 Effects of the ßi-adrenoceptor selective antagonist CGP 20712A (500 
nM, filled columns) and the ß2-adrenoceptor selective antagonist ICI 118,551 
(100 nM, hatched columns) on catecholamine-evoked inhibition (open columns) 
of mitogen-induced inositol phosphate generation in human lymphocytes: (a) 
phytohaemagglutinin (PHA); (b) concanavalin A (Con A) and (c) pokeweed mitogen 
(PWM). Data are expressed as % inhibition of the formation of [3H)-inositol 
phosphates caused by the mitogens m the respective experiments. Values are 
mean of 3-6 experimente; vertical bars show s.e.mean. * P<0.05; ** P<0.01 
vs. control. 
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In order to investigate whether the inhibitory effects of the 
catecholamines are related to their stimulation of cyclic AMP 
generation, we studied the effects of PGE^ and forskolin (which 
stimulate cyclic AMP generation independently of ß-adrenoceptor 
activation) and of the phosphodiesterase inhibitor isobutylme-
thylxanthine (IBMX). Forskolin, a poor stimulator of cyclic AMP 
generation in resting human MNL (see Table 1) , weakly reduced 
mitogen-stimulated inositol phosphate generation (20-35% inhi-
bition; Figure 5a-c). In contrast, PGE1 (which stimulates cyclic 
AMP generation considerably more than the catecholamines, see 
Table 1) inhibited mitogen-stimulated inositol phosphate accu-
mulation to a much larger extent than the catecholamines (Figure 
5a-c). Moreover, IBMX (0.1 mM) considerably enhanced the 
inhibition of mitogen-stimulated inositol phosphate generation 
by isoprenaline (Figure 6) . Thus, inhibition of inositol phosphate 
generation by these various cyclic AMP promoting agents was 
strongly related to the increase in the intracellular level of 
cyclic AMP. 
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Figure 6 Effects of the phosphodiesterase inhibitor isobutylmethylxanthine 
(0.1 mM, hatched columns) on isoprenaline-evoked inhibition of mitogen-induced 
inositol phosphate generation (open columns) in human lymphocytes. Mitogens: 
phytohaemagglutinin (PHA); concanavalin A (Con A) and pokeweed mitogen (PWM). 
Data are expressed as % inhibition of formation of [3H]-inositol phosphates 
caused by the mitogens in the respective experiments. Values are mean of 5 
experiments; vertical bars show s.e.mean. *** P<0.001 vs. control in the 
absence of isobutylmethylxanthine. 
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Figure 5 Inhibition of mitogen-induced inositol phosphate generation in human 
lymphocytes by prostaglandin Ej (open circles) and forskolin (filled circles): 
(a) phytohaemagglutinin (PHA); (b) concanavalin A (Con A) and (c) pokeweed 
mitogen (PWM). Values are mean of 3-5 experiments: vertical bars show s.e.mean. 
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Increases of intracellular Ca2* concentrations 
The basal intracellular Ca 2 + concentration was 62 ± 5 nM (n=12 
with 8-22 replicates in each experiment) . Con A and PHA con-
centration-dependently elevated intracellular Ca 2 + to a peak level 
within 1-3 min; as expected, the Ca 2 + concentration later declined 
from the peak to a plateau above the basal level which was 
maintained for more than 30 min (data not shown). From the peak 
Ca 2 + concentration elicited by 4 mitogen concentrations we con­
structed concentration-response curves (Figure 7 ) . PWM elicited 
only very small and inconsistent increases of intracellular Ca 2 + 
(maximally 25 nM at 96 дд ml - 1) regardless of whether experiments 
were performed at 25 0C or ЗУС (data not shown) . Chelation of 
extracellular Ca 2 + by addition of 5 nM EGTA immediately prior to 
the mitogens completely abolished the Ca 2 + increases stimulated 
by Con A and PHA (n=4; data not shown) . Thus, the mitogen-induced 
increases in intracellular Ca 2 + were predominantly due to influx 
rather than intracellular mobilization in accordance with recently 
reported data in human and murine resting lymphocytes (Alcover 
et al., 1987; Linch et al., 1987; Gelfand., 1987). 
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Figure 8 Inhibition of phytohaemagglutinin (PHA, open columns) and concanavalin 
A (Con A, hatched columns) -induced Ca 2 + increases in human lymphocytes by 
prostaglandin Ej (PGEi, 10 μΜ), forskolin (20 μΜ) or isoprenaline (10 μΜ). 
Values are mean of 4-7 experiments; vertical bars show s.e.mean. The mito­
gen-induced rise in intracellular Ca 2 + in these experiments was 119 ± 17 nM 
for PHA and 94 ± В nM for Con A. * P<0.05; *** P<0.001 vs. control in the 
absence of cyclic AMP increasing agents. 
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Figure 7 Mitogen-stimulated increases of intracellular Ca2 + in human lym­
phocytes. The EC50 values for phytohaemagglutinin (PHA, open circles) and 
concanavalin A (Con A, filled circles) were 22.8 μg ml-l and 65.5 μ9 ml~l, 
respectively. Inset: Maximal Ca^+ increase expressed in nM. Data are mean of 
7 experiments; vertical bars show 9.e.mean. 
Overnight pretreatment of MNL cells with pertussis toxin (100 
ng ml-1) ADP-ribosylated more than 90% of the pertussis toxin 
substrates of these cells, but did not inhibit the mito­
gen-stimulated Ca 2 + increases (data not shown) . Such a lack of 
effect of pertussis toxin to inhibit Ca2+ increases has previously 
also been reported in human and murine T-lymphocytes (Macintyre 
et al., 1988; Aussei et al., 1988; Gray et al., 1989; Stewart et 
al., 1989). 
The cyclic AMP generation-stimulating agents PCE1 (10 μΜ) , 
forskolin (20 μΜ) , and isoprenaline (10 μΜ) did not significantly 
alter the intracellular Ca2+ concentration of resting MNL (2 ± 
2 nM for PGEj, 1 ± 0 nM for forskolin, and 1 ± 1 nM for isoprenaline, 
л=4-8 each). However, all three agents inhibited the PHA- and 
Con Α-stimulated Ca2+ elevations (Figure 8). Inhibition of the 
Ca 2 + elevation was associated with a prolonged time-to-peak (data 
not shown) which was not quantified in detail. Inhibition of 
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PWM-stimulated Ca2+ increases was not tested because these 
increases were too small and inconsistent to begin with (see 
above). Blocking the degradation of cyclic AMP with the phos­
phodiesterase inhibitors IBMX (0.1 mM) and Ro 20-1724 (0.25 mM) 
enhanced the inhibitory effects of PGE^ forskolin, and 
isoprenaline (Figure 9) , demonstrating that the inhibition is 
mediated by cyclic AMP. 
a PHA 
PGE, Forskolin Isoprenaline 
Figure 9 Effect of phosphodiesterase inhibition by isobutylmethylxanthine 
and Ro 20-1724 (100 and 250 μΗ, respectively) on mitogen-stimulated Ca 2 + 
increases in human lymphocytes. Either the phosphodiesterase inhibitors 
(hatched columns) or vehicle (open columns) were added to the cells, followed 
20-30 s later by prostaglandin Εχ (1 μΜ), forskolin (2 μΜ), or isoprenaline 
(10 μΜ), and 20-30 s later by phytohaemagglutinin (PHA, 100 μς ml - 1, a) or 
concanavalin A (Con A, 100 μg ml-l, b) . Data shown are mean of 4-6 experiments; 
vertical bars show s.e.mean. * P<0.05 vs. inhibition of Ca2 + increase in the 
absence of phosphodiesterase inhibitors. 
Discussion 
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The activation of T-lymphocytes is a multistep process. Two of 
the first signals which can be observed biochemically are an 
elevation of the free intracellular Ca2* concentration and the 
hydrolysis of phosphatidyl-inositol-bisphosphate into 
inositol-(l,4,5)-trisphosphate (IP3) and diacylglycerol (DAG) 
leading to activation of a protein kinase С (Chen et al., 1986; 
Cambier et al., 1987; Linch et al., 1987; Gelfand et al., 1987; 
Hadden, 1988; Gupta, 1989). Although generation of IP3 is the 
major stimulus to elevate intracellular Ca2+ in many model systems 
(Berridge & Irvine, 1989) it is still a matter of debate whether 
Ca 2 + increases in lymphocytes by mitogenic lectins are caused by 
IP3 or not (King, 1988) . Our study did not directly address this 
question, but the observation that PWM was approximately half as 
effective as Con A in generating inositol phosphates but a very 
poor stimulus for Ca 2 + elevations, support the idea that Ca2+ 
influx in lymphocytes may not necessarily be predominantly caused 
by inositol phosphate generation. 
In our study we have used the T-lymphocyte specific mitogenic 
lectins PHA and Con A and the non-specific B- and T-lymphocyte 
mitogen PWM to mimic the activation of resting lymphocytes by 
antigens. The characteristics of inositol phosphate generation 
and elevation of intracellular Ca2+ in human MNL as stimulated 
by PHA, Con A and PWM in our and other studies (i.e. concen­
tration-dependency; dependency of Ca2+ increase on influx; lack 
of pertussis toxin sensitivity) are very similar to those described 
previously for other polyclonal T-lymphocyte activators such as 
monoclonal anti-CD3 antibodies (for review see Chen et al. , 1986; 
Cambier et al., 1987; Hadden, 1988). Therefore, this paradigm is 
likely to give reliable estimates of the biochemical alterations 
occurring in resting lymphocytes undergoing activation by 
antigens. On the other hand, it should be noted that the mitogenic 
lectins used in this study may utilize (at least partially) 
different pathways for lymphocyte activation. 
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Various authors have shown that cyclic AMP can play an inhibitory 
role in the activation of resting T-lymphocytes. Thus, increases 
in the intracellular level of cyclic AMP inhibit mitogen- or 
antigen-induced T-cell proliferation, cytotoxic T-lymphocyte 
function, lymphokine secretion, and production and effects of 
11-2 (Bourne et al., 1974; Feiten et al., 1987; Feldman et al., 
1987; Mary et al., 1987; Kammer, 1988; Johnson et al., 1988). 
Whether this inhibitory effect of cyclic AMP, however, is due to 
interaction with the phospholipase C/IP3/DAG pathway, is still 
a matter of debate. Imboden et al., (1986) and Sommermeyer & 
Resch (1990) found in the human Τ cell tumour line Jurkat that 
cholera toxin (which via ADP-ribosylation activates the adenylate 
cyclase coupled G
s
-protein thereby stimulating cyclic AMP for­
mation) inhibits antigen-induced ІРз-formation and increases in 
intracellular Ca2+, but this effect could not be mimicked by other 
cyclic AMP increasing agents and/or cyclic AMP analogues. On the 
other hand. Lerner et al., (1988) in mouse T-lymphocytes and 
Windebank et al., (1988) in cloned human NK cell lines could 
demonstrate that increases in the intracellular level of cyclic 
AMP, regardless of whether it was receptor-dependent (PGEjJ or 
-independent (forskolin), evoked inhibition of IP3 formation and 
increases in intracellular Ca2+. 
These data prompted us to investigate in mixed human lymphocytes 
the effects of various agents known to stimulate the formation 
of cyclic AMP on the mitogen-induced generation of inositol 
phosphates (as a parameter of phosphatidyl-inositol-bisphosphate 
hydrolysis) and increases in intracellular Ca2+. The results 
clearly demonstrate that all agents used in this study that 
elevate cyclic AMP levels (see Table 1) also inhibited mito­
gen-induced generation of inositol phosphates and increases in 
the intracellular Ca 2 + concentration. 
The fact, that (i) inhibition of the break-down of cyclic AMP 
by phosphodiesterase inhibitors potentiated the inhibition of 
inositol phosphate generation and of intracellular Ca2+ rises and 
(ii) the amount of inhibition of inositol phosphate generation 
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was strongly related to the magnitude of cyclic AMP elevations 
is in favour of the idea that cyclic AMP is responsible for 
inducing these inhibitory effects. Thus, the present data obtained 
in human MNL confirm those of Lerner et al., (1988) obtained in 
mouse T-lymphocytes and of Windebank et al. (1988) obtained in 
cloned human NK cells that cyclic AMP-induced inhibition of cell 
proliferation and cytotoxicity, respectively, is accompanied 
(and/or induced?) by inhibition of increases in the intracellular 
Ca2+ concentrations and generation of inositol phosphates. 
In the present study, ß-adrenoceptor agonists increased the 
intracellular cyclic AMP content and inhibited the mitogen-induced 
generation of inositol phosphates with an order of potency: 
isoprenaline > adrenaline > noradrenaline. This order of potency 
(Lands et al., 1967) and the fact that catecholamine-induced 
inhibition of inositol phosphate generation could be abolished 
by the ß2-adrenoceptor selective antagonist ICI 118,551 (Bilski 
et al., 1983) but not by the ßj^-adrenoceptor selective antagonist 
CGP 20712A (Dooley et al., 1986) strongly support the view that 
this effect is mediated via ß2-adrenoceptor stimulation, as is 
to be expected since human MNL contain exclusively ß2-adreno-
ceptors (for review see Brodde et al., 1987). 
It should be noted that cyclic AMP (a) inhibited inositol 
phosphate generation and Ca2+ increases, although both responses 
may occur independently; (b) inhibited the second messenger 
generation by all three mitogens, although they may stimulate 
second messenger generation via at least partially different 
pathways (see above); and (c) inhibited second messenger gene-
ration independently whether near maximally effective (Con A and 
PWM) or low (PHA) mitogen concentrations were used. Thus, our 
data suggest a prominent role of cyclic AMP-increasing agents in 
the regulation of the generation of second messengers which are 
important in the activation of resting lymphocytes. 
Taken together our data demonstrate that catecholamines can 
attenuate the generation of two second messengers which are 
important in the activation of resting human lymphocytes. This 
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appears to be mediated via ßj-adrenoceptors by elevating 
intracellular cyclic AMP. Thus, attenuation of early second 
messenger responses involved in the activation of resting lym-
phocytes may represent (or at least participate in) the molecular 
basis for the immunomodulatory effects of the sympathetic nervous 
system. 
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CHAPTER 5. Adrenergic involvement in control of lymphocyte 
immune function 
ABSTRACT 
Sympathetic involvement in control of immune function has been 
demonstrated by effects of catecholamines (and other compounds 
which elevate intracellular cAMP content) on immune parameters 
in vitro, ex vivo, and in vivo. In the present study, we examined 
the effects of ß-blocker treatments on parameters of cellular 
immune function. 
9 Day treatments with the ß-blockers bisoprolol, Celiprolol or 
propranolol had neither effect on in vitro lymphocyte prolif-
eration, nor on circulating lymphocyte numbers, indicating that 
the basal sympathetic tone does not play an important role in 
control of cellular immune function via ß2-adrenoceptors. 
Acute activation of the sympathetic nervous system by infusion 
of isoprenaline, was accompanied by a redistribution of circu-
lating lymphocyte numbers, causing a decrease in the helper to 
suppressor/cytolytic -cell ratio. Neither bisoprolol or 
Celiprolol nor propranolol, independently whether given acutely 
or chronically, blocked the redistribution of circulating lym-
phocytes. Accordingly, this effect is either not ß-adrenoceptor 
mediated, or might involve an atypical ß-adrenoceptor. Infusion 
of isoprenaline also caused a depression of in vitro lymphocyte 
proliferative responses. This depression, however, could be 
prevented by treatment with propranolol but not bisoprolol or 
Celiprolol, indicating involvement of the ß2-adrenoceptor in the 
effect. Accordingly, the phenotypical profile (e.g. the helper 
to suppressor/cytolytic -cell ratio) is not responsible for the 
depressed lymphocyte in vitro proliferation. More likely, lym-
phocytes possessing altered intrinsic properties, and released 
into the circulation via stimulation of ß2-adrenoceptors, are 
responsible for the reduced proliferative capacity. 
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It is concluded that chronic ß-blocker therapy might be expected 
to cause no major changes in cellular immune function. However, 
in states of short-term elevated sympathetic activity, ß-blocker 
therapy with propranolol prevents a depression of lymphocyte 
proliferative capacity. 
INTRODUCTION 
Evidence is accumulating that the sympathetic nervous system 
participates in the control of the immune system. Sympathetic 
nerve endings densely innervate lymphoid tissues (for a review 
see 1) and lymphoid cells have membrane receptors of the 
ß2-adrenergic type for the sympathetic neurotransmitters (2) . In 
vitro, stimulation of these ß-adrenoceptors has been shown to 
inhibit lymphocyte proliferation and several steps preceding 
proliferation (for a review see 3). Moreover, we have recently 
shown inhibitory effects of catecholamines in the nanomolar range 
on the earliest events following mitogenic activation of lym-
phocytes, namely the generation of inositol phosphates and an 
elevation of intracellular calcium (4). 
Functional evidence for influence on immune function by the 
sympathetic nervous system іл vivo concerns changes in the numbers 
of circulating lymphocytes. Acute increases in the activity of 
the sympathetic nervous system and concomitant increases in 
endogenous plasma catecholamines by exercise (5,6,7) or by 
insulin-induced hypoglycemia (8), or acute stimulation of 
ß-adrenoceptors by infusion of isoprenaline (9) or epinephrine 
(10) , cause a relative lymphocytosis with increases in the numbers 
of suppressor/cytolytic T-cells and natural killer cells and a 
decrease in the number of helper T-cells. 
The aim of the present study was to determine influences of the 
basal sympathetic tone on cellular immune function. For this 
purpose the effects of a 9 day treatment of healthy volunteers 
with the ß-blockers bisoprolol (ß1-selective without intrinsic 
sympathomimetic activity (ISA)), Celiprolol (ßi-selective with 
ß2-ISA) and propranolol (non-selective without ISA) on basal 
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lymphocyte subset composition and in vitro proliferative responses 
of lymphocytes to various mitogenic agents were investigated. In 
addition the effects of ß-blocker treatment on isoprenaline 
infusion-induced changes in lymphocyte subset composition and in 
vitro proliferative responses were studied. 
METHODS 
.Experimental protocol. 
28 Healthy male volunteers (age 28.7 ±2.7 (25-34) yr) participated 
in the study after having given informed written consent. All 
volunteers were drug free for at least 3 wk before the study, 
and had undergone physical and electrocardiogram examination to 
exclude signs of cardiovascular and pulmonary diseases. 
Volunteers were treated with ß-adrenoceptor antagonists for 9 
days. 8 Volunteers received propranolol (4x40 mg/day), a 
non-selective ß-antagonist without intrinsic sympathomimetic 
activity; 8 volunteers received bisoprolol (1x10 mg/day), a 
ßj^-selective antagonist without intrinsic sympathomimetic 
activity (11); and 7 volunteers received Celiprolol (1x200 
mg/day) , a ßj^-selective antagonist with ß2-selective intrinsic 
sympathomimetic activity (11). The doses of the ß-blockers were 
chosen as such because they have previously been shown to be 
effective in modulating lymphocyte ß2-adrenoceptor number (11) 
or in antagonizing ßj-adrenoceptor mediated effects (12). The 
last intake of bisoprolol and Celiprolol was at 1900 h in the 
evening before and for propranolol at 0600 h in the morning of 
the isoprenaline infusion. 
Additional isoprenaline infusion tests were performed in five 
male volunteers (age 26.3 ± 1.8 yr) who received propranolol 
intravenously (Dociton, 5 mg) 45 minutes before the test. 
After an initial rest period of 1 h in the supine position, 
isoprenaline (seguential doses of 3.5, 7, 17.5, 35 and 70 
ng.kg~1.min"1 for 5 min each) was infused in a large peripheral 
fore-arm vein. Blood pressure and heart rate were recorded 
automatically by a Tonomed (Speidel & Keller, Jungingen, FRG) 
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and an electrocardiogram. Immediately before and after infusion, 
30 ml peripheral venous blood was withdrawn from the opposite 
fore-arm with 500 IU heparin/10 ml blood. 
Cell isolation. 
Peripheral blood lymphocytes were prepared from whole heparinized 
blood by Ficoll gradient centrifugation according to the method 
of Böyum (13) with minor modifications (9). 
Lymphocyte proliferation. 
Lymphocyte function was monitored by the ability of cells to 
proliferate upon mitogenic stimulation with phytohemagglutinin 
(PHA; 1.8 ßg/ml) , concanavalin A (ConA; 9 /ig/ml) , pokeweed mitogen 
(PWM; 4.6 дд/ті), anti-T-cell globulin (ATG; 360 дд/ті) and 
staphylococcus enterotoxin (STE; 0.09 дд/ті). These mitogen 
concentrations had been shown to maximally stimulate uptake of 
3H-thymidine (9) . Cells were cultured for 4 days at 37 0C in 
microtiter plates, containing the mitogens in 220 μΐ RPMI 1640 
with 0.29 mg/ml L-glutamine, 0.16 mg/ml gentamycin-sulfate and 
10% heat inactivated pooled human serum at 2 χ 105 cells per 
well. For the last 16 hours the cultures were labeled with 2 дСі 
3H-thymidine per well. The cells were harvested with a multiple 
sample precipitator (O. Hiller, Madison USA) and incorporated 
radioactivity was assessed in a liquid scintillation counter 
(TRI-CARB, Packard). 
Analysis of lymphocyte subsets. 
Lymphocytes were analyzed by indirect immunofluorescence with 
the following monoclonal antibodies: Jot3 for pan-T cells; Jot4a 
and BMA040 for helper T-cells (Th); Jot8a and BMA080 for sup-
pressor/cytolytic T-cells (Tg/C) ; aDR for B-cells; JotlO for 
natural killer cells (NK). LeuMl was used for quantification of 
monocytes and granulocytes present in the cell suspensions. 
FITC-labeled goat anti-mouse IgG + IgM was used as the second 
antibody. In short, lymphocytes were incubated with appropriate 
dilutions of monoclonal antibody for 40 min, washed, labeled with 
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FITC-conjugated goat anti-mouse antibody for 40 min and washed; 
all procedures were performed at room temperature. Cells were 
analyzed within 2 hours under a Zeiss fluorescence microscope. 
Materials. 
Isoprenaline (Aludrin) was obtained from Boehringer (Ingelheim, 
FRG). Tablets of bisoprolol and Celiprolol were kindly provided 
by Merck (Darmstadt, FRG) and Woelm Pharma, respectively. Dociton 
and tablets of propranolol were obtained from ICI Pharma 
(Plankstadt, FRG). 
[3H]-thymidine (5 Ci/mmol) was purchased from Amersham. 
RPMI 1640, L-glutamine and gentamycin-sulfate were obtained from 
Nunc (Wiesbaden, FRG). PHA was from Welcome (Beckenham, U.K.), 
Con A from Sigma (Deisenhofen, FRG) , PWM from Boehringer (Mannheim, 
FRG), ATG from Fresenius (Oberursel, FRG), and STE from Serva 
(Heidelberg, FRG). All other chemicals were from Sigma and of 
the highest purity grade available. 
FITC coupled goat anti-mouse IgG + IgM was purchased from Medac 
(Hamburg, FRG). Monoclonal antibodies were obtained from the 
following sources (specificities in parentheses): Jot3 (CD3), 
Jot4a (CD4) , JotSa (CD8) and JotlO (NK-cell marker) from Immunotech 
Dianova (Hamburg, FRG), LeuMl (pan-monocyte/granulocyte marker) 
and aDR (class II) from Becton Dickinson (Heidelberg, FRG), BMA040 
(CD4) and BMA080 (CD8) from Behring (Frankfurt/Main, FRG). 
Data evaluation. 
All data are shown as means ± SEM of η experiments. Differences 
between groups were compared with two-tailed paired t-test. 
RESULTS 
Effects of ß-blocker treatments on basal lymphocyte subset 
composition. 
Pan T-, helper T-, suppressor/cytolytic T-, pan B-, and natural 
killer cells were monitored. The number of granulocytes and 
monocytes present in the lymphocyte suspensions did not exceed 
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5% and was similar for all preparations. Treatment with a 
ß-adrenoceptor antagonist for 9 days did not influence basal 
lymphocyte subset composition (Fig 1) . 
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Figure 1. Isoprenaline infusion-induced changes in circulating lymphocyte 
subsets of healthy volunteers under control conditions and after treatment 
with the ß-blockers bisoprolol (n=8), Celiprolol (n=7) and propranolol (n=8). 
For each subset the first two columns represent pre-treatment values before 
and after infusion of isoprenaline, respectively, and the thirth and fourth 
column represent post-treatment values before and after infusion of isopre-
naline, respectively. Shown are means ± SEM of η subjects. * P<0.05, P<0.01 
vs. the corresponding pre-infusion value. 
Effects of ß-blocker treatments on isoprenaline infusion-induced 
changes in lymphocyte subset composition. 
Infusion of isoprenaline did not change the relative amounts of 
pan T-cells and pan B-cells. However, within the population of 
T-cells, the percentage of helper cells decreased (39.1 ± 1.0 
before vs. 27.6 ± 1.2 after infusion, n=23, p<0.0001) and of 
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suppressor/cytolytic cells increased (25.9 ± 1.0 before vs. 31.8 
± 0.9 after infusion, n=23 , p=0.0003). Accordingly, Thel_ 
per/Tsuppressor/cytoiyti.c -cell ratio decreased from 1.57 ± 0.07 to 
0.89 ± 0.05 (n=23, p<0.0001) . The percentage of NK cells increased 
from 5.1±0. 8 to 11.0 ± 1.4 (n=23, p=0.0007) following isoprenaline 
infusion. 
A 9 day treatment with bisoprolol or Celiprolol did not influence 
the isoprenaline infusion-induced changes in lymphocyte subset 
composition (Fig 1,2). Treatment with propranolol for 9 days 
blocked the isoprenaline infusion-induced increase in the per-
centage of natural killer cells (Fig 1), but had no influence on 
changes within the population of T-cells: 
Thelper/Tguppre3sor/cytolytic -cell ratio still decreased from 1.73 
± 0.16 to 1.06 ± 0.09 (n=8, p=0.0007) following isoprenaline 
infusion (Fig 2). 
bisoprolol Celiprolol propranolol 
Figure 2. The effect of xnfusion of isoprenaline on the ratio of helper to 
suppressor/cytolytic T-cells of healthy volunteers under control conditions 
and after treatment with the ß-Ыоскег bisoprolol (n=8), Celiprolol (n=7) 
and propranolol (n=8). For each group the first two columns represent 
pre-treatment values before and after infusion of isoprenaline, respectively, 
and the thirth and fourth column represent post-treatment values before and 
after infusion of isoprenaline, respectively. Shown are means ± SEM of η 
subjects. ** P<0.01 vs. the corresponding pre-infusion value. 
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Effects of acute propranolol administration on isoprenaline 
infusion-induced changes in lymphocyte subset composition. 
Since a 9 day propranolol treatment had no effect on isoprenaline 
infusion-induced changes in lymphocyte subset composition (and 
decrease in the Thelper/Tsuppreggor/cytolytic -cell ratio) we studied 
the effects of acute propranolol administration on these para-
meters. For this purpose 5 healthy volunteers were administered 
with 5 mg propranolol intravenously 45 minutes before the infusion 
of isoprenaline. In this dose, propranolol markedly attenuated 
the isoprenaline-induced increase in heart rate (data not shown), 
indicating that the dose was sufficient to antagonize ß-adre-
noceptor mediated effects. However, as shown in Table 1, iso-
prenaline still caused a granulocytosis and lymphocytosis. Within 
the population of T-cells, lymphocytosis concerned 
suppressor/cytolytic cells only. Since the absolute number of 
helper T-cells did not change, the percentage of helper T-cells 
decreased. The Thelper/T3uppressor/cytolytic -cell ratio accordingly 
decreased from 1.44 ± 0.09 to 0.84 ± 0.02 (n=5, p=0.004). Fur-
thermore pan-B and NK cell numbers increased following infusion 
of isoprenaline. 
Effects of ß-blocker treatments on lymphocyte in vitro pro-
liferative responsiveness. 
3H-thymidine uptake of lymphocytes upon stimulation with mitogenic 
agents was taken as a measure of their ability to proliferate. 
Compared to pre-treatment responses, no changes were found after 
a 9 day ß-blocker treatment (Fig 3). After infusion of isopre-
naline, in vitro proliferative responses of lymphocytes upon 
stimulation with all five mitogens had decreased, in agreement 
with recently published data from our laboratory (9). Treatment 
with bisoprolol or Celiprolol for 9 days had no effect on this 
isoprenaline infusion-induced depression of the proliferative 
responses. However, a 9 day treatment with propranolol completely 
prevented the isoprenaline infusion-induced depression of the 
proliferative responses (Fig 3). 
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TABLE 1 : ISOPRENALINE INFUSION-INDUCED CHANGES IN CIRCULATING LEUKOCYTES IN 
5 HEALTHY SUBJECTS ACUTELY PRETREATED INTRAVENOUSLY WITH PROPRANOLOL 
Leukocytes 
Granulocytes 
Lymphocytes 
Pan-T cells 
Thelper cells 
T
suppressor/cytolytic 
cells 
Pan-B cells 
Natural Killer cells 
Thelper/Tsuppressor/cy 
tolytic cell ratio 
Isoprenaline Infusion 
Before 
Rel (*) 
71.0±2.4 
40.2±1.6 
28.2*1.1 
16.4±1.4 
2.0±0.5 
1.44 
Abs 
(cells/μΐ) 
4980±429 
3140±304 
1840±178 
1314±155 
745±90 
519+58 
304±41 
35±8 
tO.09 
After 
Rel (%) 
71.8±3.2 
31.0±0.8** 
37.4±1.2** 
22.4±2.0** 
9.6±2.0* 
Abs 
(cells/μΐ) 
6440±367* 
3900+272 
2560+223** 
1864±239* 
799±87 
967±43** 
578±82** 
241±25* 
0.84±0.02** 
Relat ive p r o p o r t i o n s ( r e l %) of lymphocyte subsets were obtained as a percentage 
of t h e t o t a l lymphocytes counted (see Methods). The absolute (abs) number in 
each subset was c a l c u l a t e d by mult iply ing t h e percentage of each subset with 
the absolute lymphocyte count derived from t h e t o t a l leukocyte count and 
d i f f e r e n t i a l count . Values are means ± SEM. * P<0.05, ** P<0.01 vs. t h e 
corresponding pre- infus ion va lue. 
DISCUSSION 
During the l a s t decade, several authors have shown e f fec t s of 
catecholamines (and other compounds which e levate i n t r a c e l l u l a r 
c y c l i c AMP content) on c e l l u l a r immune functions in vitro (for 
reviews see 1,3,14,15). Thus, increases in the i n t r a c e l l u l a r 
leve l s of c y c l i c AMP i n h i b i t mitogen- or antigen-induced T-cel l 
p r o l i f e r a t i o n , cytotoxic Τ lymphocyte function, lymphokine 
s e c r e t i o n , and production and e f fect s of 11-2 (9,16-18). 
Accordingly, in physiological and pathologica l condi t ions of 
e levated plasma catecholamine l e v e l s , c e l l u l a r immune function 
might be a l t e r e d . An impaired in vitro p r o l i f e r a t i v e respon­
siveness a f t e r acute increases in endogenous catecholamines іл 
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Figure 3. In vitro proliferative responses of lymphocytes isolated before and 
after infusion of isoprenaline in healthy volunteers under control conditions 
(dashed lines) and after treatment (solid lines) with the ß-blockers bisoprolol 
(n=8), Celiprolol (n=7) and propranolol (n=B). Immediately before and after 
25 min of infusion of isoprenaline heparinized blood was withdrawn and lym-
phocyte in vitro proliferative responses to PHA (1.8 μq/ml), Con A (9 pg/ml), 
PWM (4.6 μg/ml), ATG (360 fjg/ml ) and STE (0.09 pg/ml) were determined as 
described in Methods. Ordinates, [Эщ-thymidine incorporation into lymphocytes 
in counts per min (cpm) χ 10~3. Values are means ± SEM of η experiments. * 
P<0.05, ** P<0.01. 
vivo, supplies indirect evidence for adrenergic control of immune 
function (9,19). This depression of the immune responsiveness is 
accompanied by a relative lymphocytosis with a predominant rise 
in suppressor/cytolytic Τ cells and natural killer cells 
(9,10,20). Moreover, recently Maisel et al (20) demonstrated a 
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reduced number of circulating lymphocytes in patients with chronic 
heart failure, with a decrease in suppressor/cytolytic Τ and 
natural killer cells but no change in helper Τ cells. This 
alteration could be reproduced by treatment of healthy volunteers 
with the lÎ2~adrener9:i-c agonist terbutaline. Whether these 
alterations in lymphocyte numbers play a role in the depressed 
immune responsiveness is not known. 
In the present study, 9 day treatments with the ß-blockers 
bisoprolol, Celiprolol or propranolol had neither effect on in 
vitro proliferative responsiveness nor on circulating lymphocyte 
numbers, indicating that the basal sympathetic tone does not play 
an important role in control of immune function, at least via 
ß-adrenergic receptors. 
In agreement with the above mentioned findings, infusion of 
isoprenaline caused changes in circulating lymphocyte numbers 
and a depression of lymphocyte in vitro proliferative responses. 
The depression of in vitro proliferation could be prevented by 
a 9 day treatment with propranolol but not with bisoprolol or 
Celiprolol, thus indicating involvement of the ß2-adrenoceptor 
in the effect. 
The depression of lymphocyte proliferative responsiveness seemed 
to be not simply caused by the changes in the phenotypes of the 
lymphocytes present in the circulation, since after propranolol 
treatment lymphocyte numbers still changed following infusion 
with isoprenaline but, in vitro proliferation was not depressed. 
The reduced proliferative responses of the lymphocytes after 
infusion with isoprenaline might be intrinsic to freshly released 
lymphocytes. Freshly released lymphocytes have been suggested to 
carry more ß2-adrenergic receptors than those found in the 
circulation (9) . However, since no catecholamines are present 
during the proliferation assay, these receptors might be of no 
influence. Still, this is an indication that other more relevant 
parameters, e.g. transmembrane signalling, function of protein 
kinase С or the production, secretion and effects of lymphokines, 
in freshly released lymphocytes can be different as well. 
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Accordingly, the release of these lymphocytes, expressing altered 
intrinsic properties towards mitogenic stimulation, should be 
ß2-adrenoceptor-mediated. Furthermore, since neither Celiprolol 
or bisoprolol, nor propranolol, independently of to whether given 
acutely or chronically, affect the distribution of lymphocytes 
that express normal proliferative responses, it is hypothesized 
that either distribution of these lymphocytes is not ß-adreno-
ceptor mediated or an atypical ß-adrenoceptor is involved. 
Recently, besides the classical ßj- and ß2-adrenoceptors (21), 
an additional subtype of ß-adrenoceptors has been suggested to 
mediate the sympathetic control of various metabolic processes 
(22,23). Evidence for the existence of such atypical ß-adreno-
ceptor sites includes their low affinity for standard ß-adre-
noceptor blockers in binding as well as in functional experiments. 
Moreover, recently a human gene has been isolated that encodes 
an atypical ß-adrenoceptor, referred to as the '^-adrenergic 
receptor" (22). The receptor protein was expressed in Chinese 
hamster ovary (CHO) cells transfected with the cloned gene and 
was found to posses atypical ß-adrenoceptor properties. For 
example, besides all three catecholamines the atypical agonist 
BRL 37344 also is a full agonist, and propranolol is a poor 
inhibitor of ß-adrenoceptor mediated cyclic AMP accumulation in 
СНО-Вз cells. The ß3-adrenoceptor is postulated to mediate 
lipolytic effects of catecholamines. The present finding that 
propranolol was ineffective in blocking the isoprenaline infusion 
induced redistribution of circulating lymphocyte subsets, could 
be an indication that the ß3-adrenergic receptor is involved. 
However, more studies are necessary to proof this hypothesis. 
In conclusion, ß-blocker treatment in healthy volunteers does 
not affect lymphocyte function in basal conditions. This argues 
against an important role of the sympathetic nervous system to 
regulate immune function via ß-adrenoceptors. Thus, chronic 
ß-blocker therapy might be expected to cause no important changes 
in immune function. However, in states of short-term activation 
of the sympathetic nervous system lymphocytes may be freshly 
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released into the circulation. Part of these lymphocytes have a 
depressed proliferative capacity, probably due to altered 
intrinsic properties, and are released via stimulation of 
ß2-adrenoceptors. The other part of lymphocytes appear to express 
normal proliferative capacity and are released either by a 
ß-adrenoceptor independent pathway, or via stimulation of an 
atypical ß-adrenoceptor. The physiological significance of this 
differential release of lymphocytes is not known. 
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CHAPTER 6. Reduced proliferation of human lymphocytes after 
infusion of isoprenaline is unrelated to impair-
ments in transmembrane signalling 
Abstract 
Peripheral blood lymphocytes of normal healthy volunteers exposed 
to acute stress or elevated concentrations of exogenously applied 
adrenaline or isoprenaline, have a reduced proliferative capacity 
in response to mitogenic stimulation with lectins. Although the 
effect is accompanied by a redistribution of lymphocyte subsets, 
the altered phenotypic distribution of T-cells does not explain 
the reduced proliferative responses. We examined whether the 
effect is due to a decreased intrinsic efficiency of transmembrane 
signalling. 
Isoprenaline was infused into normal healthy volunteers for 25 
min at increasing doses. Lymphocytes obtained after the infusion 
incorporated significantly less [3H]-thymidine when stimulated 
with mitogenic lectins, and the proportions of different phe-
notypes of lymphocytes present in the circulation, had changed. 
Thus, suppressor/cytolytic T-cells and natural killer cells had 
increased, and helper T-cells had decreased. 
Comparison of second messenger responses of lymphocytes obtained 
before and after infusion of isoprenaline showed that upon 
stimulation with PHA or Con A, lymphocytes obtained after infusion 
of isoprenaline exhibited a higher formation of inositol phos-
phates and a higher or at least equal [Ca',","]i response compared 
with lymphocytes obtained before infusion of isoprenaline. Thus, 
the reduced proliferative capacity of lymphocytes obtained after 
infusion of isoprenaline cannot be attributed to impairments in 
membrane-associated events in signal transduction. 
Introduction 
Immune homeostasis is the result of a delicate balance of subsets 
of the immunocompetent lymphocytes and can be modulated by 
endocrine and nervous systems (1-4), including the sympathetic 
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nervous system (for reviews see 5-7). Jn vitro, catecholamines 
inhibit various functions of lymphocytes (5-10) . Also in vivo, 
stress is increasingly reported in association with immunosup­
pression (11-16). Acute exposure of normal healthy volunteers to 
elevated concentrations of circulating adrenaline, either 
increased by insulin-induced hypoglycemia (17) or applied 
exogenously (18), causes a depression of the proliferative 
capacity of circulating lymphocytes. The activation of resting 
lymphocytes is a multistep process involving early biochemical 
alterations such as formation of inositol phosphates and increases 
in intracellular free calcium leading to activation of protein 
kinase С (19-21). Administration of adrenaline or isoprenaline 
to human subjects causes an absolute and relative lymphocytosis 
(14,16,17). In addition, alterations occur in the relative 
proportions of major lymphocyte subclasses present in the 
circulation (22,23). Since intracellular free calcium responses 
of subpopulations of peripheral blood lymphocytes are hetero­
geneous (24) , these alterations in lymphocyte numbers could 
contribute to the depression of the proliferative response towards 
mitogenic lectins. However, we have recently shown that the 
depression of proliferative capacity can be prevented despite 
alterations in lymphocyte numbers (25). Apparently, the changes 
in the phenotypical profile of the circulating lymphocytes may 
be not responsible for the reduced proliferative responses. 
Alternatively, the reduced mitogenic responsiveness of lympho­
cytes after infusion with isoprenaline might be due to altered 
intrinsic properties of the freshly released lymphocytes. For 
example, freshly released lymphocytes have been shown to carry 
more ß2-adrenergic receptors than those found in the circulation 
(23). The aim of the present study was to determine whether an 
altered efficiency of transmembrane signalling underlies the 
depression of proliferative responses. For this purpose, before 
and immediately after infusion of isoprenaline in young healthy 
volunteers, blood was withdrawn by venipuncture and formation of 
inositol phosphates and elevations of intracellular free Ca++ in 
lymphocytes upon stimulation with the mitogenic lectins phy-
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tohemagglutinin and concanavalin A, were determined. In addition, 
circulating lymphocyte subsets were analyzed and incorporation 
of [3H]-thymidine after the lectin challenge was assessed. 
Materials and Methods 
Experimental protocol 
Six young healthy volunteers (aged 25-29 yr) participated in the 
study after having given informed written consent. At 0800 h an 
indwelling cannula was inserted into a forearm vein. In the 
opposite forearm a needle was placed into a large vein and kept 
patent with infusion of 0.9 % saline. After one hour of rest in 
the supine position, isoprenaline was infused in sequential doses 
of 3.5, 7, 17.5, 35 and 70 ng·kg-1 -min"1 for 5 min each. Before 
and immediately after the infusion, blood samples were withdrawn 
after first flushing saline from the infusion needle with about 
3 ml blood. For analysis of lymphocyte subsets and for measurements 
of second messenger responses upon mitogenic stimulation, blood 
was anticoagulated with EDTA, for assessment of lymphocyte 
proliferative responses blood was anticoagulated with heparin 
(500 IU heparin/10 ml blood). 
Cell isolation 
Peripheral blood lymphocytes were prepared from whole blood by 
Ficoll gradient centrifugation according to the method of Böyum 
(26) with minor modifications (23). 
Analysis of lymphocyte subsets 
Lymphocyte subsets were analyzed by indirect immunofluorescence 
with the following monoclonal antibodies: Jot3 for pan-T cells; 
Jot4a and BMA040 for helper T-cells; Jot8a and BMA080 for sup-
pressor/cytolytic T-cells; aDR for pan-B cells; JotlO for natural 
killer cells. LeuMl was used for quantification of monocytes and 
granulocytes present in the cell suspensions. Fluorescein iso-
thiocyanate (FITC)- labeled goat anti-mouse immunoglobulin G 
(IgG) + IgM was used as the second antibody. In short, lymphocytes 
were incubated with appropriate dilutions of monoclonal antibody 
for 40 min, washed, labeled with FITC-conjugated goat antimouse 
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antibody for 40 min and washed; all procedures were performed at 
room temperature. Cells were analyzed within 2 h under a Zeiss 
fluorescence microscope (Zeiss, Oberkochen, Germany). 
3H-Thymidine incorporation 
Lymphocytes were stimulated to proliferate with the mitogenic 
lectins phytohemagglutinin (PHA; 0.45, 0.9, 1.8 and 3.6 ßg/ml) 
and concanavalin A (Con A; 4.5, 9, 18 and 36 дд/ml). The cells 
were cultured for 4 days at 37 "C in microtiter plates containing 
the lectins in 220 μΐ RPMI-1640 with 0.29 mg/ml L-glutamine, 0.16 
mg/ml gentamycin-sulfate, and 10% heat-inactivated pooled human 
serum at 2·105 cells/well. For the last 16 h the cultures were 
labeled with 2 дСі [3H]-thymidine/well. The cells were harvested 
with a multiple sample precipitator (Skatron, Lier, Norway), and 
incorporated radioactivity was assessed in a liquid scintillation 
counter (LKB 1212, Freiburg, Germany). 
Second messenger responses 
Formation of inositol phosphates (IPs) was determined according 
to previously published techniques (27) . In short, lymphocytes 
were labeled with [3H]-myoinositol in Krebs-Henseleit solution 
for 2 h at 37 "С, washed, stimulated and incubated for another 
30 min at 37 "C in the presence of 10 mM LiCl. PHA (1.8 ßg/ml) 
and Con A (18 ßg/ml) were used as stimuli. Accumulated 
water-soluble [3H]-IPs were extracted with a water-metha-
nol/chloroform system and loaded onto Dowex anion exchange resin 
columns. [3H]-IPs were eluted in one fraction and counted in a 
Beekman LS 9000 liquid scintillation counter (Beekman Inst., 
Fullerton, CA) at an efficiency of about 42%. 
Intracellular free calcium ([Ca++]i) was measured with the flu-
orescent dye Fura-2 as previously described (27) . For this purpose, 
lymphocytes were incubated with 1 μΜ Fura-2 for 1 h at room 
temperature, washed and stimulated with various concentrations 
of PHA or Con A. For conversion of raw fluorescence data into 
[Ca++]i, the presence of extracellular Fura-2 was taken into 
account. 
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Data evaluation 
All data are shown as means ± SEM of η experiments. Differences 
between groups were compared with two-tailed paired t-test; a 
p-value smaller than 0.05 was considered to be significant. 
Materials 
[3H]-thymidine (5 Ci/mmol) was purchased from Amersham and 
Myo-[2-3H(N)]-inositol (specific activity 20 Ci/mmol) was from 
New England Nuclear (Dreiech, FRG). 
Isoprenaline (Aludrin) was obtained from Boehringer (Ingelheim, 
FRG) . 
FITC coupled goat anti-mouse IgG + IgM was purchased from Medac 
(Hamburg, FRG). Monoclonal antibodies were obtained from the 
following sources (specificities in parenthesis): Jot3 (CD3), 
Jot4a (CD4), JotSa (CD8) and JotlO (natural killer cell marker) 
from Immunotech Dianova (Hamburg, FRG); LeuMl (pan-monocy-
te/granulocyte marker) and aDR (class II) from Becton Dickinson 
(Heidelberg, FRG); BMA040 (CD4) and BMA080 (CD8) from Behring 
(Frankfurt/Main, FRG). 
RPMI 1640, L-glutamine and gentamycin-sulfate were obtained from 
Nunc (Wiesbaden, FRG). PHA was from Welcome (Beckenham, U.K.), 
Con A from Sigma (Deisenhofen, FRG). 
Dowex l-x8 anion exchange resin (200-400 mesh, formate form) was 
obtained from Bio-Rad Laboratories (Richmond, USA), Fura-2 
acetoxymethoxyester was obtained from Molecular Probes (Eugene, 
OR) . 
All other chemicals were from Sigma and of the highest purity 
grade available. 
Results 
Effects of isoprenaline infusion on lymphocyte subset composition 
The number of granulocytes and monocytes present in the lymphocyte 
suspensions did not exceed 5% and was similar for all preparations. 
Infusion of isoprenaline did not change the relative amounts of 
pan-T cells and pan-B cells (Table 1) . However, within the 
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population of T-cells, the percentage of helper cells decreased 
(38.2 ± 1.7 before vs. 30.8 ± 1.9 after infusion, n=6, p=0.09) 
and of suppressor/cytolytic cells increased (24.3 ± 2.0 before 
vs. 33.0 ± 2.4 after infusion, n=6, p=0.007). Accordingly, 
Theiper/Tsuppressor/cytoiytic -cell ratio, a commonly used indicator 
of immunoregulatory cell disbalance (28), decreased from 1.62 ± 
0.12 to 0.98 + 0.14 (n=6, p=0.02). The percentage of natural 
killer cells increased from 5.8 ± 1.7 to 9.0 ± 1.8 (n=6, p=0.15) 
following isoprenaline infusion. 
TABLE 1: RELATIVE DISTRIBUTION OF LYMPHOCYTE SUBSETS IN 6 HEALTHY SUBJECTS 
BEFORE AND AFTER INFUSION OF ISOPRENALINE 
PAN-T CELLS 
HELPER-T CELLS 
SUPPRESSOR/CYTOLYTIC-T CELLS 
PAN-B CELLS 
NATURAL KILLER CELLS 
HELPER TO SUPPRESSOR/CYTOLYTIC CELL 
RATIO 
BEFORE 
67.512.6 
38.2±1.7 
24.3±2.0 
16.812.9 
5.811.7 
1.6210.12 
AFTER 
70.312.4 
30.811.9 
33.012.4* 
20.511.6 
9.011.8 
0.9810.14* 
Immediately before infusion and after 25 min of infusion of isoprenaline, 
blood was withdrawn for determination of distribution of lymphocyte subsets. 
Values are means 1 SEM of 6 experiments. * Ρ < 0.05 vs. the corresponding 
preinfusion level. 
Lymphocyte proliferative responses 
After a 4 day culture in the presence of the mitogenic lectin 
PHA or Con A, lymphocytes obtained before infusion of isoprenaline 
incorporated significantly more [3H]-thymidine than did lym­
phocytes obtained immediately after infusion of isoprenaline 
(Figure 1). 
Forjnation of [3H]-IPs 
Incorporation of [3H]-myoinositol was identical in lymphocytes 
obtained before and after infusion of isoprenaline (data not 
shown) . Basal formation of [3H]-IPs in lymphocytes obtained before 
or after infusion of isoprenaline was similar (Figure 2) . However, 
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Figure 1. Lectin-stimulated incorporation of (^Н)-thymidine in human lym­
phocytes obtained before (open circles) and after (closed circles) infusion 
of isoprenaline. Immediately before infusion and after 25 min of infusion 
(see Materials and Methods: experimental protocol), hepannized blood was 
withdrawn and lymphocyte in vitro proliferative responses to PHA and Con A 
were determined as described in Waterials and Methods. Ordinates, (^HJ-thy-
midine incorporation into lymphocytes in counts per min (cpm) χ lO-^; abscissae, 
lectin concentrations in pg/ml. Values are means ± SEM of η experiments. * Ρ 
< 0.05 vs. the corresponding preinfusion level. 
lectin-stimulated formation of IPs was significantly greater in 
lymphocytes obtained after infusion of isoprenaline. Upon 
stimulation with 1.8 ßg/ml PHA the response was about 5 times as 
large, and upon stimulation with 18 ßg/ml Con A the response was 
about 2.5 times as large in lymphocytes obtained after infusion 
of isoprenaline compared to lymphocytes obtained before infusion 
of isoprenaline (Figure 2). 
[Ca++]i measurements 
Basal levels of [Ca++]i of lymphocytes obtained before and after 
infusion of isoprenaline were similar (60.2 ± 2.5 nM before vs 
64.4 ± 2.1 nM after infusion of isoprenaline, n=5). PHA and Con 
A concentration-dependently elevated [Ca++]i to a peak level 
within 1-3 min. From the peak [Ca++]i elicited by 4-5 lectin 
concentrations, we constructed concentration-response curves 
(Figure 3). The curves for Con Α-stimulated increases in [Ca++]i 
in lymphocytes obtained before and after infusion of isoprenaline 
were superimposable. PHA-stimulated increases in [Ca++]i were 
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Figure 2. Formation of [^HJ-inositol phosphates (IPs) in human lymphocytes 
obtained before (open columns) and after (hatched columns) infusion of iso-
prenaline. Lymphocytes, prelabeled with [ ^ HJ-myoinositol, were incubated for 
30 min in the presence and absence of PHA (1.8 μg/ml) or Con A (18 pg/ml) at 
370C and formation of [^HJ-IPS was determined as described in Materials and 
Methods. Ordinate, formation of [^HJ-IPs m counts per min (cpm) per 5 10° 
lymphocytes. Values are means ± SEM of б experiments. * Ρ < 0.05 vs. the 
corresponding preinfusion level. 
slightly but significantly higher in lymphocytes obtained after 
infusion of isoprenaline compared to lymphocytes obtained before 
infusion of isoprenaline. 
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Figure 3. Lectin-stimulated increases of [Ca++]i in human lymphocytes obtained 
before (open circles) and after (closed circles) infusion of isoprenaline. 
Lymphocytes were incubated with various concentrations of PHA and Con A at 
250C and alterations of (Ca++)i were monitored with Fura-2. Ordinate, increase 
of (Ca++]i in nM; abscissae, lectin concentrations in pg/ml. Values are means 
± SEM of 5 experiments. * Ρ < 0.05 vs. the corresponding preinfusion level. 
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Discussion 
The human immune system consists of discrete subsets of immu-
nocompetent lymphocytes that are critical for immune homeostasis 
(28). The present study shows that intravenous administration of 
isoprenaline to human subjects produces a shift in the proportion 
of certain lymphocyte subsets in the peripheral blood. Although 
the percentage of pan-T cells remained unchanged following 
infusion of isoprenaline, the relative amount of helper cells 
decreased and that of suppressor/cytolytic cells increased. 
Previous studies showed that the decline in the percentage of 
helper T-cells is due to both an increase in the absolute numbers 
of natural killer cells and suppressor/cytolytic lymphocytes, as 
well as a decrease in the absolute number of helper T-cells (23). 
A disturbed lymphocyte migration into peripheral tissues (29,30) 
as well as an altered adherence of lymphocytes to endothelial 
cells and tissue-specific receptors (31-33) might account for 
the change in lymphocyte numbers. Isoprenaline may act directly 
by activation of lymphocyte ß2-adrenergic receptors (23,34), or 
indirectly, by activation of ß-adrenergic receptors on other 
tissues. 
The outcome of an immune response largely depends on the number 
of lymphocytes and monocytes, as well as on the composition of 
lymphocyte subsets. Human T-lymphocytes are endowed with the 
capacity to recognize specific antigens, execute effector 
functions, and regulate the type and intensity of virtually all 
cellular and humoral immune responses. Perturbations in subset 
dynamics may initiate a variety of immunopathologic disorders 
(28). 
In the present study, lymphocytes obtained after infusion of 
isoprenaline showed a reduced proliferative capacity in response 
to the mitogenic lectins PHA and Con A. Previous studies indicated 
that the alterations in T-lymphocyte subsetcomposition may be 
not responsible for the reduced proliferative responses: infusion 
of isoprenaline in healthy volunteers treated with propranolol 
induced an increase in the percentage of suppressor/cytolytic 
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cells and a decrease in the percentage of helper cells but did 
not affect lymphocyte іл vitro proliferative responses to various 
mitogenic agents (25). It was hypothesized that the effect might 
be due to intrinsic properties of freshly released lymphocytes. 
In the present study we investigated the efficiency of transduction 
of the signal across the membrane (19-21). Our results suggest 
that the reduced proliferative capacity of lymphocytes obtained 
after infusion of isoprenaline is not related to decreased 
efficiency of transmembrane signal transduction. Lymphocyte 
activation involves very early increases in [Ca',",']i and formation 
of IPs. A decreased production of IPs and/or an attenuated increase 
in [Ca + +] i could result in a reduced proliferative respons. 
However, after infusion of isoprenaline PHA-stimulated formation 
of IPs was markedly, and [Ca++]i responses were slightly increased; 
Con Α-stimulated formation of IPs had increased somewhat less 
and [Ca++]i responses were similar. According to these findings, 
proliferative capacity might be expected to increase or at least 
remain constant, but in fact it was decreased (see above). The 
enhancement of second messenger responses might be caused by a 
higher number and/or by an increased affinity of the receptors 
for the lectins in lymphocytes obtained after infusion of iso­
prenaline. Freshly released lymphocytes have recently been 
reported to carry about twice as many ß2-adrenergic receptors 
than those already present in the circulation (23). 
Alternatively, proliferative abnormalities might be caused by 
alterations in activation steps subsequent to transmembrane 
signalling, for example the activation and/or function of protein 
kinase С (35,36), or the production, secretion and effects of 
lymphokines (4,37,38). 
Observations regarding in vitro treatment of lymphocytes with 
catecholamines have been rather conflicting. Crary et al. (18) 
reported that incubation of human mononuclear cells with adre­
naline had no effect on the incorporation of [3H]-thymidine 
following mitogenic stimulation with PHA or pokeweed mitogen. On 
the other hand, inhibitory effects of catecholamines on mitogen-
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or antigen-induced T-cell proliferation, cytotoxic T-lymphocyte 
function, lymphokine secretion, and production and effects of 
IL-2 have been reported (5-10). Moreover, we have recently shown 
inhibitory effects of catecholamines on lectin stimulated for­
mation of IPs and elevation of [Ca++]i in human lymphocytes in 
vitro (27) . However, since 1> the in vitro effects are found in 
the presence of the catecholamine only, and 2) ex vivo increases 
in transmembrane signalling are found (this study), different 
mechanisms seem to underlie the effects of catecholamines in vivo 
and іл vitro. It is suggested that in vivo the catecholamine acts 
indirectly, causing an exchange of lymphocytes between the 
circulation and peripheral tissues, whereby the freshly released 
lymphocytes might have altered intrinsic properties concerning 
activation steps post transmembrane signal transduction. 
We conclude that the reduced proliferative capacity towards 
mitogenic lectins in lymphocytes obtained after infusion of 
isoprenaline appears not to be due to a decreased efficiency of 
transmembrane signal transduction. Future studies must show 
whether the reduction in proliferative response of lymphocytes 
in relation to acute increases in catecholamines, might be caused 
by impaired activation pathways subsequent to transmembrane 
signalling. 
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SUMMARY 
Circulating blood lymphocytes contain a homogeneous population 
of ß2-adrenoceptors. These cells are frequently used to monitor 
changes of ß-adrenoceptor function in humans. This thesis presents 
in vitro and іл vivo studies which were designed to investigate 
1) the mechanisms underlying the dynamic regulation of lymphocyte 
ß2-adrenoceptors and 2> the role of lymphocyte ß2-adrenoceptors 
for human immune function. 
Jn vitro, ßj-adrenoceptors in lymphocytes are subject to 
homologous and heterologous desensitization in a manner similar 
to that observed in various other model systems. Catecholamines 
induced a time- and concentration-dependent homologous 
desensitization of ßj-adrenoceptor function with an order of 
potency typical for a ß2-adrenoceptor: isoprenaline > adrenaline 
>> noradrenaline. The phorbol ester 12-o-tetradecanoyl-
phorbol-13-acetate (TPA) was shown to cause heterologous 
desensitization of the lymphocyte ß2-adrenoceptor, possibly by 
an impairment of the function of the Gs-protein and/or the ability 
of the ß-adrenoceptor to couple to GB. 
Jn vivo, acute exposure to catecholaminergic agonists caused 
an increase of ß2-adrenoceptors on circulating blood lymphocytes, 
in contrast to what has been observed in all other model systems. 
Measurements of intracellular cAMP content and of adenylate 
cyclase activity showed an increased isoprenaline-induced cAMP 
generation after infusion of isoprenaline, suggesting that the 
additional receptors were functional. The effect was ß2-adre-
noceptor mediated, since (1) adrenaline was much more potent than 
noradrenaline and (2) it could be abolished by acute pretreatment 
of the volunteers with the ß2-selective antagonist ICI 118,551 
but not with the ßj^-selective antagonist bisoprolol. 
It seemed impossible to induce similar increases in ß2-adre-
noceptor density in vitro. Incubation of lymphocytes, obtained 
before infusion of isoprenaline, in autologous plasma obtained 
immediately after the infusion did not influence ß2-adrenoceptor 
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density at all. Thus, unless a local and short-living substance 
is involved, the possibility that the alteration was caused by 
direct effect of substances released in the plasma during the 
infusion (for example adrenal corticosteroids), was unlikely but 
can not be ruled out completely. Furthermore the phenomenon was 
lymphocyte specific (no alteration was observed in platelet or 
monocyte ß2-adrenoceptors). 
Lymphocytes are not a homogeneous population but consist of 
different subsets and, acute exposure to catecholamines іл vivo 
is known to cause a lymphocytosis. Analysis of the subsetcom-
position of circulating blood lymphocytes following infusion of 
isoprenaline revealed unequal changes in lymphocyte numbers. 
Whereas the number of pan-B cells and pan-T cells remained fairly 
constant, the number of NK cells increased. Among the T-cells 
T3uppressor/cytolytic cells increased and T h e l p e r cells decreased. 
Infusion of noradrenaline, which did not affect ß2-adrenoceptors, 
did not change lymphocyte numbers. 
In case of a different distribution of ß2-adrenoceptors on 
lymphocyte subsets, this alteration of the subsetcomposition of 
circulating blood lymphocytes might contribute to the increase 
in ß2-adrenoceptors on unfractionated lymphocytes following 
infusion of isoprenaline. Indeed, there were marked differences 
in ß2-adrenoceptor densities of different lymphocyte subsets. 
Pan-B cells had significantly more ß2-adrenoceptors than pan-T 
cells, and among the T-cells, Tsuppre3sor/cytolytic cells had more 
ß2-adrenoceptors than Thelper cells. These differences however, 
were not large enough to explain the 2-fold increase in 
ß2-adrenoceptor density on unfractionated lymphocytes. In fact, 
the contribution of the alteration of the subsetcomposition to 
the increase in ß2-adrenoceptors, seemed relatively unimportant, 
since ß2-adrenoceptor density had increased in each subset. 
The rapid time course of the increase of ß2-adrenoceptors on 
circulating blood lymphocytes (within 15 minutes) makes de novo 
synthesis of ß2-adrenoceptors very unlikely. It has been 
postulated that sympathetic stimulation might shift receptors 
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from sequestered compartments to the cell surface. However, 
increases in ß2-adrenoceptor density determined on intact cells 
and on membranes were similar, and experiments to induce increases 
in ß2-adrenoceptor density in vitro were not successfull. Thus 
the rapid increase in lymphocyte ß2-adrenoceptors is not likely 
to be caused by receptor regulation. The fact that receptors had 
still increased on each subset (even on pan-B cells, which did 
not change in number!) can be explained by assuming that an 
exchange of lymphocytes had taken place, or in other words, that 
the cells pre-infusion and the cells post-infusion were from 
different populations. This exchange can not be determined 
directly by the method available. However, the role of the exchange 
process can be assessed by taking away an organ that might be 
involved in it. The spleen is a large source of lymphocytes in 
the body. The role of this organ was assessed in some patients 
who had to undergo splenectomy. Infusion of isoprenaline in two 
Hodgkin's patients before splenectomy induced similar changes in 
ßj-adrenoceptor density and in lymphocyte subsetcomposition as 
in healthy subjects. Thus, interference of the disease itself 
could be excluded. After splenectomy, however, isoprenaline 
infusion increased ß2-adrenoceptor density on unfractionated 
lymphocytes only by 40%, and, apart from an increase in the 
percentage of NK cells, lymphocyte subset composition was not 
affected. The still remaining slight increase in ß-adrenoceptor 
density in splenectomized patients could partly be explained by 
the increase in the percentage of NK cells, which contain a rather 
high number of ß-adrenoceptors. However, exchange of lymphocytes 
between the circulation and secondary lymphoid organs other than 
the spleen, like for example the thoracic duct, the lung or the 
lymph nodes, is a more likely explanation. 
Taken together, the rapid increase in ß2-adrenoceptors on 
unfractionated lymphocytes following isoprenaline infusion does 
not represent receptor regulation, but instead is a lymphocyte 
specific phenomenon. It is possibly caused by a release of 
lymphocytes into the circulation and/or by an exchange of lym-
phocytes between peripheral lymphoid tissues and the circulation. 
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Hereby freshly released lymphocytes appear to carry more 
ß2-adrenoceptors than those found in the circulation. The two 
phenomena, however, are not strictly coupled. The pharmacological 
characteristics of the isoprenaline infusion-induced redis-
tribution of lymphocytes differed from those of the isoprenaline 
infusion-induced increase in lymphocyte ß2-adrenoceptors. Whereas 
the increase in ßj-adrenoceptors was ß2-adrenoceptor-mediated 
(see above: inhibition by ICI 118,551 but not by bisoprolol), 
neither bisoprolol or Celiprolol (administered chronically) nor 
propranolol (independent whether administered acutely or 
chronically) inhibited the isoprenaline infusion-induced 
redistribution of lymphocytes. Apparently the exchange of lym-
phocytes concerns "normal" as well as "receptor rich" lymphocytes. 
Whereas the release of "receptor-rich" lymphocytes is 
ß2-adrenoceptor-mediated, the release of "normal" lymphocytes is 
neither ß ^ nor ß2-adrenoceptor-mediated. 
In order to determine the relevance of alterations in lymphocyte 
numbers and ß2-adrenoceptors for immune function, we assessed 
the in vitro proliferative response of non-fractionated lym-
phocytes towards mitogenic lectins. After isoprenaline but not 
noradrenaline infusion, proliferative responsiveness was reduced. 
Similar to the increases in ß2-adrenoceptors, this depression of 
in vitro proliferation could be prevented by a 9 day treatment 
with propranolol but not with bisoprolol or Celiprolol, thus 
indicating involvement of the ß2-adrenoceptor in the effect. 
Furthermore, since after propranolol treatment lymphocyte sub-
setcomposition still changed following infusion with isoprenaline 
(see above) but, in vitro proliferation was not depressed, it 
could also be concluded that the depression of lymphocyte pro-
liferative responsiveness was not caused by the alteration in 
lymphocyte subsetcomposition. These findings suggest a 
relationship between ß2-adrenoceptor density and proliferative 
responsiveness of circulating lymphocytes. 
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The reduced mitogenic responsiveness of the lymphocytes after 
infusion with isoprenaline might be caused by altered intrinsic 
properties of freshly released lymphocytes. An obvious candidate 
for a role in this phenomenon is the ß2-adrenoceptor. Indeed, in 
vitro stimulation of lymphocyte ß2-adrenoceptors inhibited the 
lectin-induced accumulation of inositol phosphates and influx of 
extracellular calcium, both very early events following lymphocyte 
activation. This inhibitory effect seemed to be mediated by cAMP 
since it was mimicked by prostaglandin E1 and forskolin and 
enhanced by inhibition of phosphodiesterases. However, studies 
on transmembrane signalling of lymphocytes obtained before and 
after infusion of isoprenaline revealed that formation of inositol 
phosphates and increases in intracellular calcium following the 
lectin challenge were enhanced instead of decreased in lymphocytes 
obtained after the infusion. Thus, although the inhibitory effect 
of catecholamines on transmembrane signalling might take place 
in vivo, it does not seem to play an important role in determining 
lymphocyte in vitro proliferative capacity. 
The reduced proliferative capacity of lymphocytes obtained 
after infusion of isoprenaline, might be due to altered properties 
concerning activation steps subsequent to transmembrane sig-
nalling, like for example the activation and/or function of 
protein kinase C, or the production, secretion and effects of 
lymphokines. 
The physiological significance of these catecholamine-induced 
changes in lymphocyte immune function was investigated in the 
model of insulin-induced hypoglycemia in healthy volunteers. The 
nadir of decreased blood glucose levels following intravenous 
injection of insulin was associated with an about 10-fold increase 
in plasma adrenaline, but an only modest increase in plasma 
noradrenaline. This vigorous increase in plasma adrenaline was 
accompanied by an increase in functional lymphocyte ßj-adreno-
ceptors comparable with those evoked by infusion of exogenous 
adrenaline or isoprenaline. Concomitantly, lymphocyte 
subsetcomposition was markedly altered and proliferative 
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responses to various mitogenic lectins were attenuated. Thus, 
acute changes in ß2-adrenoceptor function, subsetcomposition and 
proliferative responses of peripheral blood lymphocytes do not 
only occur in response to exogenously applied ß-adrenoceptor 
agonists, but also in response to acute (patho)physiological 
elevations of endogenous catecholamines. The effect was transient 
and paralleled the changes in plasma catecholamines: when plasma 
catecholamine levels had reached pre-drug levels, also the above 
mentioned parameters had returned to the corresponding values 
obtained before insulin application. Whether these transient 
changes of circulating lymphocytes, accompanying acute changes 
in plasma catecholamines, are a reflection of immune respon-
siveness in vivo, remains to be elucidated. 
Accordingly, in physiological and pathological conditions of 
acutely elevated sympathetic nervous activity, (cellular) immune 
function might be altered. The basal sympathetic tone, however, 
does not seem to play an important role in control of immune 
function via ß-adrenoceptors. Treatment with ß-adrenoceptor 
antagonists (bisoprolol or Celiprolol or propranolol) for 9 days 
did not influence circulating lymphocyte numbers and also no 
changes were found in in vitro proliferative responses. 
In conclusion, in vitro studies yielded indications for an 
inhibitory role of lymphocyte ß2-adrenoceptors in immune function. 
The in vivo situation, however, appeared to be much more complex. 
Jn vivo basal sympathetic tone did not seem to play an important 
role in control of immune function via ß-adrenoceptors, but acute 
stimulation of the sympathetic nervous system (endogenously as 
well as exogenously) affected two parameters of lymphocyte immune 
function: 1) the subset composition of circulating lymphocytes 
changed, probably due to an exchange of lymphocytes with secondary 
lymphoid organs, and 2> the proliferative capacity of circulating 
lymphocytes was reduced. Since freshly released lymphocytes appear 
to carry more ß2-adrenoceptors than those already present in the 
circulation, these lymphocytes could be expected to be more 
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sensitive to inhibitory effects of catecholamines. However, the 
opposite was the case: transmembrane signalling had increased in 
these lymphocytes. 
Thus, the mechanisms regulating number and subset composition 
as well as proliferative capacity of human circulating lymphocytes 
remain to be elucidated. 
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SAMENVATTING 
Prikkels die via sympathische zenuwbanen worden voortgeleid 
resulteren uiteindelijk in de afgifte van de neurotransmitterstof 
noradrenaline. Deze neurotransmitter overbrugt de afstand van 
zenuwuiteinde tot cellen van het doelorgaan. Deze cellen bevatten 
eiwit structuren, receptoren genaamd, waarop zeer specifiek de 
neurotransmitter kan binden. De interactie van de neurotransmitter 
met de receptor initieert een reeks van biochemische gebeurte­
nissen in de cel welke uiteindelijk leiden tot een biologisch 
effect. De receptoren van het sympathische zenuwstelsel worden 
adrenoceptoren genoemd. Naar gelang de voorkeursvolgorde van de 
catecholamines isoprenaline, adrenaline en noradrenaline om de 
receptoren te bezetten, worden α- en ß-adrenoceptoren onder-
scheiden. Een verdere onderverdeling in subtypen van α- en 
ß-adrenoceptoren berust op verschillen in voorkeursvolgorden van 
synthetische stoffen die de receptoren bezetten. 
Lymfocyten bevatten een homogene populatie ß-adrenoceptoren 
van het subtype ß2· Omdat lymfocyten vrij eenvoudig te isoleren 
zijn uit perifeer bloed werden en worden deze cellen vaak gebruikt 
om de functie van adrenerge receptoren te bestuderen en te meten, 
soms in de hoop hiermee een maat te hebben voor de functie van 
ß2-adrenoceptoren op andere weefsels. Het in dit proefschrift 
beschreven onderzoek werd opgezet om de regulatie en de functie 
van deze ßj-adrenoceptoren op humane lymfocyten te bestuderen. 
De gevoeligheid van een cel voor een neurotransmitter is onder 
andere afhankelijk van het aantal receptoren voor de neuro-
transmitter op deze cel. Deze receptor dichtheid is een dynamische 
grootheid die door een groot aantal fysiologische en 
pathofysiologische variabelen gereguleerd wordt. Een algemeen 
voorkomend verschijnsel is de afnemende gevoeligheid voor een 
neurotransmitter onder invloed van langdurige stimulatie door 
diezelfde of door een andere neurotransmitter. We spreken dan 
van respectievelijk homologe en heterologe desensitisatie. In 
deze studie wordt aangetoond dat de ß2-adrenoceptor op lymfocyten 
zowel homologe als heterologe desensitisatie kan ondergaan. De 
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catecholamines isoprenaline, adrenaline en noradrenaline ver-
oorzaakten een tijds- en concentratie-afhankelijke homologe 
desensitisatie van de ß2-adrenoceptor functie op lymfocyten. De 
volgorde van potentie was typisch voor een ß2-adrenoceptor: 
isoprenaline > adrenaline >> noradrenaline. Aan homologe 
desensitisatie ligt een afname van het aantal functionele 
receptoren ten grondslag, dit door een verstoorde koppeling met 
het G-eiwit eventueel gevolgd door internalisatie van de receptor. 
De phorbol ester TPA induceerde heterologe desensitisatie van de 
ß2-adrenoceptor op lymfocyten. Via welke weg 
12-o-tetradecanoyl-phorbol-13-acetate (TPA) de functie van de 
ß2-adrenoceptor op lymfocyten beïnvloedt, is niet duidelijk. 
In tegenstelling tot de effecten van catecholamines op de 
ß2-adrenoceptor van lymfocyten in vitro, veroorzaakte intrave-
neuze toediening van isoprenaline of adrenaline, maar niet van 
gelijke doses noradrenaline, aan een proefpersoon, een 
dosisafhankelijke toename in functionele ß2-adrenoceptoren op 
perifere lymfocyten. Dergelijke veranderingen werden niet 
gevonden voor andere bloedcellen zoals bloedplaatjes of monocyten. 
Omdat lymfocyten uit verschillende subpopulaties bestaan die 
onderling zouden kunnen verschillen in receptor dichtheid is de 
centrale vraag of veranderingen in receptor aantallen onder 
invloed van isoprenaline of adrenaline veroorzaakt worden door 
een reeële toename van receptoren op circulerende cellen of door 
een verschuiving in de samenstelling van de lymfocyten populatie. 
Een methode werd ontwikkeld om de verschillende subpopulaties te 
scheiden, zodat metingen konden worden uitgevoerd aan gezuiverde 
subpopulaties. De verschillende subpopulaties verschilden 
onderling in ß2-adrenoceptor dichtheid. Verder bleek echter dat 
de toename in receptor dichtheid onder invloed van intraveneuze 
toediening van isoprenaline het resultaat is van een verhoogde 
receptor dichtheid op elke subpopulatie. 
De veranderingen in de receptor dichtheid gingen gepaard met 
veranderingen in de samenstelling van de lymfocyten populatie. 
Zo daalde bijvoorbeeld de ratio van helper en suppressor/cy-
140 
tolytische T-cellen van een normaal waarde van ± 1.7 naar een 
duidelijk verlaagde waarde van ±0.7. Aldus ontstond de hypothese 
dat een uitwisseling van lymfocyten tussen secundaire lymfoïde 
weefsels, zoals bijvoorbeeld de milt, en het perife bloed, waarbij 
de "nieuwe" lymfocyten een hogere ß2-adrenoceptor dichtheid 
bezitten, ten grondslag ligt aan bovengenoemde veranderingen in 
ß2-adrenoceptor dichtheid. De bevinding dat zowel veranderingen 
in de samenstelling van de lymfocyten populatie als ook veran-
deringen in de receptor dichtheid minder duidelijk waren bij 
patiënten waarbij de milt operatief was verwijderd, leverde een 
indirecte aanwijzing voor de juistheid van deze hypothese. 
Een indicatie omtrent de immuun functie van lymfocyten is de 
capaciteit van lymfocyten om zich te vermeerderen (prolifereren). 
Hiertoe worden de lymfocyten geactiveerd met mitogene agentia 
zoals bijvoorbeeld de lectinen phytohemagglutinine en concana-
valin A. De activatie van rustende lymfocyten berust op een 
cascade van gebeurtenissen. Aan de basis hiervan staan produktie 
van inositol fosfaten en een stijging van de intracellulaire 
calcium concentratie. Na intraveneuze toediening van isoprenaline 
was de proliferatie van de perifere lymfocyten verminderd. Deze 
verlaagde proliferatie capaciteit van de lymfocyten zou in verband 
kunnen staan met de verhoogde ß2-adrenoceptor dichtheid op de 
lymfocyten. Γη vitro stimulatie van de ß2-adrenoceptor remde de 
produktie van inositol fosfaten en de stijging van de intra-
cellulaire calcium concentratie tijdens de activatie van lym-
focyten met mitogene agentia. De concentratie van adrenaline 
waarbij deze werking optrad ligt in de nano-molaire range. Het 
effect zou dan ook van (patho)fysiologische betekenis kunnen 
zijn. Een remmende werking op deze vroege signalen tijdens de 
activatie van lymfocyten zou de oorzaak kunnen zijn van een 
verminderde proliferatie. Echter, analyse van deze vroege bio-
chemische signalen aan lymfocyten welke werden geïsoleerd vóór 
en ná intraveneuze toediening van isoprenaline, bracht niet een 
verminderde maar eerder een sterk verhoogde signaal transductie 
aan het licht. 
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Naast de toename van ß-agonisten door intraveneuze toediening 
gaf ook een endogene stijging van plasma catecholamines effecten 
op de perifere lymfocyten populatie. Intraveneuze toediening van 
insuline aan gezonde vrijwilligers leidde tot een daling van de 
glucose concentratie in het bloed. Deze hypoglykemie veroorzaakte 
een stijging in de plasma adrenaline concentratie tot ongeveer 
tien maal haar basale waarde. De plasma noradrenaline concentratie 
daarentegen steeg nauwelijks. Parallel aan deze endogene toename 
in plasma catecholamines veranderden ook de samenstelling van de 
lymfocyten populatie, en de ß2-adrenoceptor dichtheid en de 
proliferatie capaciteit van de lymfocyten. De veranderingen waren 
zowel kwalitatief als kwantitatief vergelijkbaar met de veran-
deringen die optraden onder invloed van intraveneuze toediening 
van isoprenaline. Verder waren de effecten van tijdelijke aard. 
120 Minuten na de toediening van insuline werden voor alle 
parameters waarden genoteerd die niet significant afweken van 
uitgangswaarden. 
Terwijl dus acute stimulatie van het sympathische zenuwstelsel, 
door exogene of endogene verhoging van de plasma catecholamine 
spiegels, veranderingen teweeg brengt in de perifere lymfocyten 
populatie, leek de endogene sympathische tonus hierop geen invloed 
te hebben. Langdurige medicatie met de ß-blokkers bisoprolol, 
Celiprolol en propranolol, had geen effect op de samenstelling 
van de perifere lymfocyten populatie en ook niet op haar pro-
liferatie capaciteit in vitro. Wel werd gevonden dat medicatie 
met bisoprolol, Celiprolol en propranolol de door isoprenaline 
gemedieerde veranderingen in de samenstelling van de perifere 
lymfocyten populatie niet blokkeerde. Dit zou kunnen betekenen 
dat dit fenomeen berust op een aspecifiek effect van isoprenaline. 
Echter, het is ook mogelijk dat er een atypische ß-adrenoceptor 
betrokken is bij de regulatie van de aantallen circulerende 
lymfocyten. 
Samenvattend kan worden gezegd dat in vitro studies aanwijzingen 
leverden voor een immunosuppressieve functie van de ß2-adreno-
ceptor op lymfocyten. Echter, in vivo is de situatie veel com-
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plexer. De endogene sympathische tonus lijkt van ondergeschikt 
belang te zijn voor de immuun functie van lymfocyten, maar acute 
stimulatie van het sympathische zenuwstelsel beïnvloedt wel 
degelijk de perifere lymfocyten populatie. Zo verandert onder 
invloed van exogene of endogene verhoging van de plasma cate-
cholamine spiegels de samenstelling van de perifere lymfocyten 
populatie, waarschijnlijk ten gevolge van een uitwisseling van 
lymfocyten met secundaire lymfoide organen, en, wordt de pro-
liferatie capaciteit van de circulerende lymfocyten onderdrukt. 
Omdat de nieuwe lymfocyten een hogere ß2-adrenoceptor dichtheid 
bezitten zouden ze gevoeliger kunnen zijn voor het immunosup-
pressieve effect van catecholamines. Dit kon echter niet worden 
aangetoond. 
Toekomstig onderzoek zal zich moeten richten op het mechanisme 
en de fysiologische betekenis van de acute veranderingen in de 
perifere lymfocyten populatie. 
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